2021/12/25 更新

写真a

キウラ カツユキ
木浦 勝行
KIURA Katsuyuki
所属
岡山大学病院 教授
職名
教授
外部リンク

学位

  • 医学博士 ( 岡山大学 )

研究キーワード

  • 呼吸器内科学

  • 肺癌

  • 胸部腫瘍学

研究分野

  • ライフサイエンス / 呼吸器内科学

学歴

  • 岡山大学   Medical School   Faculty of Medicine

    - 1983年

      詳細を見る

    国名: 日本国

    researchmap

  • 岡山大学   Faculty of Medicine  

    - 1983年

      詳細を見る

経歴

  • 岡山大学病院呼吸器・アレルギー内科 教授

    2011年 - 現在

      詳細を見る

  • 岡山大学岡山大学病院倫理委員会 教授   Okayama University Hospital

    2010年 - 2014年

      詳細を見る

  • 岡山大学岡山大学病院肺移植適応判定委員会 教授

    2008年 - 現在

      詳細を見る

  • 岡山大学医歯薬学総合研究科血液・腫瘍・呼吸器内科学 准教授

    2004年 - 2011年

      詳細を見る

  • State Univ. of New York at Buffalo 研究員

    1993年 - 1996年

      詳細を見る

所属学協会

▼全件表示

委員歴

  • 日本肺癌学会   第61回日本肺癌学会学術集会 会長  

    2020年11月   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本呼吸器学会   COI(利益相反)委員会 副委員長  

    2018年4月   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本呼吸器学会   Respiratory Investigation編集委員  

    2017年 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本呼吸器学会   学術講演会プログラム委員会 委員  

    2016年4月 - 2017年4月   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本呼吸器学会   学術部会統合委員会 委員  

    2016年4月 - 2017年4月   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本呼吸器学会   専門医制度審議会 施設審査委員会 委員長  

    2015年4月 - 2018年4月   

      詳細を見る

    団体区分:学協会

    日本呼吸器学会

    researchmap

  • 日本呼吸器学会   腫瘍学術部会 部会長  

    2015年4月 - 2016年4月   

      詳細を見る

    団体区分:学協会

    日本呼吸器学会

    researchmap

  • 日本呼吸器学会   第56回プログラム委員会 委員  

    2015年 - 2016年   

      詳細を見る

  • 日本内科学会   中国支部評議員  

    2015年   

      詳細を見る

    団体区分:学協会

    日本内科学会

    researchmap

  • 日本呼吸器学会   腫瘍学術部会 副部会長  

    2014年4月 - 2015年4月   

      詳細を見る

  • 日本呼吸器学会   財務委員会 委員  

    2014年 - 2015年   

      詳細を見る

    団体区分:学協会

    日本呼吸器学会

    researchmap

  • 日本呼吸器学会   第48回中国四国地方会会長  

    2012年12月   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本肺癌学会   理事  

    2012年11月 - 2020年11月   

      詳細を見る

    団体区分:学協会

    日本肺癌学会

    researchmap

  • 日本呼吸器学会   和文誌編集委員会委員  

    2012年6月 - 2018年4月   

      詳細を見る

    団体区分:学協会

    日本呼吸器学会

    researchmap

  • 日本呼吸器学会   理事  

    2012年4月 - 2020年4月   

      詳細を見る

    団体区分:学協会

    日本呼吸器学会

    researchmap

  • 日本呼吸器学会   専門医制度審議会 委員  

    2012年4月 - 2014年4月   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本癌治療学会   がん診療ガイドライン委員会G-CSF適正使用ガイドライン改訂ワーキンググループ委員長  

    2010年 - 2019年   

      詳細を見る

    団体区分:学協会

    日本癌治療学会

    researchmap

  • 日本肺癌学会   選挙管理委員会委員  

    2010年 - 2012年   

      詳細を見る

    団体区分:学協会

    日本肺癌学会

    researchmap

  • 日本呼吸器学会   日本呼吸器学会雑誌編集委員  

    2010年 - 2012年   

      詳細を見る

    団体区分:学協会

    日本呼吸器学会

    researchmap

  • 日本呼吸器学会   診療行為に関連した死亡の調査分析モデル事業 委員  

    2008年 - 2013年4月   

      詳細を見る

    団体区分:学協会

    日本呼吸器学会

    researchmap

  • 日本肺癌学会   中国四国地方会事務局  

    2008年 - 2011年   

      詳細を見る

    団体区分:学協会

    日本肺癌学会

    researchmap

  • 日本肺癌学会   倫理委員会委員  

    2008年 - 2010年   

      詳細を見る

    団体区分:学協会

    日本肺癌学会

    researchmap

  • 日本肺癌学会   利益相反管理委員会委員  

    2008年 - 2009年   

      詳細を見る

    団体区分:学協会

    日本肺癌学会

    researchmap

  • 日本臨床腫瘍学会   評議員  

    2006年   

      詳細を見る

    団体区分:学協会

    日本臨床腫瘍学会

    researchmap

  • 日本呼吸器学会   腫瘍学術部会委員  

    2005年4月 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本内科学会   中国支部事務局  

    2005年 - 2011年   

      詳細を見る

    団体区分:学協会

    日本内科学会

    researchmap

  • 日本呼吸器学会   代議員  

    2004年 - 2022年1月   

      詳細を見る

    団体区分:学協会

    日本呼吸器学会

    researchmap

  • 日本肺癌学会   財務委員会委員  

    2004年 - 2008年   

      詳細を見る

    団体区分:学協会

    日本肺癌学会

    researchmap

  • 日本肺癌学会   化学療法効果判定委員会委員  

    2004年   

      詳細を見る

    団体区分:学協会

    日本肺癌学会

    researchmap

  • 日本癌治療学会   評議員  

    2003年 - 2019年   

      詳細を見る

    団体区分:学協会

    日本癌治療学会

    researchmap

  • 日本肺癌学会   代議員  

    2002年 - 現在   

      詳細を見る

    団体区分:学協会

    日本肺癌学会

    researchmap

  • 日本内科学会   中国地方会評議員  

    2002年 - 現在   

      詳細を見る

    団体区分:学協会

    日本内科学会

    researchmap

  • 日本呼吸器学会   用語委員会委員  

    2002年 - 2014年   

      詳細を見る

    団体区分:学協会

    日本呼吸器学会

    researchmap

  • 日本呼吸器内視鏡学会   評議員、中国・四国地方会事務局  

    2002年 - 2010年   

      詳細を見る

    団体区分:学協会

    日本呼吸器内視鏡学会

    researchmap

  • 岡山県生活習慣病検診等管理指導協議会肺がん部会 委員(1998-2014)  

    1998年 - 現在   

      詳細を見る

  • 岡山地方裁判所 専門委員(1995-2017)  

    1995年 - 2017年   

      詳細を見る

▼全件表示

 

論文

  • Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells. 査読 国際誌

    Nozomu Nakagawa, Noriko Miyake, Nobuaki Ochi, Hiromichi Yamane, Masami Takeyama, Yasunari Nagasaki, Tomoko Ikeda, Etsuko Yokota, Takuya Fukazawa, Hidekazu Nakanishi, Daijiro Harada, Katsuyuki Kiura, Nagio Takigawa

    Experimental cell research   409 ( 2 )   112940 - 112940   2021年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Lung cancer that exhibits epidermal growth factor receptor (EGFR) gene mutation is sensitive to EGFR-tyrosine kinase inhibitors (TKIs), such as osimertinib. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) may be involved in overcoming EGFR-TKI resistance. Growth inhibition, colony formation, apoptosis, and mRNA/protein levels in four osimertinib-sensitive and resistant cell lines transfected with small interfering RNA (siRNA) targeting ROR1 (siROR1) were evaluated. Cell growth and colony formation were suppressed and apoptosis was increased in all cell lines treated with siROR1. Although EGFR, AKT, and ERK phosphorylation were not suppressed in all cell lines, TGF-β2, AXL, CDH2, PARP1, PEG10, and TYMS mRNA expression levels were reduced. The combination of osimertinib with siROR1 was effective for the four cell lines, particularly in the two osimertinib-sensitive lines. In conclusion, targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer may be a novel therapeutic option.

    DOI: 10.1016/j.yexcr.2021.112940

    PubMed

    researchmap

  • Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. 査読 国際誌

    Naofumi Hara, Eiki Ichihara, Daijiro Harada, Koji Inoue, Keiichi Fujiwara, Shinobu Hosokawa, Daizo Kishino, Kawai Haruyuki, Nobuaki Ochi, Naohiro Oda, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Journal of cancer research and clinical oncology   147 ( 12 )   3749 - 3755   2021年12月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: The programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) in tumor tissue samples is an established clinical biomarker for non-small cell lung cancer (NSCLC). However, the significance of PD-L1 expression in other types of samples has not been fully investigated. PATIENTS AND METHODS: We conducted a multicenter retrospective cohort study of advanced NSCLC patients who received ICI treatment during the clinical course and investigated the effects of ICIs according to PD-L1 expression in cytology samples, including cell block and endobronchial ultrasound-guided (EBUS) transbronchial needle aspiration (TBNA) samples. RESULTS: A total of 264 patients were included in this study: PD-L1 expression was determined in cell block or TBNA specimens in 55 patients, and in tissue samples in 209 patients. Among the former patients, the median progression-free survival (PFS) of those with a TPS for PD-L1 ≥ 50% was significantly longer compared to that of those with a TPS < 50% (6.5 vs. 1.9 months, respectively, p = 0.008). When the cutoff value was set at 1%, the median PFS was 4.2 months in patients with a TPS ≥ 1% and 1.5 months in patients with a TPS < 1% (p < 0.001). CONCLUSION: PD-L1 expression determined using cytology specimens predicts the efficacy of ICIs.

    DOI: 10.1007/s00432-021-03615-5

    PubMed

    researchmap

  • Transformed diffuse large B-cell lymphoma from marginal zone lymphoma in the anterior mediastinum: A case report and review of the literature. 査読

    Wataru Kitamura, Noboru Asada, Tetsuya Tabata, Rei Shibata, Tatsuya Nishi, Yuka Kato, Hiroki Takasuka, Hideaki Fujiwara, Daisuke Ennishi, Hisakazu Nishimori, Nobuharu Fujii, Ken-Ichi Matsuoka, Katsuyuki Kiura, Tadashi Yoshino, Yoshinobu Maeda

    Journal of clinical and experimental hematopathology : JCEH   2021年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Marginal zone lymphoma (MZL) arising from the anterior mediastinum is rare. In the majority of reported cases, the tumor was incidentally discovered, reflecting its indolent clinical features. We present a 38-year-old woman who had no medical history, and presented with a bulky anterior mediastinal tumor complicated by life-threatening compression of the vasculature and bronchi. Biopsy specimens of the neoplasm suggested transformed diffuse large B-cell lymphoma (DLBCL) from MZL. To our best knowledge, this is the first case report of anterior mediastinum MZL associated with an aggressive clinical course and life-threatening complications likely due to transformation to DLBCL.

    DOI: 10.3960/jslrt.21010

    PubMed

    researchmap

  • Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosis. 査読 国際誌

    Satoru Senoo, Akihiko Taniguchi, Junko Itano, Naohiro Oda, Daisuke Morichika, Utako Fujii, Lili Guo, Ryota Sunami, Arihiko Kanehiro, Fumiaki Tokioka, Akihiko Yoshimura, Katsuyuki Kiura, Yoshinobu Maeda, Nobuaki Miyahara

    American journal of physiology. Lung cellular and molecular physiology   321 ( 5 )   L925-L940   2021年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Acute exacerbation of idiopathic pulmonary fibrosis has a poor prognosis associated with neutrophilic inflammation. Interleukin-23 is a proinflammatory cytokine involved in neutrophilic inflammation. However, little is known about its role in acute exacerbation of pulmonary fibrosis. This study was performed to determine the role of interleukin-23 in acute exacerbation of pulmonary fibrosis. For assessment of acute exacerbation of pulmonary fibrosis, mice were intratracheally administered bleomycin followed by lipopolysaccharide. Inflammatory cells, cytokine levels, and morphological morphometry of the lungs were analyzed. Cytokine levels were measured in the bronchoalveolar lavage fluid of idiopathic pulmonary fibrosis patients with or without acute exacerbation. Interleukin-23, -17A, and -22 levels were increased in the airway of mice with acute exacerbation of pulmonary fibrosis. Interleukin-23p19-deficient mice with acute exacerbation of pulmonary fibrosis had markedly reduced airway inflammation and fibrosis associated with decreased levels of interleukin-17A and -22 compared with wild-type mice. Treatment with an anti-interleukin-23 antibody attenuated airway inflammation and fibrosis and reduced interleukin-17A and -22 levels in mice with acute exacerbation of pulmonary fibrosis. T-helper type 17 cells were the predominant source of interleukin-17A in mice with acute exacerbation of pulmonary fibrosis. Interleukin-23 levels in bronchoalveolar lavage fluid tended to be higher in idiopathic pulmonary fibrosis patients with than without acute exacerbation. The data presented here suggest that interleukin-23 is essential for the development of acute exacerbation of pulmonary fibrosis and that blockade of interleukin-23 may be a new therapeutic strategy for acute exacerbation of pulmonary fibrosis.

    DOI: 10.1152/ajplung.00582.2020

    PubMed

    researchmap

  • Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression. 査読 国際誌

    Nobuaki Ochi, Eiki Ichihara, Nagio Takigawa, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    European journal of cancer (Oxford, England : 1990)   157   523 - 524   2021年11月

     詳細を見る

    担当区分:最終著者   記述言語:英語  

    DOI: 10.1016/j.ejca.2021.07.044

    PubMed

    researchmap

  • Dramatic Response to Carboplatin Plus Paclitaxel in Pancreatic Mucinous Cystadenocarcinoma with Liver Metastasis. 査読

    Naohiro Oda, Masahiro Tabata, Masatoshi Uno, Yuzo Umeda, Hironari Kato, Toshio Kubo, Satoru Senoo, Takahito Yagi, Toshiyoshi Fujiwara, Yoshinobu Maeda, Katsuyuki Kiura

    Internal medicine (Tokyo, Japan)   60 ( 18 )   2967 - 2971   2021年9月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Mucinous cystic neoplasm (MCN) of the pancreas is a rare cystic tumor occurring in the pancreatic body and tail in young to middle-aged women that is pathologically characterized by an ovarian-like stroma. Chemotherapy for recurrent/advanced pancreatic MCN has been based on chemotherapy regimens for pancreatic ductal adenocarcinoma, but the prognosis is poor. We herein report a 37-year-old woman with pancreatic mucinous cystadenocarcinoma with liver metastasis that responded dramatically to carboplatin plus paclitaxel therapy (CBDCA+PTX). CBDCA+PTX may be a treatment option for recurrent/advanced pancreatic MCN with an ovarian-like stroma.

    DOI: 10.2169/internalmedicine.6730-20

    PubMed

    researchmap

  • Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease. 査読

    Sachi Okawa, Kammei Rai, Nobuharu Fujii, Yuka Gion, Kiichiro Ninomiya, Yuka Kato, Akihiko Taniguchi, Toshio Kubo, Eiki Ichihara, Kadoaki Ohashi, Nobuaki Miyahara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Internal medicine (Tokyo, Japan)   60 ( 17 )   2831 - 2837   2021年9月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A 68-year-old man presented with a solid mass at the left renal pelvis and ureter with multiple systemic lymphadenopathies and a mass with a cavity in the right lower lobe of the lung. While a transbronchial lung biopsy revealed no malignancy, a biopsy of the renal pelvis showed marginal zone lymphoma with polyclonal IgG4-positive cells. The serum IgG4 level and presence of a bilateral orbital mass suggested Mikulicz disease. The lesions shrank following the administration of steroids. A rebiopsy confirmed lung adenocarcinoma, and its background showed IgG4-positive cells a year later. IgG4-related diseases require careful follow-up because they can be complicated by malignancy.

    DOI: 10.2169/internalmedicine.6470-20

    PubMed

    researchmap

  • A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401. 招待 査読 国際誌

    Kiichiro Ninomiya, Toshihide Yokoyama, Katsuyuki Hotta, Isao Oze, Kuniaki Katsui, Tae Hata, Hiroshige Yoshioka, Akihiro Bessho, Shinobu Hosokawa, Shoichi Kuyama, Kenichiro Kudo, Toshiyuki Kozuki, Daijiro Harada, Masayuki Yasugi, Toshi Murakami, Masamoto Nakanishi, Nagio Takigawa, Yoshinobu Maeda, Katsuyuki Kiura

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   29 ( 9 )   5237 - 5244   2021年9月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Radiation esophagitis is a critical adverse event that needs to be appropriately managed while administering thoracic irradiation. This trial aimed to investigate whether sodium alginate has preventative effects on esophagitis in patients with non-small-cell lung cancer (NSCLC) receiving concurrent chemoradiotherapy (CRT). METHODS: Patients with untreated stage III NSCLC who were eligible for concurrent CRT were randomly assigned at a 1:1:1 ratio to receive one of the following treatments: initial or late use of oral sodium alginate (arms A and B) or water as control (arm C). The primary endpoint was the proportion of patients developing G3 or worse esophagitis. RESULTS: Overall, 94 patients were randomly assigned between February 2014 and September 2018. The study was prematurely terminated because of slow accrual. The proportions of patients with G3 or worse esophagitis were 12.5%, 9.8%, and 19.4% in arms A, B, and C, respectively. Patients receiving sodium alginate had fewer onsets of G3 esophagitis; however, differences compared with arm C were not significant (A vs. C: p = 0.46; B vs. C: p = 0.28). The rates of grade 3 or worse non-hematologic toxicities besides esophagitis were 29%, 26%, and 43% in arms A, B, and C, respectively. Interestingly, compared with arm C, a low rate of febrile neutropenia was observed in arm A (3.1% vs. 19.4%: p = 0.04). CONCLUSIONS: Sodium alginate did not show significant preventative effects on radiation-induced esophagitis in patients with NSCLC. The frequency of CRT-induced febrile neutropenia was lower in the early use sodium alginate arm. TRIAL REGISTRATION: ClinicalTrials.gov Identifier Registry number: UMIN000013133.

    DOI: 10.1007/s00520-021-06092-1

    PubMed

    researchmap

  • Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression. 査読 国際誌

    Kazuya Nishii, Kadoaki Ohashi, Hiromi Watanabe, Go Makimoto, Takamasa Nakasuka, Hisao Higo, Kiichiro Ninomiya, Yuka Kato, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Oncology letters   22 ( 3 )   639 - 639   2021年9月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Osimertinib, a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is the standard treatment for patients with lung cancer harboring EGFR T790M; however, acquired resistance is inevitable due to genetic and epigenetic changes in cancer cells. In addition, a recent randomized clinical trial revealed that the combination of osimertinib and bevacizumab failed to exhibit superior progression-free survival compared with osimertinib alone. The present study aimed to investigate the effect of triple therapy with osimertinib, bevacizumab and cetuximab in xenograft tumors with different initial tumor volumes (conventional model, 200 mm3 and large model, 500 mm3). The results demonstrated that osimertinib significantly inhibited tumor growth in both the conventional and large models; however, maximum tumor regression was attenuated in the large model in which hypoxia-inducible factor-1α (HIF-1α) and transforming growth factor-α (TGF-α) expression levels increased. Although the combination of osimertinib and bevacizumab exerted a greater inhibitory effect on tumor growth compared with osimertinib in the conventional model, the effect of this combination therapy was attenuated in the large model. TGF-α attenuated sensitivity to osimertinib in vitro; however, this negative effect was counteracted by the combination of osimertinib and cetuximab, but not osimertinib and bevacizumab. In the large xenograft tumor model, the triple therapy induced the greatest inhibitory effect on tumor growth compared with osimertinib alone and its combination with bevacizumab. Clinical trials of the triple therapy are required for patients with lung cancer with EGFR mutations and HIF-1α/TGF-α.

    DOI: 10.3892/ol.2021.12900

    PubMed

    researchmap

  • Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan: A Case Report. 査読

    Eri Ando, Takamasa Nakasuka, Toshio Kubo, Akihiko Taniguchi, Kiichiro Ninomiya, Yuka Kato, Eiki Ichihara, Kadoaki Ohashi, Kammei Rai, Katsuyuki Hotta, Masaomi Yamane, Nobuaki Miyahara, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Internal medicine (Tokyo, Japan)   2021年8月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A 16-year-old boy with asthma participated in recovery volunteer work following the 2018 heavy rains in Japan. One month later, he experienced chest pain and dyspnea. Chest computed tomography revealed a cavity with a fungal ball, and Aspergillus fumigatus was detected in his bronchoalveolar lavage fluid. He was treated with voriconazole, but new consolidations appeared rapidly. He also experienced allergic bronchopulmonary aspergillosis. After prednisolone prescription, the consolidations improved; however, his asthma worsened. He underwent partial lung resection to avoid allergens, and his symptoms improved. We must recognize cases of infection after a disaster, especially in patients with chronic respiratory diseases.

    DOI: 10.2169/internalmedicine.7124-21

    PubMed

    researchmap

  • Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. 査読 国際誌

    Takashi Ninomiya, Naoyuki Nogami, Toshiyuki Kozuki, Daijiro Harada, Toshio Kubo, Kadoaki Ohashi, Eiki Ichihara, Shoichi Kuyama, Kenichiro Kudo, Akihiro Bessho, Makoto Sakugawa, Nobukazu Fujimoto, Keisuke Aoe, Daisuke Minami, Keisuke Sugimoto, Nobuaki Ochi, Nagio Takigawa, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Japanese journal of clinical oncology   51 ( 8 )   1269 - 1276   2021年8月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: In a phase I study, afatinib (30 mg/body daily) plus bevacizumab (15 mg/kg every 3 weeks) was well tolerated and showed favourable outcomes in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer. Herein, we report the 2-year progression-free survival, overall survival and safety profile of these patients. METHODS: Chemo-naïve patients with EGFR-mutant advanced non-small-cell lung cancer were enrolled. One group of patients received 40 mg afatinib daily and 15 mg/kg bevacizumab every 3 weeks (level 0) until disease progression or severe toxicity. Another group of patients received 30 mg afatinib daily and the same dose of bevacizumab (level 1). Dose-limiting toxicity was the primary endpoint, whereas long-term progression-free survival, overall survival and tolerability were secondary endpoints. Survival rates were estimated using the Kaplan-Meier method. RESULTS: The study included 19 patients (level 0: 5; level - 1: 14). Until the data cut-off date, seven patients continued the treatment, whereas 12 discontinued due to disease progression (n = 5) or toxicity (n = 7). The median PFS was 24.2 months, while the median overall survival was not reached. All patients developed adverse effects. Diarrhoea and skin rash were frequently observed as severe adverse events (grade 3). A secondary EGFR mutation (T790M) was detected in two patients after progression. CONCLUSIONS: Prolonged follow-up revealed that combination therapy with afatinib and bevacizumab might improve survival outcomes in EGFR-mutant advanced non-small-cell lung cancer patients and seems to be promising. TRIAL REGISTRATION: UMIN000015944.

    DOI: 10.1093/jjco/hyab084

    PubMed

    researchmap

  • Erratum to: Impact of previous thoracic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer. 国際誌

    Shinobu Hosokawa, Eiki Ichihara, Akihiro Bessho, Daijiro Harada, Koji Inoue, Takuo Shibayama, Daizo Kishino, Shingo Harita, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Japanese journal of clinical oncology   51 ( 8 )   1348 - 1348   2021年8月

     詳細を見る

    担当区分:最終著者   記述言語:英語  

    DOI: 10.1093/jjco/hyab113

    PubMed

    researchmap

  • Sarcopenia is related to poor prognosis in patients after trimodality therapy for locally advanced non-small cell lung cancer. 査読

    Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Kotaro Yoshio, Masahiro Kuroda, Masaomi Yamane, Takao Hiraki, Katsuyuki Kiura, Shinichi Toyooka, Susumu Kanazawa

    International journal of clinical oncology   26 ( 8 )   1450 - 1460   2021年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The association between sarcopenia and prognosis in patients with locally advanced non-small cell lung cancer (NSCLC) undergoing trimodality therapy, consisting of preoperative concurrent chemoradiotherapy and surgery, has not been reported. Therefore, we aimed to investigate the association of sarcopenia and fat mass with prognosis after trimodality therapy. METHODS: To assess sarcopenia, the psoas muscle mass was measured. Using computed tomography data, including third lumbar vertebra level images, psoas muscle mass and visceral and subcutaneous fat mass were measured. Additionally, body mass indices, and visceral/subcutaneous fat ratio, obtained by dividing the visceral fat index by the subcutaneous fat index, were calculated. We investigated the relationship between these parameters and overall survival. RESULTS: Ninety-nine eligible patients were included. In the univariate analysis, age, clinical stage, tumor location, psoas muscle index, and visceral/subcutaneous fat ratio were significant prognostic factors for overall survival (P = 0.008, P = 0.04, P = 0.04, P = 0.02, and P = 0.02, respectively). In the multivariate analysis, age and psoas muscle index were significant prognostic factors for overall survival (P = 0.01 and P = 0.03, respectively). The 5-year overall survival rates for the high and low psoas muscle index groups were 79.6% [95% confidence interval (CI), 67.1-94.5%] and 66.2% (95% CI, 54.1-81.1%), respectively; whereas, the 10-year overall survival rates were 61.9% (95% CI, 42.0-91.4%) and 25.3% (95% CI, 8.6-74.2%), respectively. CONCLUSION: Sarcopenia was related to poor overall survival in patients with locally advanced NSCLC undergoing trimodality therapy. Assessment of body composition prior to treatment may provide important information for formulating rational therapeutic strategies.

    DOI: 10.1007/s10147-021-01927-7

    PubMed

    researchmap

  • Chemopreventive effects and anti-tumorigenic mechanisms of 2,6-dimethoxy-1,4-benzoquinone, a constituent of Vitis coignetiae Pulliat (crimson glory vine, known as yamabudo in Japan), toward 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in A/J mice. 査読 国際誌

    Sakae Arimoto-Kobayashi, Kensuke Sasaki, Ryoko Hida, Naoko Miyake, Nana Fujii, Yusuke Saiki, Kyohei Daimaru, Hirono Nakashima, Toshio Kubo, Katsuyuki Kiura

    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association   154   112319 - 112319   2021年8月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Previously, we isolated and identified anti-mutagenic and anti-inflammatory components from Vitis coignetiae (crimson glory vine, known as yamabudo in Japan) as 2,6-dimethoxy-1,4-benzoquinone (DBQ), fertaric acid and caftaric acid. We also reported that the oral intake of a partially purified fraction from yamabudo juice (yamabudo-fr) or DBQ affords significant protection against two-stage skin carcinogenesis in mice. In this study, we found that oral intake of yamabudo-fr or DBQ affords significant protection against a tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced mouse model of lung tumorigenesis. Furthermore, we investigated the anti-tumorigenic mechanisms of yamabudo juice and DBQ. NNK is known to be a DNA-methylating and alkylating agent; thus, we investigated the anti-tumorigenic mechanisms of yamabudo juice and DBQ in relation to DNA methylation. Pretreatment with yamabudo-fr or DBQ dose-dependently decreased formation of O6-methylguanine and N7-methylguanine in DNA of the A549 human lung epithelial-like cell line treated with a methylating agent, 1-methyl-3-nitro-1-nitrosoguanidine. Yamabudo juice and DBQ inhibited the mutagenicity of NNK in the Ames test using Salmonella typhimurium TA1535 but not S. typhimurium YG7108, an alkylguanine DNA alkyltransferase-deficient strain (same as TA1535 but Δadast::Kmr, Δogtst::Cmr). Yamabudo juice and DBQ might accelerate the repair of DNA damage caused by NNK and reduce DNA damage to cells. We also investigated the effects of yamabudo juice and DBQ on signaling pathways in A549 cells. With or without epidermal growth factor stimulation, phosphorylation of Erk1/2, Akt and Stat3 in A549 cells was significantly decreased in the presence of yamabudo juice or DBQ, indicating that yamabudo juice and DBQ suppressed PI3K/AKT, MAPK/ERK and JAK/STAT3 signaling pathways. These results suggest that both initiation and growth/progression steps in carcinogenesis, especially anti-oxidant effects, stimulation of repair of alkyl DNA adducts and suppressed growth signaling pathways are potential anti-tumorigenic targets of yamabudo juice and DBQ in NNK-induced lung tumorigenesis.

    DOI: 10.1016/j.fct.2021.112319

    PubMed

    researchmap

  • Publisher Correction: Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis. 査読 国際誌

    Kuniaki Katsui, Takeshi Ogata, Soichi Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Scientific reports   11 ( 1 )   14586 - 14586   2021年7月

     詳細を見る

  • Chronic Lung Injury After Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer. 国際誌

    Junichi Soh, Seiichiro Sugimoto, Kei Namba, Akihiro Miura, Toshio Shiotani, Haruchika Yamamoto, Ken Suzawa, Kazuhiko Shien, Hiromasa Yamamoto, Mikio Okazaki, Kuniaki Katsui, Masaomi Yamane, Katsuyuki Kiura, Susumu Kanazawa, Shinichi Toyooka

    The Annals of thoracic surgery   112 ( 1 )   279 - 288   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Trimodality therapy is a treatment option for patients with locally advanced non-small cell lung cancer (LA-NSCLC). Thoracic radiation has both early (radiation pneumonitis) and late (chronic lung injury [CLI]) adverse effects on the lung. While CLI is expected to result in various problems in long-term survivors, these manifestations have not been precisely investigated. METHODS: We enrolled 112 LA-NSCLC patients who had received induction chemoradiotherapy followed by surgery, and then undergone follow-up computed tomography (CT) every 6 months for greater than 1 year. All chest CT images were reviewed to evaluate any injury of the pulmonary parenchyma. RESULTS: CLI at 1 year after surgery and its progression were observed in 94 (84%) and 38 (34%) patients, respectively. Progressive lung fibrosis as the first manifestation of CLI progression was most frequent after right middle and lower lobectomy. Cavity formation was the subsequent manifestation after progressive lung fibrosis , and chronic infection was the final stage of CLI. The cumulative rate of chronic infection was 76.4% at 10 years in patients with cavity formation. Ten patients with chronic infection included 7 cases of pulmonary aspergillosis and 2 cases of cavity infections with methicillin-resistant Staphylococcus aureus or Stenotrophomonas maltophilia. Among them, 4 patients required surgical interventions including completion pneumonectomy or fenestration. CONCLUSIONS: CLI is a common incidence after trimodality therapy for LA-NSCLC. CLI frequently results in cavity formation, which is a precursor of highly refractory chronic infections requiring surgical intervention. Appropriate management needs to be established for CLI developing after trimodality therapy.

    DOI: 10.1016/j.athoracsur.2020.07.068

    PubMed

    researchmap

  • A case of interstitial pneumonia associated with systemic sclerosis and primary peritoneal serous carcinoma successfully treated with cyclophosphamide. 査読 国際誌

    Shunichi Kawamura, Toshio Kubo, Kenji Takada, Ryota Sunami, Sachi Okawa, Yoshitaka Iwamoto, Atsuko Hirabae, Akihiko Taniguchi, Yoshinobu Maeda, Katsuyuki Kiura, Masahiro Tabata

    International cancer conference journal   10 ( 3 )   197 - 200   2021年7月

     詳細を見る

    記述言語:英語  

    A 62-year-old woman with edema and color changes in her fingers underwent computed tomography (CT); slight interstitial changes were detected in the lungs with multiple tumors in the anterior and hilar region of the liver. Based on the blood test findings, she was diagnosed with interstitial pneumonia associated with systemic sclerosis. Ultrasound-guided biopsy from the hepatic hilar lymph node revealed poorly differentiated serous adenocarcinoma cells. High serum CA-125 levels suggested primary peritoneal serous carcinoma (PPSC). Owing to increased interstitial shadows on chest CT images and worsening respiratory distress, intravenous cyclophosphamide and oral prednisolone treatment was started. The skin-related symptoms, respiratory distress, and interstitial shadows improved, and the tumor size reduced. Eighteen months later, the patient has had no exacerbation of interstitial pneumonia, and the PPSC is well controlled.

    DOI: 10.1007/s13691-021-00475-1

    PubMed

    researchmap

  • SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non-small Cell Lung Cancer. 査読 国際誌

    Hirohisa Kano, Eiki Ichihara, Hiromi Watanabe, Kazuya Nishii, Chihiro Ando, Takamasa Nakasuka, Kiichiro Ninomiya, Yuka Kato, Toshio Kubo, Kammei Rai, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Molecular cancer therapeutics   20 ( 9 )   1653 - 1662   2021年6月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    After molecular-targeted therapy, some cancer cells may remain that are resistant to therapies targeting oncogene alterations, such as those in the genes encoding the EGFR and anaplastic lymphoma kinase (ALK) as well as c-ros oncogene 1 (ROS1). The mechanisms underlying this type of resistance are unknown. In this article, we report the potential role of Src homology 2 domain-containing phosphatase 2 (SHP2) in the residual cells of ALK/ROS1/EGFR-altered non-small cell lung cancer (NSCLC). Molecular-targeted therapies failed to inhibit the ERK signaling pathway in the residual cells, whereas the SHP2 inhibitor SHP099 abolished their remaining ERK activity. SHP099 administered in combination with molecular-targeted therapy resulted in marked growth inhibition of cancer cells both in vitro and in vivo Thus, treatment combining an SHP2 inhibitor and a tyrosine kinase inhibitor may be a promising therapeutic strategy for oncogene-driven NSCLC.

    DOI: 10.1158/1535-7163.MCT-20-0965

    PubMed

    researchmap

  • Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis. 査読 国際誌

    Kuniaki Katsui, Takeshi Ogata, Soichi Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Scientific reports   11 ( 1 )   11882 - 11882   2021年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We intended to investigate whether muscle and adipose masses were associated with prognosis among patients with stage III non-small-cell lung cancer (NSCLC) who were undergoing chemoradiotherapy (CCRT). We retrospectively explored data of patients with stage III NSCLC who underwent definitive CCRT (≥ 60 Gy) between January 2004 and March 2018 at our hospital. We examined the relationship of overall survival (OS) with body mass index (BMI), skeletal muscle index (SMI), psoas muscle index (PMI), visceral adipose tissue index (VAI), subcutaneous adipose tissue index (SAI), and visceral-to-subcutaneous adipose tissue area ratio (VSR) using log-rank tests for the univariate analysis and Cox proportional hazard models for the multivariate analysis. Overall, 16, 32, and 12 patients had stage IIIA, IIIB, and IIIC NSCLC, respectively. The total radiotherapy dose ranged from 60 Gy/30 fractions to 66 Gy/33 fractions. In the univariate analysis, the performance status (PS), BMI, and SMI were associated with OS, whereas the PMI, VAI, SAI, and VSR were not. In the multivariate analysis, the PS and SMI were associated with OS. The hazard ratios and 95% confidence intervals were 2.91 and 1.28-6.64 for PS, and 2.36 and 1.15-4.85 for SMI, respectively. The 1, 3, and 5-year OS rates were 92.1%, 59.6%, and 51.0% in patients with high SMI, and 63.6%, 53.8%, and 17.9% in patients with low SMI, respectively. The SMI correlated with prognosis in our study population, whereas adipose mass did not. Therefore, sarcopenia should be considered while predicting the OS in such patients.

    DOI: 10.1038/s41598-021-91449-z

    PubMed

    researchmap

  • Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer. 査読

    Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Acta medica Okayama   75 ( 3 )   269 - 277   2021年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Palliative concurrent chemoradiotherapy (CCRT) is often administered to patients with stage III non-small cell lung cancer (NSCLC). We investigated the clinical outcomes of patients receiving palliative CCRT for NSCLC. Data of patients with NSCLC who underwent palliative CCRT (n=16), preoperative CCRT plus surgery (n=97), or definitive CCRT (n=48) were evaluated. In all groups, the concurrent chemotherapy regimens consisted of cisplatin and docetaxel. Rates of local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), overall survival (OS), and prognosis were compared. The 2-year rates of LC, DMFS, PFS, and OS in 16 patients who underwent palliative CCRT were 44.4%, 12.5%, 12.5%, and 18.8%, respectively. Univariate analysis showed that palliative CCRT was associated with poor LC (p<0.001), DMFS (p<0.001), PFS (p<0.001), and OS (p<0.001) outcomes in patients who completed CCRT as a preoperative treatment and poor LC (p=0.01), DMFS (p=0.003), PFS (p=0.04), and OS (p=0.004) outcomes in patients who were considered for definitive CCRT. Although there were some long-term survivors, the clinical outcomes of palliative CCRT were significantly inferior to those of the ideal treatments. Therefore, careful determination of the appropriate treatment indications and further studies are warranted.

    DOI: 10.18926/AMO/62218

    PubMed

    researchmap

  • Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset. 査読 国際誌

    Kazuto Nishio, Takashi Seto, Makoto Nishio, Martin Reck, Edward B Garon, Kazuko Sakai, Koichi Goto, Terufumi Kato, Yoichi Nakanishi, Toshiaki Takahashi, Nobuyuki Yamamoto, Katsuyuki Kiura, Yuichiro Ohe, Tomohide Tamura, Carla Visseren-Grul, Bente Frimodt-Moller, Rebecca R Hozak, Sameera R Wijayawardana, Annamaria Zimmermann, Gosuke Homma, Sotaro Enatsu, Kazuhiko Nakagawa

    JTO clinical and research reports   2 ( 6 )   100171 - 100171   2021年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Introduction: The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL) compared with placebo plus ERL (PL + ERL) in untreated EGFR-mutated metastatic NSCLC (hazard ratio [HR] = 0.59 [95% confidence interval (CI): 0.46-0.76, p < 0.0001]). This prespecified analysis evaluates efficacy, safety, and postprogression EGFR T790M rates of RELAY patients enrolled in Japan. Methods: Patients were randomized (1:1) to oral ERL (150 mg/d) plus intravenous RAM (10 mg/kg) or PL every 2 weeks. End points included PFS (primary), safety (secondary), and biomarker analyses (exploratory). Plasma samples collected at baseline and poststudy treatment discontinuation were evaluated for EGFR T790M mutations by next-generation sequencing. Results: The Japanese subset included 211 of 449 (47.0%) RELAY patients (RAM + ERL, n = 106; PL + ERL, n = 105). Median PFS was 19.4 versus 11.2 months for RAM + ERL versus PL + ERL treatment (HR = 0.610 [0.431-0.864]) in the Japanese intent-to-treat population, 16.6 versus 12.5 months (HR = 0.701 [0.424-1.159]) in the EGFR exon 19 deletion subgroup, and 19.4 versus 10.9 months (HR = 0.514 [0.317-0.835]) in the EGFR exon 21 L858R subgroup, respectively. Adverse events of grade 3 or above with RAM + ERL included hypertension (24.8%, all grade 3) and dermatitis acneiform (23.8%). Postprogression treatment-emergent T790M rates were similar between arms (RAM + ERL: 47%, 9 of 19 patients; PL + ERL: 50%, 20 of 40 patients). Conclusions: Clinically meaningful efficacy was observed with RAM + ERL versus PL + ERL in the RELAY Japanese subset, with no new safety concerns. Postprogression T790M rates were similar across treatment arms, indicating the addition of RAM did not affect the ERL-associated EGFR T790M rates at disease progression.

    DOI: 10.1016/j.jtocrr.2021.100171

    PubMed

    researchmap

  • A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations. 査読 国際誌

    Takamasa Nakasuka, Kadoaki Ohashi, Hiromi Watanabe, Toshio Kubo, Shingo Matsumoto, Koichi Goto, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Lung cancer (Amsterdam, Netherlands)   156   1 - 4   2021年6月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Pembrolizumab is a standard treatment for non-small cell lung cancer (NSCLC) with high-PD-L1 expression; however, its effect is dismal in patients with poor physical condition. Additionally, the effect of immunotherapy is generally limited in NSCLC harboring driver mutations such asEGFR, ALK, or RET gene aberrations. RESULTS: We report the beneficial effect of pembrolizumab in a patient with poor performance status and PD-L1+ lung adenocarcinoma with theCCDC6-RET fusion gene and co-occurring NF1/TP53 mutations, complicated by multiple cancer-associated thrombi and respiratory failure. CONCLUSIONS: Further studies are warranted to establish the role of co-occurring NF1/TP53 mutations as a positive predictive biomarker for pembrolizumab in NSCLC harboring RET fusion genes.

    DOI: 10.1016/j.lungcan.2021.03.022

    PubMed

    researchmap

  • A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. 査読 国際誌

    Go Makimoto, Kiichiro Ninomiya, Toshio Kubo, Ryota Sunami, Yuka Kato, Eiki Ichihara, Kadoaki Ohashi, Kammei Rai, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Japanese journal of clinical oncology   51 ( 6 )   956 - 965   2021年5月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: A third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, is the standard treatment for patients with non-small cell lung cancer harbouring mutant EGFR. Unfortunately, these patients inevitably acquire resistance to EGFR-TKI therapies, including osimertinib. However, the mechanism associated with this resistance remains unclear. METHODS: A 63-year-old Japanese female with lung adenocarcinoma underwent right upper lobectomy (pT1bN2M0 pStage IIIA, EGFR Ex21 L858R). She manifested post-operative tumour recurrence with multiple lung metastases 8 months later and began gefitinib treatment. The lung lesions re-grew 15 months later, and EGFR T790M mutation was detected in the lung metastasis re-biopsy. She was administered osimertinib; however, it relapsed with pleural effusion 16 months later. We isolated cells from the osimertinib-resistant pleural effusion to establish a novel cell line, ABC-31. RESULTS: Although the EGFR L858R mutation was detected in ABC-31 cells, the T790M mutation was lost. ABC-31 cells were resistant to EGFR-TKIs, including osimertinib. Phospho-receptor tyrosine kinase array revealed activation of the insulin-like growth factor 1 receptor (IGF1R), whereas overexpression of the IGF1R ligand, IGF2, induced IGF1R activation in ABC-31 cells. Combination therapy using EGFR-TKIs and IGF1R inhibitor acted synergistically in vitro. She was re-administered osimertinib since EGFR-TKIs and IGF1R inhibitor combination therapy was impossible in clinical practice. This had a slight and short-lived effect. CONCLUSIONS: Taken together, we have successfully established a new osimertinib-resistant lung adenocarcinoma cell line with activated IGF1R. These ABC-31 cells will help develop novel therapeutic strategies for patients with lung adenocarcinoma resistant to specific treatment via IGF1R activation.

    DOI: 10.1093/jjco/hyab048

    PubMed

    researchmap

  • Loss of IL-33 enhances elastase-induced and cigarette smoke extract-induced emphysema in mice. 査読 国際誌

    Daisuke Morichika, Akihiko Taniguchi, Naohiro Oda, Utako Fujii, Satoru Senoo, Junko Itano, Arihiko Kanehiro, Yoshiaki Kitaguchi, Masanori Yasuo, Masayuki Hanaoka, Takashi Satoh, Shizuo Akira, Katsuyuki Kiura, Yoshinobu Maeda, Nobuaki Miyahara

    Respiratory research   22 ( 1 )   150 - 150   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: IL-33, which is known to induce type 2 immune responses via group 2 innate lymphoid cells, has been reported to contribute to neutrophilic airway inflammation in chronic obstructive pulmonary disease. However, its role in the pathogenesis of emphysema remains unclear. METHODS: We determined the role of interleukin (IL)-33 in the development of emphysema using porcine pancreas elastase (PPE) and cigarette smoke extract (CSE) in mice. First, IL-33-/- mice and wild-type (WT) mice were given PPE intratracheally. The numbers of inflammatory cells, and the levels of cytokines and chemokines in the bronchoalveolar lavage (BAL) fluid and lung homogenates, were analyzed; quantitative morphometry of lung sections was also performed. Second, mice received CSE by intratracheal instillation. Quantitative morphometry of lung sections was then performed again. RESULTS: Intratracheal instillation of PPE induced emphysematous changes and increased IL-33 levels in the lungs. Compared to WT mice, IL-33-/- mice showed significantly greater PPE-induced emphysematous changes. No differences were observed between IL-33-/- and WT mice in the numbers of macrophages or neutrophils in BAL fluid. The levels of hepatocyte growth factor were lower in the BAL fluid of PPE-treated IL-33-/- mice than WT mice. IL-33-/- mice also showed significantly greater emphysematous changes in the lungs, compared to WT mice, following intratracheal instillation of CSE. CONCLUSION: These observations suggest that loss of IL-33 promotes the development of emphysema and may be potentially harmful to patients with COPD.

    DOI: 10.1186/s12931-021-01705-z

    PubMed

    researchmap

  • VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers 査読 国際誌

    Hiromi Watanabe, Eiki Ichihara, Hiroe Kayatani, Go Makimoto, Kiichiro Ninomiya, Kazuya Nishii, Hisao Higo, Chihiro Ando, Sachi Okawa, Takamasa Nakasuka, Hirohisa Kano, Naofumi Hara, Atsuko Hirabae, Yuka Kato, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    CANCER SCIENCE   112 ( 5 )   1853 - 1864   2021年5月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY  

    Molecular agents targeting the epidermal growth factor receptor (EGFR)-, anaplastic lymphoma kinase (ALK)- or c-ros oncogene 1 (ROS1) alterations have revolutionized the treatment of oncogene-driven non-small-cell lung cancer (NSCLC). However, the emergence of acquired resistance remains a significant challenge, limiting the wider clinical success of these molecular targeted therapies. In this study, we investigated the efficacy of various molecular targeted agents, including erlotinib, alectinib, and crizotinib, combined with anti-vascular endothelial growth factor receptor (VEGFR) 2 therapy. The combination of VEGFR2 blockade with molecular targeted agents enhanced the anti-tumor effects of these agents in xenograft mouse models of EGFR-, ALK-, or ROS1-altered NSCLC. The numbers of CD31-positive blood vessels were significantly lower in the tumors of mice treated with an anti-VEGFR2 antibody combined with molecular targeted agents compared with in those of mice treated with molecular targeted agents alone, implying the antiangiogenic effects of VEGFR2 blockade. Additionally, the combination therapies exerted more potent antiproliferative effects in vitro in EGFR-, ALK-, or ROS1-altered NSCLC cells, implying that VEGFR2 inhibition also has direct anti-tumor effects on cancer cells. Furthermore, VEGFR2 expression was induced following exposure to molecular targeted agents, implying the importance of VEGFR2 signaling in NSCLC patients undergoing molecular targeted therapy. In conclusion, VEGFR2 inhibition enhanced the anti-tumor effects of molecular targeted agents in various oncogene-driven NSCLC models, not only by inhibiting tumor angiogenesis but also by exerting direct antiproliferative effects on cancer cells. Hence, combination therapy with anti-VEGFR2 antibodies and molecular targeted agents could serve as a promising treatment strategy for oncogene-driven NSCLC.

    DOI: 10.1111/cas.14801

    Web of Science

    PubMed

    researchmap

  • The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. 査読 国際誌

    Nobuaki Ochi, Eiki Ichihara, Nagio Takigawa, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    European journal of cancer (Oxford, England : 1990)   149   73 - 81   2021年5月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Immune checkpoint inhibitors (ICIs) are essential for treatment of various malignancies, including non-small-cell lung cancer (NSCLC). Recently, several studies have shown that the gut microbiome plays an important role in ICI treatment of solid cancers, and antibiotic (ATB) use had a negative impact on the outcomes of ICI treatment via dysbiosis in the gut. However, whether this is applicable to NSCLC remains unclear. The impact of ATBs based on PD-L1 expression also remains unclear. METHODS: We retrospectively reviewed the medical records of patients with NSCLC who received ICI monotherapy (anti-PD-1 or anti-PD-L1 antibody) at nine institutions from December 2015 to May 2018. Outcomes with use of ATBs during the 2 months before or a month after initiation of ICI treatment, including progression-free survival (PFS) and overall survival (OS), were investigated using the Kaplan-Meier method. Multivariate analysis was also conducted using a Cox proportional hazards model. RESULTS: A total of 531 patients were included in this study, among whom 98 (18.5%) received ATBs before or after ICI treatment. ATB use was significantly associated with a shorter median OS (11.7 months in the ATB group vs. 16.1 months in the non-ATB group; p = 0.028), whereas the difference in PFS was not significant (3.5 months in both the groups; p = 0.287). We next investigated the association based on PD-L1 expression in the 265 patients for whom PD-L1 expression was determined. There was no significant difference in the median OS or PFS between patients with NSCLC and PD-L1 expression <50% receiving ATBs and those not receiving ATBs (PFS: 3.3 vs. 2.8 months, p = 0.88; OS: 9.5 vs. 17.1 months, p = 0.24). Conversely, patients with NSCLC and PD-L1 expression ≥50% receiving ATBs showed significantly shorter median PFS and OS (PFS: 4.2 vs. 9.4 months, p = 0.012; OS: 11.9 vs. 28.4 months, p = 0.011). The impact of ATBs in patients with NSCLC and PD-L1 expression ≥50% was more significant than that in the entire cohort. CONCLUSIONS: Our results indicate that the impact of ATB use on the efficacy of ICIs differed based on PD-L1 expression in patients with advanced NSCLC. A negative impact of ATB use was found in patients with NSCLC and PD-L1 expression ≥50% but not in those with PD-L1 expression <50%.

    DOI: 10.1016/j.ejca.2021.02.040

    PubMed

    researchmap

  • A PET/CT volumetric parameter predicts prognosis of non-small cell lung cancer treated using preoperative chemoradiotherapy and surgery: A retrospective case series study. 査読 国際誌

    Kuniaki Katsui, Takeshi Ogata, Akihiro Tada, Kenta Watanabe, Kotaro Yoshio, Masahiro Kuroda, Katsuyuki Kiura, Takao Hiraki, Shinichi Toyooka, Susumu Kanazawa

    Molecular and clinical oncology   14 ( 4 )   73 - 73   2021年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The purpose of the present study was to clarify whether positron emission tomography/computed tomography (PET/CT) volumetric parameters were prognostic predictors of non-small cell lung cancer (NSCLC) treatment in patients who had undergone preoperative concurrent chemoradiotherapy (CCRT) and surgery. In the present study, retrospectively surveyed the data of patients with NSCLC who underwent preoperative CCRT and surgery at Okayama University Hospital (Okayama, Japan) between April 2006 and March 2018. The maximum standardized uptake value (SUVmax) and volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), were calculated using PET/CT and the percentage decrease (Δ) in each parameter value post-CCRT. The SUVmax threshold for defining MTV was set at 2.5. Furthermore, the association between survival and PET parameter values was analyzed. A total of 52 patients were included in the present study. The median follow-up period was 50.65 months. In univariate analysis, ΔTLG was identified to be a significant predictor of progression-free survival (PFS; P=0.03). The 5-year PFS rates were 48.6 and 76.6% for patients with low ΔTLG and high ΔTLG, respectively. High ΔTLG was indicative of a higher overall survival rate (P=0.08). The present results suggest that ΔTLG calculated using PET/CT is a prognostic predictor of NSCLC treated using preoperative CCRT and surgery, and may help physicians determine treatment strategies.

    DOI: 10.3892/mco.2021.2235

    PubMed

    researchmap

  • Interstitial Pneumonia Secondary to Hermansky-Pudlak Syndrome Type 4 Treated with Different Antifibrotic Agents. 査読

    Junko Itano, Yasushi Tanimoto, Goro Kimura, Noboru Hamada, Hisaaki Tanaka, Shinsuke Ninomiya, Kenjiro Kosaki, Nobuaki Miyahara, Yoshinobu Maeda, Katsuyuki Kiura

    Internal medicine (Tokyo, Japan)   60 ( 5 )   783 - 788   2021年3月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hermansky-Pudlak syndrome (HPS) is an autosomal recessive hereditary disease that may be complicated by progressive and potentially fatal interstitial pneumonia. We herein report a 64-year-old woman with interstitial pneumonia associated with HPS type 4 whom we treated with nintedanib after pirfenidone proved ineffective. To our knowledge, there have been no previous reports of nintedanib being used to treat a patient with HPS type 4. There is a need for clinical trials of antifibrotic agents, including nintedanib, pirfenidone, and new therapeutic agents with different mechanisms of action in these patients.

    DOI: 10.2169/internalmedicine.5493-20

    PubMed

    researchmap

  • Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. 査読 国際誌

    Daijiro Harada, Hideko Isozaki, Toshiyuki Kozuki, Toshihide Yokoyama, Hiroshige Yoshioka, Akihiro Bessho, Shinobu Hosokawa, Ichiro Takata, Nagio Takigawa, Katsuyuki Hotta, Katsuyuki Kiura

    Thoracic cancer   12 ( 5 )   643 - 649   2021年3月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The efficacy of crizotinib treatment for recurring EML4-ALK-positive non-small cell lung cancer (NSCLC) previously treated with alectinib is unclear. Based on our preclinical findings regarding hepatocyte growth factor/mesenchymal epithelial transition (MET) pathway activation as a potential mechanism of acquired resistance to alectinib, we conducted a phase II trial of the anaplastic lymphoma kinase/MET inhibitor, crizotinib, in patients with alectinib-refractory, EML4-ALK-positive NSCLC. METHODS: Patients with ALK-rearranged tumors treated with alectinib immediately before enrolling in the trial received crizotinib monotherapy. The objective response rate was the primary outcome of interest. RESULTS: Nine (100%) patients achieved a partial response with alectinib therapy with a median treatment duration of 6.7 months. Crizotinib was administered with a median treatment interval of 50 (range, 20-433) days. The overall response rate was 33.3% (90% confidence interval [CI]: 9.8-65.5 and 95% CI: 7.5-70.1), which did not reach the predefined criteria of 50%. Two (22%) patients who achieved a partial response had brain metastases at baseline. Progression-free survival (median, 2.2 months) was not affected by the duration of treatment with alectinib. The median survival time was 24.1 months. The most common adverse events were an increased aspartate transaminase/alanine transaminase (AST/ALT) ratio (44%) and appetite loss (33%); one patient developed transient grade 4 AST/ALT elevation, resulting in treatment discontinuation. Other adverse events were consistent with those previously reported; no treatment-related deaths occurred. CONCLUSIONS: Although the desired response rate was not achieved, crizotinib monotherapy following treatment with alectinib showed efficacy alongside previously described adverse events.

    DOI: 10.1111/1759-7714.13825

    PubMed

    researchmap

  • Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients. 査読 国際誌

    Hirohisa Kano, Toshio Kubo, Kiichiro Ninomiya, Eiki Ichihara, Kadoaki Ohashi, Kammei Rai, Katsuyuki Hotta, Masahiro Tabata, Takao Hiraki, Susumu Kanazawa, Yoshinobu Maeda, Katsuyuki Kiura

    Respiratory investigation   59 ( 2 )   240 - 246   2021年3月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: New therapeutic drugs have been developed for non-small cell lung cancer (NSCLC), and the prognosis of advanced NSCLC patients has improved. However, resistance to these drugs is a concern, and re-biopsy is necessary to determine the mechanism of drug resistance. There are many reports about the protocols for re-biopsy, including techniques such as bronchoscopy and computed tomography-guided needle biopsy (CTNB); however, there is no consensus on which method is optimal. Therefore, we retrospectively reviewed the bronchoscopy and CTNB re-biopsies conducted at our hospital. METHODS: We retrospectively analyzed 79 cases of re-biopsies with bronchoscopy or CTNB in patients with NSCLC from January 2014 to December 2016 at our institute. RESULTS: Forty-nine cases of bronchoscopy and 30 cases of CTNB were taken for re-biopsy. The diagnostic rates of bronchoscopy and CTNB were 83.7% and 100%, respectively (p = 0.023). The complication rates of bronchoscopy and CTNB were 18.4% and 36.7%, respectively (p = 0.11), with a statistically significant difference in the incidence of pneumothorax (0% vs. 23.3%, respectively; p < 0.01). Pneumothorax required drainage in 6.7% of all CTNB cases. There were no fatalities in either group. CONCLUSIONS: CTNB showed a higher diagnostic rate; however, it was associated with a higher rate of complications such as pneumothorax. Hence, the optimal modality must be determined individually for each patient.

    DOI: 10.1016/j.resinv.2020.12.001

    PubMed

    researchmap

  • Demand for weekend outpatient chemotherapy among patients with cancer in Japan. 査読 国際誌

    Hideki Katayama, Masahiro Tabata, Toshio Kubo, Katsuyuki Kiura, Junji Matsuoka, Yoshinobu Maeda

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   29 ( 3 )   1287 - 1291   2021年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Advanced cancer therapeutics have improved patient survival, leading to an increase in the number of patients who require long-term outpatient chemotherapy. However, the available schedule options for chemotherapy are generally limited to traditional business hours. METHOD: In 2017, we surveyed 721 patients with cancer in Okayama, Japan, regarding their preferences for evening and weekend (Friday evening, Saturday, and Sunday) chemotherapy appointments. RESULTS: A preference for evening and weekend appointment options was indicated by 37% of the respondents. Patients who requested weekend chemotherapy were younger, female, with no spouse or partner, living alone, employed, and currently receiving treatment. Among these factors, age and employment status were significantly associated with a preference for weekend chemotherapy, according to multivariate analysis. CONCLUSION: Our findings reveal a demand for evening and weekend outpatient chemotherapy, especially among young, employed patients.

    DOI: 10.1007/s00520-020-05575-x

    PubMed

    researchmap

  • Novel prospective umbrella-type lung cancer registry study for clarifying clinical practice patterns: CS-Lung-003 study protocol. 査読 国際誌

    Kazuya Nishii, Masaaki Inoue, Hideto Obata, Yutaka Ueda, Toshiyuki Kozuki, Masahiro Yamasaki, Tomonori Moritaka, Yoshikazu Awaya, Keisuke Sugimoto, Kenichi Gemba, Shoichi Kuyama, Hirohisa Ichikawa, Takuo Shibayama, Tetsuya Kubota, Masahiro Kodani, Daizo Kishino, Nobukazu Fujimoto, Nobuhisa Ishikawa, Yukari Tsubata, Tomoya Ishii, Kazunori Fujitaka, Katsuyuki Hotta, Katsuyuki Kiura

    Thoracic cancer   12 ( 5 )   725 - 731   2021年3月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: Conventional cancer registries are suitable for simple surveillance of cancer patients, including disease frequency and distribution, demographics, and prognosis; however, the collected data are inadequate to clarify comprehensively diverse clinical questions in daily practice. METHODS: We constructed an umbrella-type lung cancer patient registry (CS-Lung-003) integrating multiple related prospective observational studies (linked studies) that reflect clinical questions about lung cancer treatment. The primary endpoint of this registry is to clarify daily clinical practice patterns in lung cancer treatment; a key inclusion criterion is pathologically diagnosed lung cancer. Under this registry, indispensable clinical items are detected in advance across all active linked studies and gathered prospectively and systematically to avoid excessive or insufficient data collection. Researchers are to input information mutually, irrespective of the relevance to each researcher's own study. Linked studies under the umbrella of the CS-Lung-003 registry will be updated annually with newly raised clinical questions; some linked studies will be newly created, while others will be deleted after the completion of the analysis. Enrollment began in July 2017. DISCUSSION: We successfully launched the umbrella-type CS-Lung-003 registry. Under this single registry, researchers collaborate on patient registration and data provision for their own and other studies. Thus, the registry will produce results for multiple domains of study, providing answers to questions about lung cancer treatment raised by other researchers. Through such analysis of each linked study, this registry will contribute to the comprehensive elucidation of actual daily practice patterns in lung cancer treatment. KEY POINTS: CS-Lung-003 registry directly integrates multiple linked studies created under the umbrella of this cancer registry to solve various clinical questions regarding daily practice patterns of lung cancer treatment.

    DOI: 10.1111/1759-7714.13789

    PubMed

    researchmap

  • Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Non-small-cell Lung Cancer Treated with Trimodality Therapy. 査読 国際誌

    Shimpei Tsudaka, Hiromasa Yamamoto, Hiroki Sato, Kuniaki Katsui, Ken Suzawa, Kazuhiko Shien, Kentaroh Miyoshi, Shinji Otani, Mikio Okazaki, Seiichiro Sugimoto, Masaomi Yamane, Katsuyuki Kiura, Susumu Kanazawa, Shinichi Toyooka

    Annals of surgical oncology   28 ( 9 )   4880 - 4890   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: Current evidence suggests that the neutrophil-to-lymphocyte ratio (NLR) is a prognostic factor in several types of cancer. In this study, we aimed to evaluate the prognostic impact of clinicopathological factors, including postoperative NLR, in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) who underwent surgery after chemoradiotherapy (CRT) with or without postoperative adjuvant chemotherapy. METHODS: The medical records of LA-NSCLC patients treated with trimodality therapy at our institution between June 1999 and May 2019 were reviewed. The association between several clinicopathological factors and overall survival (OS) was analyzed. RESULTS: A total of 168 patients were included in this study. Regarding the prognosis, the 5-year OS rate was 68.1%, and the 2-year recurrence-free survival rate was 66.1% in the entire population. In multivariate analysis, we identified that high postoperative NLR, not pretreatment or preoperative NLR, was one of the independent factors for unfavorable OS (NLR high vs NLR low; hazard ratio = 2.45, 95% confidence interval: 1.53-3.94, p < 0.001). In addition, among patients with high postoperative NLR, patients who received postoperative adjuvant chemotherapy showed significantly better 5-year OS compared with those who did not (p = 0.016). On the other hand, postoperative adjuvant chemotherapy had no impact on the prognosis in patients with low NLR (p = 0.19). CONCLUSIONS: Our results suggest that high postoperative NLR was not only an independent unfavorable prognostic factor in patients with LA-NSCLC who were treated with trimodality therapy, but also a promising indicator for postoperative treatment in this population.

    DOI: 10.1245/s10434-021-09690-9

    PubMed

    researchmap

  • Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer. 査読 国際誌

    Shinobu Hosokawa, Eiki Ichihara, Akihiro Bessho, Daijiro Harada, Koji Inoue, Takuo Shibayama, Daizo Kishino, Shingo Harita, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Japanese journal of clinical oncology   51 ( 2 )   279 - 286   2021年2月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Studies investigating the association between radiation therapy and the efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer have provided inconsistent results, likely due to relatively small cohort sizes. This study investigated the effect of previous thoracic radiation therapy on the efficacy of immune checkpoint inhibitor therapy in a large non-small-cell lung cancer cohort. PATIENTS AND METHODS: We conducted a retrospective cohort study using data from 531 non-small-cell lung cancer patients who received monotherapy with programmed cell death protein 1/programmed death-ligand 1 inhibitors at nine institutions. The effects of thoracic radiation therapy on the efficacy of immune checkpoint inhibitors were investigated. RESULTS: A total of 531 non-small-cell lung cancer patients treated with immune checkpoint inhibitors were included in this study. The progression-free survival period was significantly longer in patients that had received thoracic radiation therapy before immune checkpoint inhibitor therapy compared to those without previous thoracic radiation therapy (median progression-free survival 5.0 vs. 3.0 months, P = 0.0013). A multivariate analysis showed that thoracic radiation therapy was an independent predictive factor of improved progression-free survival (hazard ratio of progression-free survival: 0.79, P = 0.049). In contrast, extra-thoracic radiation therapy was associated with inferior outcomes (median progression-free survival 3.0 vs. 4.2 months, P = 0.0008). CONCLUSION: Previous thoracic radiation therapy, but not prior extra-thoracic radiation therapy, enhanced the efficacy of anti-programmed cell death protein 1/programmed death-ligand 1 therapy in non-small-cell lung cancer patients.

    DOI: 10.1093/jjco/hyaa180

    PubMed

    researchmap

  • Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial. 査読 国際誌

    Go Makimoto, Katsuyuki Hotta, Isao Oze, Kiichiro Ninomiya, Masamoto Nakanishi, Naofumi Hara, Hirohisa Kano, Hiromi Watanabe, Yusuke Hata, Kazuya Nishii, Takamasa Nakasuka, Junko Itano, Takashi Ninomiya, Toshio Kubo, Kadoaki Ohashi, Eiki Ichihara, Daisuke Minami, Akiko Sato, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Asia-Pacific journal of clinical oncology   17 ( 1 )   101 - 108   2021年2月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Evidence is lacking on the best standard method for forced diuresis to prevent cisplatin-induced nephrotoxicity. We compared the cisplatin-induced nephrotoxicity prevention effect of furosemide or mannitol in patients with advanced non-small cell lung cancer. METHODS: Patients with advanced non-small cell lung cancer suitable to receive cisplatin-containing regimen were randomly assigned to receive furosemide or mannitol with appropriate hydration. The primary endpoint was the proportion of ≥ grade 1 serum creatinine elevation in the first cycle. RESULTS: The trial was terminated early with 44 (22 per arm) of the planned 66 patients because of slow accrual. Patients' characteristics were well balanced with median baseline creatinine clearance of 98.0 and 95.1 mL/min in the furosemide and mannitol arms, respectively. In the first cycle, two (9%) and four (18%) patients developed grade 1 creatinine elevation (P = .66), respectively, despite no ≥ grade 2 toxicity. The median times to develop the worst creatinine score were 10 and 8 days, respectively. For all cycles, median times to recover to grade 0 were 56 and 20 days, respectively. The furosemide arm was characterized by relatively high urine output after cisplatin administration (900 vs 550 mL/h), low frequency of unplanned additional hydration (14% vs 32%), and high incidence of hyponatremia (18% and 5%) compared with the mannitol arm. Both arms showed similar progression-free survival and overall survival. CONCLUSION: The preventive effect of the two forced diuretics on cisplatin-induced nephrotoxicity was not significantly different. However, the two diuretics have some distinct types of clinical presentations.

    DOI: 10.1111/ajco.13423

    PubMed

    researchmap

  • Volumetric PET Parameters Predict Prognosis after Definitive Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-Small Cell Lung Cancer. 査読

    Kuniaki Katsui, Takeshi Ogata, Akihiro Tada, Soichi Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Takao Hiraki, Susumu Kanazawa

    Acta medica Okayama   75 ( 1 )   15 - 23   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The aim of this study was to investigate whether volumetric positron emission tomography (PET) parameters are prognostic predictors in stage III non-small cell lung cancer patients receiving definitive concurrent chemo-radiotherapy (CCRT) with cisplatin/docetaxel. Cases involving definitive CCRT were reviewed retrospectively, and the maximum standardized uptake value, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated. The relationships between these PET parameters and prognosis were analyzed. MTV and TLG were significant predictors of distant metastasis-free survival (DMFS) (p = 0.0003 and 0.0005, respectively) and progression-free survival (PFS) (p = 0.001 and 0.0007, respectively). The three-year DMFS rates in patients with low and high MTV were 13.3% and 64.6%, respectively, and the corresponding values in those with low and high TLG were 13.3% and 65.2%, respectively. The three-year PFS rates in patients with low and high MTV were 13.3% and 57.8%, respectively, and the corresponding values in patients with low and high TLG were 13.3% and 57.8%, respectively. However, MTV and TLG were not predictors of local control or overall sur-vival. We demonstrated that volumetric PET parameters were predictors of patients receiving definitive CCRT. Our findings contradict the findings of previous reports and warrant further research to validate them.

    DOI: 10.18926/AMO/61429

    PubMed

    researchmap

  • Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. 査読 国際誌

    Eiki Ichihara, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Cancer immunology, immunotherapy : CII   70 ( 1 )   101 - 106   2021年1月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Immune checkpoint inhibitors (ICIs) are less effective in non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. However, a small percentage of patients with EGFR-mutant NSCLC do respond, and the characteristics of these patients are not known. Here, we identify the characteristics of patients who may respond to ICI therapy for EGFR-mutant NSCLC. PATIENTS AND METHODS: The medical records of NSCLC patients with EGFR mutations who received PD-1/PD-L1 antibody monotherapy at nine institutions were reviewed. RESULTS: In total, 58 patients with EGFR-mutant NSCLC were analyzed. Various clinical factors such as smoking history and EGFR mutation type were not associated with progression-free survival (PFS) of ICIs, while the PFS of prior EGFR tyrosine kinase inhibitors (TKIs) was inversely associated with that of ICIs. Patients who responded to prior EGFR TKIs for > 10 months exhibited a significantly shorter response to ICIs compared to those who had responded for ≤ 10 months (PFS of ICI: 1.6 vs. 1.9 months; hazard ratio: 2.54; 95% confidence interval 1.26-5.12; p = 0.009). However, patients who responded to ICIs for > 6 months responded to prior EGFR TKIs for significantly shorter periods compared to those who responded to ICIs for ≤ 6 months (PFS of prior EGFR TKI: 5.3 vs. 12.1 months; log-rank test: p = 0.0025). CONCLUSION: The duration of response to prior EGFR TKIs could be a predictive marker of ICI therapy in EGFR-mutant NSCLC patients.

    DOI: 10.1007/s00262-020-02662-0

    PubMed

    researchmap

  • Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. 査読 国際誌

    Toshio Kubo, Hiromi Watanabe, Kiichiro Ninomiya, Kenichiro Kudo, Daisuke Minami, Etsuko Murakami, Nobuaki Ochi, Takashi Ninomiya, Daijiro Harada, Masayuki Yasugi, Eiki Ichihara, Kadoaki Ohashi, Kammei Rai, Keiichi Fujiwara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Japanese journal of clinical oncology   50 ( 12 )   1447 - 1453   2020年12月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Immune checkpoint inhibitors offer longer survival than chemotherapy in several clinical trials for advanced non-small cell lung cancer. In subset analyses of clinical trials, immune checkpoint inhibitors extended survival in patients aged ≥65 years, but the effects in patients aged ≥75 years are controversial. We performed multicenter, collaborative and retrospective analyses of immune checkpoint inhibitor efficacy and safety in non-small cell lung cancer patients aged ≥75 years. METHODS: We retrospectively studied 434 advanced non-small cell lung cancer patients who received immune checkpoint inhibitors from December 2015 to December 2017, and retrospectively applied the Geriatric (G) 8 screening tool with medical records. RESULTS: Of the 434 patients who received immune checkpoint inhibitors, 100 were aged ≥75 years. Five patients with performance status 3 were omitted from the final analysis. Immune checkpoint inhibitors were given as a first-line treatment to 20 patients. The objective response rates, median progression-free survival rates and median survival times were 35.0%, 6.1 months and 10.7 months for first-line treatment, and 20.0%, 2.9 months and 14.7 months for second- or later-line treatments, respectively. The median modified G8 score was 11.0. The median survival time was longer in the high modified G8 (≥12.0) group than in the low modified G8 (≤11.0) group (18.7 vs. 8.7 months; P = 0.02). Likewise, the median survival time was 15.5 months (performance status 0-1) vs. 3.2 months (performance status 2) (P < 0.01). The grade ≥ 2 immune-related adverse events incidence was 36.8%. CONCLUSIONS: In this study, immune checkpoint inhibitors were effective and tolerable for patients aged ≥75 years. The modified G8 screening tool and performance status were associated with the outcome of older non-small cell lung cancer patients treated with immune checkpoint inhibitors.

    DOI: 10.1093/jjco/hyaa152

    PubMed

    researchmap

  • Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. 査読 国際誌

    Kadoaki Ohashi, Kiichiro Ninomiya, Hiroshige Yoshioka, Akihiro Bessho, Takuo Shibayama, Keisuke Aoe, Nobuhisa Ishikawa, Toshiyuki Kozuki, Haruyuki Kawai, Shoichi Kuyama, Seigo Miyoshi, Kazunori Fujitaka, Hideto Obata, Yukari Tsubata, Yoshikazu Awaya, Masaaki Inoue, Koji Inoue, Naokatsu Horita, Hiroyuki Yanai, Katsuyuki Hotta, Katsuyuki Kiura

    Lung cancer (Amsterdam, Netherlands)   150   83 - 89   2020年12月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small-cell lung carcinoma (NSCLC); however, a biomarker to predict their efficacy has not been established. Although human epidermal growth factor receptor-2 (HER2) aberrations constitute a potential mechanism for acquired resistance to EGFR-TKIs, the impact of HER2 on EGFR-TKI treatment outcomes has not been systematically evaluated. In this post-hoc subgroup study, we examined the impact of HER2 on the effect of EGFR-TKIs in patients with NSCLC harboring EGFR mutations. MATERIALS AND METHODS: Of 1126 patients with NSCLC enrolled into a prospective cohort study (HER2-CS study), we analyzed data of 356 (32 %) patients with EGFR-mutant tumors. HER2 protein expression levels were determined by immunohistochemistry (IHC) with the gastric cancer criteria. Patients were divided either to an HER2-P group (HER2-IHC2+/3+) or an HER2-N group (HER2-IHC0/1+). We primarily assessed differences in the time-to-treatment failure (TTF) of EGFR-TKI between the groups. RESULTS: The HER2 scoring was as follows: IHC0 (n = 76, 21 %), IHC1+ (n = 199, 56 %), IHC2+ (n = 72, 20 %), and IHC3+ (n = 9, 3 %). The patients' demographics were similar in the HER2-P and HER2-N groups. The HER2-P group showed a significantly shorter EGFR-TKI TTF than the HER2-N group (hazard ratio [HR]: 1.657, 95 % confidence interval [CI]: 1.076-2.552; median: 13.3 vs. 19.1 months). The magnitude of the negative impact of TTF was especially dependent on performance status (PS). HER2 expression significantly deteriorated the TTF in the subgroup with PS 2 (HR: 5.497, 95 % CI: 1.510-20.02), but not in that with better PS (HR: 1.437, 95 % CI: 0.899-2.298) (pinteraction = 0.015). CONCLUSION: In the current cohort, HER2 protein expression in EGFR-mutant NSCLC may have a negative impact on the effect of EGFR-TKIs, the effect of which was PS dependent.

    DOI: 10.1016/j.lungcan.2020.09.024

    PubMed

    researchmap

  • Prognostic nutrition index affects the prognosis of patients undergoing trimodality therapy for locally advanced non-small cell lung cancer. 査読

    Junichi Soh, Ken Suzawa, Kazuhiko Shien, Shinji Otani, Hiromasa Yamamoto, Mikio Okazaki, Seiichiro Sugimoto, Kuniaki Katsui, Masaomi Yamane, Katsuyuki Kiura, Susumu Kanazawa, Shinichi Toyooka

    Surgery today   50 ( 12 )   1610 - 1618   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: Trimodality therapy, comprised of induction chemoradiotherapy (iCRT) followed by surgery, is a highly invasive treatment option for locally advanced non-small cell lung cancers (LA-NSCLCs; defined as a heterogenous disease). We conducted this study to investigate the prognostic nutritional index (PNI) of LA-NSCLC patients undergoing trimodality therapy, which has not been studied in detail before. METHODS: The subjects of this retrospective study were 127 patients who underwent trimodality therapy between 1999 and 2016. We measured the PNI at three points: before iCRT (pre-iCRT), before the operation, and after the operation. RESULTS: PNIs decreased significantly as treatment progressed. Patients with clinical T3/4 (cT3/4) disease had a significantly lower PNI than those with cT1/2 disease, but the extent of lymph-node metastasis did not affect the PNI at any point. Using the cut-off values of receiver-operating curve analyses, multivariable analyses revealed that a high PNI pre-iCRT correlated significantly with a better survival of LA-NSCLC patients, especially those with cT3/4 disease (hazard ratio 3.84; 95% confidential interval 1.34-12.5, P = 0.012). CONCLUSIONS: Measuring the PNI before trimodality therapy is important for predicting the clinical outcome of patients with LA-NSCLC, with differing predictive ability according to the disease extent. Perioperative intensive nutritional intervention must be considered for patients who undergo trimodality therapy for LA-NSCLC.

    DOI: 10.1007/s00595-020-02067-7

    PubMed

    researchmap

  • Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reaction. 査読 国際誌

    Kazuya Nishii, Kadoaki Ohashi, Tomoki Tamura, Kiichiro Ninomiya, Takehiro Matsubara, Satoru Senoo, Hirohisa Kano, Hiromi Watanabe, Naohiro Oda, Go Makimoto, Hisao Higo, Yuka Kato, Takashi Ninomiya, Toshio Kubo, Hiromasa Yamamoto, Shuta Tomida, Katsuyuki Hotta, Masahiro Tabata, Shinichi Toyooka, Yoshinobu Maeda, Katsuyuki Kiura

    Oncology letters   20 ( 6 )   393 - 393   2020年12月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The detection of certain oncogenic driver mutations, including those of epidermal growth factor receptor (EGFR), is essential for determining treatment strategies for advanced non-small cell lung cancer (NSCLC). The current study assessed the feasibility of testing exhaled breath condensate (EBC) for EGFR mutations by droplet digital PCR (ddPCR). Samples were collected from 12 patients with NSCLC harboring EGFR mutations that were admitted to Okayama University Hospital between June 1, 2014 and December 31, 2017. A total of 21 EBC samples were collected using the RTube™ method and EGFR mutations (L858R, exon 19 deletions or T790M) were assessed through ddPCR analysis (EBC-ddPCR). A total of 3 healthy volunteer samples were also tested to determine a threshold value for each mutation. Various patient characteristics were determined, including sex (3 males and 9 females), age (range 54-81 years; median, 66 years), smoking history (10 had never smoked; 2 were former smokers), histology (12 patients exhibited adenocarcinoma), clinical stage (9 patients were stage IV; 3 exhibited post-operative recurrence) and EGFR mutation type (4 had L858R; 8 had exon 19 deletions; 8 had T790M). EBC-ddPCR demonstrated positive droplets in 8 of the 12 patients. The sensitivity and specificity of each mutation was as follows: 27.3 and 80.0% for EGFR L858R, 30.0 and 90.9% for EGFR Ex19del, and 22.2 and 100% for EGFR T790M. EBC-ddPCR analysis of EGFR mutations exhibited modest sensitivity and acceptable specificity. EBC-ddPCR is a minimally invasive and replicable procedure and may be a complementary method for EGFR testing in patients where blood or tissue sampling proves difficult.

    DOI: 10.3892/ol.2020.12256

    PubMed

    researchmap

  • Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations. 査読 国際誌

    Hiroe Kayatani, Kadoaki Ohashi, Kiichiro Ninomiya, Go Makimoto, Kazuya Nishii, Hisao Higo, Hiromi Watanabe, Hirohisa Kano, Yuka Kato, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Biochemical and biophysical research communications   532 ( 3 )   341 - 346   2020年11月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is the standard therapy for non-small cell lung cancer (NSCLC) harboring EGFR mutations, but the resistance is inevitable. The drug-tolerant persister cancer cells are thought to be involved in the resistance. We recently reported that HER2 expression had a negative impact on time-to-treatment-failure in patients with EGFR mutant NSCLC. In this study, we hypothesized that HER2 might be a potential target for alternative combination therapy in NSCLC harboring EGFR mutations. In vitro study showed that the level of HER2 expression had no correlation with the sensitivity to EGFR-TKI, erlotinib but showed some correlation with HER2-inhibitor, ado-trastuzumab emtansine (T-DM1) in multiple EGFR-mutant lung cancer cell lines. In addition, HER2 expression was increased in persister cancer cells in 11-18 cell line harboring EGFR L858R or HCC827 cell line harboring EGFR exon 19 deletion after the exposure to erlotinib in vitro and in vivo. The combination of erlotinib and T-DM1 showed a superior inhibitory effect on cell proliferation compared with those of the erlotinib or T-DM1 alone in either 11-18 or HCC827 cells in vitro. The combination therapy also induced a significantly greater inhibitory effect on tumor growth in xenograft model in mice transplanted with either 11-18 or HCC827 cells compared with erlotinib alone or T-DM1 alone. No body weight loss was observed in these mice. These results suggested that the combination therapy with EGFR-TKI and T-DM1 might be a potentially promising strategy for treating lung cancer harboring EGFR mutations.

    DOI: 10.1016/j.bbrc.2020.07.055

    PubMed

    researchmap

  • Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies. 査読

    Go Makimoto, Kadoaki Ohashi, Yoshinobu Maeda, Katsuyuki Kiura

    Acta medica Okayama   74 ( 5 )   371 - 379   2020年10月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The prognosis of advanced non-small cell lung cancer (NSCLC) patients has improved in recent decades, especially for patients with an oncogenic driver mutation. Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are effective for patients with the echinoderm microtubule-associated protein-like 4-ALK fusion gene. Several ALK-TKIs have been established: the first-generation ALK-TKI, crizotinib; second-generation ALK-TKIs, alectinib and ceritinib; and third-generation ALK-TKI, lorlatinib. Some ALK-TKIs are effective for tumors that are resistant to other ALK-TKIs; however, as is known in epidermal growth factor receptormutant lung cancer, tumor resistance is inevitable. ALK-positive NSCLCs acquire resistance via various mechanisms, making it a heterogeneous disease. Therefore, it is necessary to develop next-generation treatment strategies, such as the use of next-generation ALK-TKIs for secondary mutations, or combination therapies with ALK-TKIs and other TKIs. In this review, we summarize the development and use of ALK-TKIs, prior pivotal clinical trials, and resistance mechanisms.

    DOI: 10.18926/AMO/60796

    PubMed

    researchmap

  • Chemoradiation therapy for non-small cell lung cancer exacerbates thoracic aortic calcification determined by computed tomography. 査読

    Takashi Miki, Shunsaku Miyauchi, Toru Miyoshi, Masashi Yoshida, Keishi Ichikawa, Junichi Soh, Kazufumi Nakamura, Katsuyuki Kiura, Susumu Kanazawa, Shinichi Toyooka, Hiroshi Ito

    Heart and vessels   35 ( 10 )   1401 - 1408   2020年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Preoperative chemoradiation therapy (CRT) has been considered as an effective treatment for non-small cell lung cancer. However, there is concern that CRT progresses atherosclerosis in cancer survivors. This study sought to determine if preoperative CRT exacerbated thoracic aortic calcification (TAC) detected by computed tomography (CT) in patients with lung cancer. Among 473 patients who underwent surgery for lung cancer at Okayama University Hospital between 2011 and 2015, 34 patients undergoing preoperative CRT and surgery (CRT group) and 33 matched patients undergoing initial surgery (non-CRT group) were analyzed and compared. The volume of TAC between the 2nd and 12th thoracic vertebrae was quantitatively measured by CT at baseline and 1-year follow-up. Patients in the CRT group (62 ± 7 years old, 74% male) received cisplatin chemotherapy with docetaxel or vinorelbine and radiation therapy (mean 47.3 ± 4.0 Gy). The percent change in TAC volume was significantly greater in the CRT compared with the non-CRT group (58.7%, 95% confidence interval [CI] 41.7-75.7% vs. 27.2%, 95% CI 9.9-44.4%; p = 0.01). Multivariate logistic regression analysis identified CRT as an independent factor associated with greater TAC progression (> the median value) (odds ratio 3.63, 95% CI 1.19-11.08; p = 0.02). In conclusion, preoperative CRT for lung cancer exacerbates TAC. Follow-up of such patients should thus include careful longitudinal assessment for cardiovascular disease.

    DOI: 10.1007/s00380-020-01611-2

    PubMed

    researchmap

  • Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status. 査読 国際誌

    Hirohisa Kano, Eiki Ichihara, Daijiro Harada, Koji Inoue, Hiroe Kayatani, Shinobu Hosokawa, Daizo Kishino, Kazuhiko Watanabe, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Kiichiro Ninomiya, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Cancer science   111 ( 10 )   3739 - 3746   2020年10月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Most clinical trials of non-small-cell lung cancer (NSCLC) exclude patients with poor ECOG performance status (PS). Thus, the efficacy of immune checkpoint inhibitors (ICIs) in patients with poor PS remains unclear. Herein, we used data from a retrospective cohort to assess the potential clinical benefits of ICIs in NSCLC patients with poor PS. Data from NSCLC patients who received ICI monotherapy at 9 institutions between December 2015 and May 2018 were retrospectively analyzed. After excluding 4 patients who lacked PS data, a total of 527 ICI-treated patients, including 79 patients with PS 2 or higher, were used for our analyses. The progression-free survival (PFS) and overall survival (OS) of patients with PS 2 or higher were significantly shorter compared with those of PS 0-1 patients (median PFS, 4.1 vs 2.0 months; P < .001 and median OS, 17.4 vs 4.0 months; P < .001). Among NSCLC patients with programmed cell death protein-ligand 1 (PD-L1) expression of 50% or higher who were treated with pembrolizumab as first-line therapy, the median PFS times of patients with PS 2 and 0-1 were 7.3 and 8.1 months, respectively. There was no significant difference in PFS between patients with PS 2 and 0-1 (P = .321). Although poor PS was significantly associated with worse outcomes in NSCLC patients treated with ICIs, pembrolizumab as a first-line treatment in NSCLC patients expressing high levels of PD-L1 could provide a clinical benefit, even in patients with PS 2.

    DOI: 10.1111/cas.14590

    PubMed

    researchmap

  • Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab. 査読

    Atsuko Hirabae, Eiki Ichihara, Ryota Sunami, Moeko Ota, Yoshitaka Iwamoto, Yoshinobu Maeda, Katsuyuki Kiura

    Acta medica Okayama   74 ( 5 )   423 - 425   2020年10月

     詳細を見る

    担当区分:最終著者   記述言語:英語  

    We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.

    DOI: 10.18926/AMO/60802

    PubMed

    researchmap

  • Secondary Pulmonary Alveolar Proteinosis Associated with Primary Myelofibrosis and Ruxolitinib Treatment: An Autopsy Case. 査読

    Hiroyuki Sugiura, Hisakazu Nishimori, Kazuya Nishii, Tomohiro Toji, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Koh Nakata, Katsuyuki Kiura, Yoshinobu Maeda

    Internal medicine (Tokyo, Japan)   59 ( 16 )   2023 - 2028   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Pulmonary alveolar proteinosis (PAP) is an uncommon lung disorder characterized by the excessive accumulation of surfactant-derived lipoproteins in the pulmonary alveoli and terminal bronchiole. Secondary PAP associated with primary myelofibrosis (PMF) is extremely rare, and to our knowledge, no autopsy case has been reported. We herein report an autopsy case of secondary PAP occurring in a patient with PMF who was treated with the Janus kinase 1/2 inhibitor ruxolitinib. We confirmed a diagnosis of PAP with complications based on the pathological findings at the autopsy. Notably, this case might suggest an association between ruxolitinib treatment and PAP occurrence.

    DOI: 10.2169/internalmedicine.4082-19

    PubMed

    researchmap

  • Fibrosis or Necrosis in Resected Lymph Node Indicate Metastasis Before Chemoradiotherapy in Lung Cancer Patients. 査読 国際誌

    Yuta Takahashi, Junichi Soh, Kazuhiko Shien, Hiromasa Yamamoto, Masaomi Yamane, Katsuyuki Kiura, Susumu Kanazawa, Hiroyuki Yanai, Shinichi Toyooka

    Anticancer research   40 ( 8 )   4419 - 4423   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND/AIM: The histological features of lymph nodes (LNs) treated by chemoradiotherapy (CRT) in non-small cell lung cancer (NSCLC) have not been well studied. The purpose of this study was to evaluate the histological findings of LNs affected by CRT. PATIENTS AND METHODS: Among 107 clinically N2 NSCLC patients who underwent induction CRT followed by surgery from 1999 to 2017, 24 patients who received pathological evaluation of mediastinal LN before CRT were enrolled in this study. Postoperatively, we histologically reviewed all resected LNs (n=117) of the station evaluated before CRT. RESULTS: Fibrosis and/or necrosis were observed in all investigated LN stations. Histological observation of fibrosis and/or necrosis in the resected LNs after CRT indicated the presence of LN metastasis before CRT. CONCLUSION: The metastatic LNs that responded to CRT showed specific histological features, which enabled us to know the accurate clinical stage of the patient even though cancer cells were not found in the post-treated LNs.

    DOI: 10.21873/anticanres.14447

    PubMed

    researchmap

  • Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database. 査読 国際誌

    Keigo Kobayashi, Kenzo Soejima, Koichi Fukunaga, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Nobuyuki Yamamoto, Yuichi Takiguchi, Etsuo Miyaoka, Meinoshin Okumura, Ichiro Yoshino

    Lung cancer (Amsterdam, Netherlands)   146   236 - 243   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: The efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for EGFR-mutated non-adenocarcinoma (ADC) non-small cell lung cancer patients is not well established. Herein, we investigated key prognostic factors influencing the efficacy of EGFR-TKIs in these patients. METHODS: A total of 12,320 lung cancer patients pathologically diagnosed in 2012 at teaching hospitals in Japan were retrospectively selected. The follow-up survey was closed in 2016. RESULTS: EGFR-mutated non-ADC patients were more prone to malignant pleural effusion (MPE) and distant metastasis than ADC patients (P = 0.071 and 0.022, respectively). EGFR-mutated ADC patients were likely to have a longer median overall survival (OS) than non-ADC patients [hazard ratio (HR) 1.3 (95 % CI, 0.97-1.8, P = 0.072)-29.5 months (95 % CI, 27.9-31.1 months) versus 19.5 months (95 % CI, 10.8-28.2 months) (P = 0.068)]. There was no significant difference in median OS between EGFR-positive ADC and non-ADC patients receiving treatment with first-generation EGFR-TKI. Among EGFR-positive non-ADC patients, the median OS was significantly longer for patients receiving EGFR-TKI treatment than for those who did not [HR 4.5 (95 % CI, 2.1-9.8, P < 0.001)-25.5 months (95 % CI, 8.1-42.9 months) versus 7.5 months (95 % CI, 3.4-11.6 months) (P < 0.001)]. While there was no significant difference in the median OS for ADC patients with either 19 del or L858R mutations, the median OS was significantly longer for EGFR-mutated non-ADC patients with 19 del than for those with L858R mutation (HR 3.2 [95 % CI, 1.5-6.9, P = 0.004]; it was not reached for 19 del and was 15.5 months for L858R [95 % CI, 6.6-24.4 months], P = 0.002). DISCUSSION: EGFR-mutated non-ADC patients were more prone to MPE and distant metastasis. Both ADC and EGFR del19-positive non-ADC patients can benefit from EGFR-TKI treatment, whereas EGFR L858R-positive non-ADC patients might require different therapeutic options.

    DOI: 10.1016/j.lungcan.2020.06.015

    PubMed

    researchmap

  • Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. 査読 国際誌

    Satoshi Igawa, Katsuhiko Naoki, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Nobuyuki Yamamoto, Yuichi Takiguchi, Etsuo Miyaoka, Meinoshin Okumura, Ichiro Yoshino

    Lung cancer (Amsterdam, Netherlands)   146   160 - 164   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Most patients with small-cell lung cancer (SCLC) experience relapse because of the emergence of drug-resistant tumor cells. Therefore, second-line therapy is subsequently required to prolong their survival. However, it is unclear whether second-line chemotherapy can provide a survival benefit to elderly patients with relapsed SCLC. Therefore, this study aimed to evaluate survival and identify prognostic factors in an elderly population. MATERIALS AND METHODS: Based on a nationwide registry database of patients with SCLC (the Japanese Joint Committee of Lung Cancer Registry), we retrospectively reviewed medical records of patients aged ≥ 75 years with relapsed SCLC who subsequently received second-line chemotherapy. Survival time since the initiation of second-line chemotherapy was evaluated. RESULTS: Among 731 patients aged ≥ 75 years with SCLC who were accumulated by the nationwide registry database, this study included 228 patients, comprising 190 men and 38 women with a median age of 78 years. The number of patients with performance status (PS) of 0-1 and 2-4 was 196 and 32, respectively. The overall survival (OS) and 1-year survival rates were 7.5 months and 24 %, respectively. A multivariate analysis identified PS, clinical stage at the time of starting first-line therapy, and the interval from the start of first-line therapy to that of second-line therapy as independent prognostic factors. CONCLUSION: This study with the nationwide registry database showed that among the relapsed elderly SCLC patients who received second-line chemotherapy, a substantial OS may be expected in patients with good PS, at an early clinical stage at the time of starting first-line therapy, and with a longer interval from the start of first-line therapy to that of second-line chemotherapy.

    DOI: 10.1016/j.lungcan.2020.05.038

    PubMed

    researchmap

  • Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters. 国際誌

    Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Norihisa Katayama, Masahiro Kuroda, Katsuyuki Kiura, Takao Hiraki, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Cancer medicine   9 ( 13 )   4540 - 4549   2020年7月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Radiation pneumonitis (RP) is a major pulmonary adverse event of chest radiotherapy. The PACIFIC trial that identified durvalumab as an effective subsequent-line therapy after concurrent chemoradiotherapy (CCRT) found that patients with grade 2 or higher RP may have to be excluded from treatment under certain criteria. The purpose of this study was to investigate the relationship between grade ≥2 RP and the parameters of dose-volume histograms after CCRT with cisplatin/docetaxel for stage III non-small cell lung cancer and conduct a subset analysis of severe RP that can lead to the permanent discontinuation of treatment per the PACIFIC trial criteria to help determine treatment strategy. METHODS: We calculated the percentage of the lung volume received at least 5 Gy (V5) and 20 Gy (V20), the mean lung dose (MLD), and the lung volume spared from a 5 Gy dose (VS5) to the total lung volume. Factors affecting the incidence of grade ≥2 RP were identified; severe RP was defined as grade ≥3 as well as grade 2 RP that required ≥10 mg prednisolone for at least 12 weeks. RESULTS: This study included 45 patients. On univariate analysis, all parameters and total lung volume were found to be significant predictors of grade ≥2 RP (P = .001, .003, .03, .004, and .02, respectively). On multivariate analysis, V20 was a significant predictive factor of grade ≥2 RP (P = .007). Severe RP developed in 6 of 37 patients (16.2%) whose V20 values were 35% or lower. On univariate analysis, only V20 was a significant predictor of severe RP in these patients (P = .01). CONCLUSIONS: The best approach to reduce the rate of grade ≥2 RP is to maintain the V5, V20, MLD, and VS5 as low as possible during radiotherapy planning in patients receiving definitive CCRT with cisplatin/docetaxel.

    DOI: 10.1002/cam4.3093

    PubMed

    researchmap

  • A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients. 査読 国際誌

    Ikuo Sekine, Yasushi Shintani, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Hirotoshi Dosaka-Akita, Yuichi Takiguchi, Etsuo Miyaoka, Meinoshin Okumura, Ichiro Yoshino

    Cancer science   111 ( 5 )   1685 - 1691   2020年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    This study provides the benchmark statistics on medically treated patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in Japan. Demographic background, treatment, and prognosis were obtained from patients with lung cancer pathologically diagnosed in 2012, who received nonsurgical treatment. Descriptive statistics and their associations with survival were analyzed. In total, 12 320 patients were registered from 314 institutions in Japan. The median age was 70 years, and 73% of the patients were male. The number (%) of stages I, II, III, and IV diseases were 468 (3.8%), 421 (3.4%), 3260 (26.5%), and 8171 (66.3%), respectively. NSCLC and SCLC accounted for 9872 (80.1%) and 2353 (19.1%) patients, respectively. Thoracic radiotherapy-based therapy, chemotherapy, and palliative care alone were administered to 2572 (20.9%), 7790 (63.2%), and 1952 (15.8%) patients, respectively. Clinical TNM stage was one of the strongest prognostic factors with the 3-year survival rates of 62.9%, 47.3%, 40.0%, 27.8%, 37.5%, 26.5%, and 18.2% for stages IA, IB, IIA, IIB, IIIA, IIIB, and IV, respectively. Among 6158 patients with NSCLC treated with chemotherapy, the 3-year survival rate was 33.4% in patients receiving epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) at some point in their clinical course, whereas it was 17.4% in patients who did not. The 3-year survival rate of SCLC was only 15.9%. In conclusion, approximately two-thirds of the patients were diagnosed as stage IV at the initial diagnosis. Use of EGFR-TKIs significantly improved the survival of patients with NSCLC.

    DOI: 10.1111/cas.14368

    PubMed

    researchmap

  • Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone. 査読 国際誌

    Hisao Higo, Nobuaki Miyahara, Akihiko Taniguchi, Satoru Senoo, Junko Itano, Hiromi Watanabe, Naohiro Oda, Hiroe Kayatani, Hirohisa Ichikawa, Takuo Shibayama, Kazuhiro Kajimoto, Yasushi Tanimoto, Arihiko Kanehiro, Yoshinobu Maeda, Katsuyuki Kiura

    Respiratory investigation   58 ( 3 )   185 - 189   2020年5月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Pirfenidone suppresses the decline of forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF). However, IPF progresses in some patients despite treatment. We analyzed patients with meaningful FVC declines during pirfenidone treatment and explored the factors predictive of disease progression after FVC decline. METHODS: This study was a retrospective, multicenter, observational study conducted by the Okayama Respiratory Disease Study Group. We defined initial decline in %FVC as 5% or greater per 6-month period during pirfenidone treatment. IPF patients who were treated with pirfenidone and experienced an initial decline from December 2008 to September 2017 were enrolled. RESULTS: We analyzed 21 patients with IPF. After the initial decline, 4 (19.0%) patients showed improvement in disease, 11 (52.4%) showed stable disease, and 6 (28.6%) showed progressive disease. There was no significant correlation between %FVC reduction on initial decline and subsequent %FVC change (p = 0.475). Deterioration of high-resolution computed tomography (HRCT) findings on initial decline was observed significantly more often in the progressive versus improved/stable disease groups (100% vs 20.0%, p = 0.009). CONCLUSIONS: We revealed that deterioration of HRCT findings may predict disease progression after the initial decline in %FVC in IPF patients treated with pirfenidone.

    DOI: 10.1016/j.resinv.2019.12.007

    PubMed

    researchmap

  • Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. 査読 国際誌

    Kiichiro Ninomiya, Isao Oze, Yuka Kato, Toshio Kubo, Eiki Ichihara, Kammei Rai, Kadoaki Ohashi, Toshiyuki Kozuki, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura, Katsuyuki Hotta

    Acta oncologica (Stockholm, Sweden)   59 ( 3 )   249 - 256   2020年3月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Immune checkpoint inhibitors (ICIs) represent a paradigm shift in the development of cancer treatment. However, it remains to be clarified whether the benefits that they confer differ according to patient age. We conducted a systematic review and meta-analysis to assess age differences in the benefits of ICI treatment.Methods: We systematically searched the PubMed database for randomised controlled trials of ICIs, including PD-1, PD-L1 and CTLA-4 inhibitors across multiple cancer types, such as melanoma, lung cancer and gastric cancer. We extracted trials including hazard ratios (HRs) for death stratified by patient age (cut-off age, 65 years). The primary objective of this study was to assess the difference in ICI efficacy between younger and older patients. We calculated pooled HRs and 95% confidence intervals (CIs) for younger and older cancer patients, and assessed data heterogeneity.Results: We identified 3999 studies in our search. Of these, 24 eligible randomised trials, including a total of 8157 (57%) younger and 6104 (43%) older cancer patients, fulfilled the criteria for our study and were thus further analysed. The pooled HRs of the younger and older patients were 0.76 (95% CI: 0.69-0.84) and 0.80 (95% CI: 0.71-0.86), respectively; the difference in ICI efficacy between younger and older cancer patients was not significant (p = .82). Regarding the PD-1 and PD-L1 inhibitors, the survival benefit was similar in both age groups (HR: 0.74; p = .96), whereas for the CTLA-4 inhibitors, there tended to be less survival benefit for older versus younger patients (HR: 0.90 and 0.77, respectively; p = .26).Conclusions: The survival benefit conferred by ICI was not age-dependent, amongst patients aged 65 years or younger. However, age-dependent benefits may vary amongst different types of ICIs.

    DOI: 10.1080/0284186X.2019.1695062

    PubMed

    researchmap

  • Nivolumab for the treatment of unresectable pleural mesothelioma. 査読 国際誌

    Katsuyuki Hotta, Nobukazu Fujimoto, Toshiyuki Kozuki, Keisuke Aoe, Katsuyuki Kiura

    Expert opinion on biological therapy   20 ( 2 )   109 - 114   2020年2月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Introduction: Platinum-based chemotherapy is the current first-line standard therapy for unresectable malignant pleural mesothelioma (MPM). Recently, immune-checkpoint inhibitors (ICI) have been intensively investigated as treatment options for this disease. Nivolumab, an anti-programmed cell death (PD)-1 agent, was one of the first drugs used and is representative of available ICIs.Areas covered: This review discusses previous relevant reports and current ongoing trials of nivolumab. The efficacy and safety of nivolumab have been investigated mostly in second-line or later treatment settings as both monotherapy and in combination with other ICIs. Particularly, nivolumab monotherapy yielded promising efficacy with an objective response rate of 29% and median overall survival of 17.3 months in salvage settings in the single-arm, Japanese phase 2 trial (MERIT). Notably, the study led to Japanese approval of nivolumab for unresectable recurrent MPM. Several trials with monotherapy or cotherapy with nivolumab have commenced, including randomized trials of nivolumab monotherapy vs. placebo in the salvage setting, and cotherapy with nivolumab and ipilimumab vs. the platinum doublet in the frontline setting.Expert opinion: Nivolumab seems like a reasonable option for unresectable, relapsed MPM despite the lack of randomized trial data. Ongoing pivotal trials will confirm its efficacy.

    DOI: 10.1080/14712598.2020.1703945

    PubMed

    researchmap

  • Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3. 査読 国際誌

    Hiroshige Yoshioka, Terufumi Kato, Isamu Okamoto, Hiroshi Tanaka, Toyoaki Hida, Takashi Seto, Katsuyuki Kiura, Yahui Tian, Hisaya Azuma, Nobuyuki Yamamoto

    Future oncology (London, England)   16 ( 4 )   49 - 60   2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Aim: Acquired resistance to EGFR tyrosine kinase inhibitors is inevitable in non-small-cell lung cancer. To inform subsequent treatment decisions, we retrospectively assessed therapies following afatinib in Japanese patients from LUX-Lung 3. Patients & methods: LUX-Lung 3 was a randomized, open-label, Phase III study of afatinib versus cisplatin/pemetrexed in treatment-naive patients with EGFR mutation-positive (EGFRm+) advanced lung adenocarcinoma. Results: Among 47 Japanese patients who discontinued first-line afatinib, 91/81/62% received ≥one/two/three subsequent therapies. The most common second-line therapies were platinum-based chemotherapy (38%) and a first-generation EGFR tyrosine kinase inhibitor (17%). Median overall survival (afatinib vs cisplatin/pemetrexed) was 47.8 versus 35.0 months (not significant). Conclusion: First-line afatinib does not appear to diminish suitability for subsequent therapies in EGFRm+ non-small-cell lung cancer.

    DOI: 10.2217/fon-2019-0659

    PubMed

    researchmap

  • Pulmonary aspergillosis as a late complication after surgery for locally advanced non-small cell lung cancer treated with induction chemoradiotherapy. 査読

    Seiichiro Sugimoto, Junichi Soh, Ken Suzawa, Kentaroh Miyoshi, Shinji Otani, Hiromasa Yamamoto, Mikio Okazaki, Masaomi Yamane, Takahiro Oto, Susumu Kanazawa, Katsuyuki Kiura, Shinichi Toyooka

    Surgery today   50 ( 8 )   863 - 871   2020年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: Some long-term survivors after surgery for locally advanced non-small cell lung cancer (NSCLC) treated with induction chemoradiotherapy (trimodality treatment) develop chronic pulmonary aspergillosis (CPA). The aim of our study was to assess the characteristics and outcomes of CPA that develops after trimodality treatment. METHODS: We retrospectively reviewed the data of 187 NSCLC patients who underwent trimodality treatment between 1999 and 2018. RESULTS: Six male ever-smoker patients developed CPA. All 6 patients had undergone extended resection for NSCLC and had a history of either adjuvant chemotherapy (n = 3) or radiation pneumonitis (n = 4). Among the 4 patients with CPA localized in a single lung, 3 patients were treated surgically (completion pneumonectomy or cavernostomy) and 1 patient was treated with antifungal therapy alone. Both treatments led to the improved control of CPA. In contrast, patients with CPA in both lungs were not candidates for surgery, and died of CPA. The survival rates after trimodality treatment in the CPA group and the group without CPA were comparable (10-year survival rate, 50.0% vs. 57.6%, P = 0.59). CONCLUSION: The early diagnosis of CPA localized in a single lung after NSCLC surgery is critical to improving control and survival in patients with CPA.

    DOI: 10.1007/s00595-020-01960-5

    PubMed

    researchmap

  • The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. 査読 国際誌

    Eiki Ichihara, Daijiro Harada, Koji Inoue, Ken Sato, Shinobu Hosokawa, Daizo Kishino, Kazuhiko Watanabe, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Lung cancer (Amsterdam, Netherlands)   139   140 - 145   2020年1月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Body mass index (BMI) is reported to be associated with the efficacy of immune checkpoint inhibitors (ICIs) in solid tumors such as melanomas. However, it remains unclear whether such a relationship exists in non-small cell lung cancer (NSCLC) treated with programmed cell death protein 1 (PD-1)/ programmed death-ligand 1(PD-L1) inhibitors. The purpose of this study was to investigate the relationship between BMI and the efficacy of ICI treatment in patients with advanced NSCLC. MATERIALS AND METHODS: The medical records of NSCLC patients who received PD-1/PD-L1 antibody monotherapy at nine institutions between December 2015 and May 2018 were reviewed retrospectively. The effect of BMI was investigated in two cohorts. Cohort 1 included patients with NSCLCs with high PD-L1 expression (≥ 50 %) treated with pembrolizumab as first-line therapy, and cohort 2 included patients with NSCLCs treated with nivolumab/pembrolizumab/atezolizumab as second- or later-line treatment. RESULTS: A total of 513 from nine institutions were analyzed (84 in cohort 1, 429 in cohort 2). Using a BMI cut-off value of 22 kg/m2, which is an ideal BMI in our country (high BMI:22.0 and low BMI:22.0), there was no significant difference in the PFS or OS between the high and low BMI patients in cohort 1. However, in cohort 2, survival was significantly longer in patients with a high versus low BMI (PFS: 3.7 vs. 2.8 months, p = 0.036; OS: 15.4 vs. 13.5 months, p = 0.021). CONCLUSION: BMI was significantly associated with the efficacy of ICIs in patients with NSCLC treated with second- or later-line PD-1/PD-L1 inhibitors in our cohort.

    DOI: 10.1016/j.lungcan.2019.11.011

    PubMed

    researchmap

  • Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis. 査読 国際誌

    Satoru Senoo, Nobuaki Miyahara, Akihiko Taniguchi, Naohiro Oda, Junko Itano, Hisao Higo, Naofumi Hara, Hiromi Watanabe, Hirohisa Kano, Toshimitsu Suwaki, Yasuko Fuchimoto, Kazuhiro Kajimoto, Hirohisa Ichikawa, Kenichiro Kudo, Takuo Shibayama, Yasushi Tanimoto, Shoichi Kuyama, Arihiko Kanehiro, Yoshinobu Maeda, Katsuyuki Kiura

    PloS one   15 ( 8 )   e0236935   2020年

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Nintedanib is a multi-kinase inhibitor approved for idiopathic pulmonary fibrosis (IPF); however, its efficacy and safety for patients with IPF and restricted pulmonary function remain unclear. Therefore, the objective of this study was to determine the efficacy and safety of nintedanib for patients with IPF and forced vital capacity (FVC) ≤ 50%. METHODS: This was a multi-center retrospective study performed by the Okayama Respiratory Disease Study Group. Patients were allocated into FVC ≤ 50% and FVC > 50% groups based on their predicted FVC. The primary endpoints were FVC changes from baseline after 6 and 12 months. RESULTS: 45 patients were eligible for the study. 18 patients had FVC ≤ 50%, and 27 patients had FVC > 50%. Overall, 31 and 19 patients underwent pulmonary function tests at 6 and 12 months after initiating nintedanib, respectively. FVC changes from baseline at 6 and 12 months after initiating nintedanib were comparable between the two groups. Adverse events were seen in all patients, and the rates of patients who discontinued nintedanib were also comparable (38.9% vs. 37.0%, p = 1.000). Multiple regression analysis showed that age and forced expiratory volume in 1 second (FEV1)/FVC were negatively correlated with changes in FVC at 6 months after initiating nintedanib. CONCLUSIONS: Our data suggest that nintedanib can be a useful agent for IPF patients, including those with a low FVC, and that age and FEV1/FVC are predictive markers for changes in FVC following nintedanib treatment.

    DOI: 10.1371/journal.pone.0236935

    PubMed

    researchmap

  • Pilot evaluation of a HER2 testing in non-small-cell lung cancer. 査読 国際誌

    Hotta K, Yanai H, Ohashi K, Ninomiya K, Nakashima H, Kayatani H, Takata M, Kiura K

    Journal of clinical pathology   73 ( 6 )   353 - 357   2019年12月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1136/jclinpath-2019-206204

    PubMed

    researchmap

  • Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis. 査読 国際誌

    Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Norihisa Katayama, Junichi Soh, Masahiro Kuroda, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    BMC cancer   19 ( 1 )   1144 - 1144   2019年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The relationship between lung dose-volume histogram (DVH) parameters and radiation pneumonitis (RP) associated with induction concurrent chemoradiotherapy (CCRT) followed by surgery in patients with non-small cell lung cancer (NSCLC) is unclear, particularly when concerning irradiation of the whole lung prior to resection. We performed this study to identify factors associated with grade ≥ 2 RP in such patients. METHODS: Patients who received induction CCRT (chemotherapy: cisplatin and docetaxel; radiotherapy: 46 Gy/23 fractions) between May 2003 and May 2017 were reviewed. The mean lung dose (MLD) and the percentage of the lung volume that received ≥5 Gy (V5) and ≥ 20 Gy (V20) were calculated. Factors associated with the development of grade ≥ 2 RP were analyzed. RESULTS: One hundred and eight patients were included in this study, 34 (31.5%) of whom experienced grade ≥ 2 RP. A V20 ≥ 21%, an MLD ≥10 Gy, and a lower lobe tumor location were significant predictors of grade ≥ 2 RP on univariate analysis (p = 0.007, 0.002, and 0.004, respectively). Moreover, an MLD ≥10 Gy and lower lobe location were significant predictors of grade ≥ 2 RP on multivariate analysis (p = 0.026 and 0.0043, respectively). The cumulative incidence rates of grade ≥ 2 RP at 6 months were 15.7 and 45.6% in patients with MLDs < 10 Gy and ≥ 10 Gy, respectively, and were 23.5 and 55.6% in patients with upper/middle lobe- vs. lower lobe-located tumors, respectively. CONCLUSIONS: MLD and lower lobe location were predictors of grade ≥ 2 RP in patients who received induction CCRT. It is necessary to reduce the MLD to the greatest extent possible to prevent the occurrence of this adverse event.

    DOI: 10.1186/s12885-019-6359-9

    PubMed

    researchmap

  • Solitary pulmonary nodules caused by Mycobacterium avium complex. 査読 国際誌

    Marukawa M, Taniguchi A, Kimura G, Kunichika N, Kuyama S, Maeda Y, Kiura K, Miyahara N, OKAYAMA Respiratory, Disease Study Group, ORDSG

    Respiratory investigation   57 ( 6 )   566 - 573   2019年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.resinv.2019.07.001

    PubMed

    researchmap

  • Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review. 査読

    Itano J, Higo H, Ohashi K, Makimoto G, Nishii K, Hotta K, Miyahara N, Maeda Y, Kiura K

    Internal medicine (Tokyo, Japan)   59 ( 6 )   823 - 828   2019年11月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.2169/internalmedicine.3689-19

    PubMed

    researchmap

  • Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. 査読 国際誌

    Takashi Ogura, Nagio Takigawa, Keisuke Tomii, Kazuma Kishi, Yoshikazu Inoue, Eiki Ichihara, Sakae Homma, Kazuhisa Takahashi, Hiroaki Akamatsu, Satoshi Ikeda, Naohiko Inase, Tae Iwasawa, Yuichiro Ohe, Hiromitsu Ohta, Hiroshi Onishi, Isamu Okamoto, Kazumasa Ogawa, Kazuo Kasahara, Hiroki Karata, Takumi Kishimoto, Yuka Kitamura, Akihiko Gemma, Hirotsugu Kenmotsu, Hiroyuki Sakashita, Susumu Sakamoto, Katsutoshi Sekine, Yuichi Takiguchi, Yuji Tada, Shinichi Toyooka, Yuko Nakayama, Yasuhiko Nishioka, Koichi Hagiwara, Masaki Hanibuchi, Junya Fukuoka, Yuji Minegishi, Toyoshi Yanagihara, Nobuyuki Yamamoto, Hiromasa Yamamoto, Mina Gaga, Kwun M Fong, Charles A Powell, Katsuyuki Kiura

    Respiratory investigation   57 ( 6 )   512 - 533   2019年11月

     詳細を見る

    担当区分:最終著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Dramatic progress in targeted therapy and immunotherapy has been changing clinical practices in lung cancer. With the accumulation of clinical practice, it has become clear that pre-existing interstitial pneumonia (IP) could be a risk factor for drug-induced lung injury, which has enhanced awareness regarding the difficulty in treating lung cancer with comorbid IP. Unfortunately, there is only low-grade evidence in the field of lung cancer with comorbid IP, because almost all clinical trials exclude such patients. There have been very few specialized clinical trials for patients with lung cancer and underlying IPs thus far. Therefore, it is necessary to treat such cases empirically or to give up on the treatment itself. Considering these circumstances, establishing how to treat lung cancer with comorbid IP is an urgent issue. This paper is a summary of the official statement reported by the Diffuse Lung Disease/Thoracic Oncology Assembly and the Japanese Respiratory Society (JRS) in 2017, which attempts to approach lung cancer with comorbid IP systematically.

    DOI: 10.1016/j.resinv.2019.06.001

    PubMed

    researchmap

  • A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages. 査読

    Hiromi Watanabe, Kadoaki Ohashi, Kazuya Nishii, Keisuke Seike, Go Makimoto, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Internal medicine (Tokyo, Japan)   58 ( 20 )   3033 - 3037   2019年10月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Anti-programmed cell death 1 (PD-1) antibodies have poor efficacy in epidermal growth factor receptor (EGFR)-mutated lung cancer. We herein report a 72-year-old man with programmed cell death-ligand 1 (PD-L1)-negative lung adenocarcinoma harboring an EGFR mutation that responded to nivolumab for more than 2 years. A pathological examination revealed infiltration of CD8-positive lymphocytes and macrophages expressing CD68, CD206, and PD-L1 into the PD-L1-negative tumor; CD206 expression is a marker of immunosuppressive tumor-associated macrophages (TAMs). The presence of PD-L1-positive TAMs in the tumor environment might be a predictor of a positive response to anti-PD-1 antibodies.

    DOI: 10.2169/internalmedicine.2875-19

    PubMed

    researchmap

  • EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice. 査読 国際誌

    Hisao Higo, Kadoaki Ohashi, Go Makimoto, Kazuya Nishii, Kenichiro Kudo, Hiroe Kayatani, Hiromi Watanabe, Hirohisa Kano, Kiichiro Ninomiya, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Lung cancer (Amsterdam, Netherlands)   136   86 - 93   2019年10月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Lung cancers harboring epidermal growth factor receptor (EGFR) mutations inevitably develop resistance to EGFR tyrosine-kinase inhibitors (EGFR-TKIs). Therefore, we sought to establish clinically relevant lung-cancer mouse models to achieve deep remission of cancers. MATERIALS AND METHODS: We previously established two transgenic lung-cancer mouse models harboring human EGFR exon 21 L858R substitution (hLR) and mouse Egfr exon 19 deletion (mDEL) in the C57BL/6 J background. Lung tumors from these two transgenic mouse strains were transplanted subcutaneously into BALB/c-nunu mice or C57BL/6 J mice. RESULTS: The transplanted tumors developed the ability to grow on the subcutaneous tissue, peritoneum, or lung of C57BL/6 J mice. While hLR tumors could grow only in C57BL/6 J mice carrying the transgene, mDEL tumors could grow in wild-type C57BL/6 J mice. The tumors maintained EGFR-dependency, and, thus, the EGFR-TKI gefitinib inhibited tumor growth; however, similar to human lung cancers, hLR and mDEL tumors acquired resistance in 60 and 200 days, respectively, following gefitinib administration. Secondary EGFR T790 M mutation in hLR tumors and secondary Egfr T792I mutation in mDEL tumors developed; however, no MET activation was detected. Accordingly, the third-generation EGFR-TKI osimertinib effectively inhibited gefitinib-resistant tumors in vivo. Furthermore, gefitinib-resistant tumors developed resistance to osimertinib in 100 days. CONCLUSION: These syngeneic lung-cancer mouse models harboring EGFR mutations are suitable for studying the drug-resistance mechanisms and the role of the tumor microenvironment. Further investigation with these mouse models is warranted for developing next-generation treatment strategies for lung cancer.

    DOI: 10.1016/j.lungcan.2019.08.019

    PubMed

    researchmap

  • Patients' preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406. 査読 国際誌

    Makimoto G, Hotta K, Oze I, Ninomiya K, Nakanishi M, Hara N, Kano H, Watanabe H, Hata Y, Nishii K, Nakasuka T, Itano J, Ninomiya T, Kubo T, Ohashi K, Ichihara E, Minami D, Sato A, Tabata M, Maeda Y, Kiura K

    Acta oncologica (Stockholm, Sweden)   59 ( 3 )   1 - 5   2019年10月

     詳細を見る

    担当区分:最終著者   記述言語:英語  

    DOI: 10.1080/0284186X.2019.1679880

    PubMed

    researchmap

  • Managing Lung Cancer with Comorbid Interstitial Pneumonia. 招待 査読

    Ichihara E, Miyahara N, Maeda Y, Kiura K

    Internal medicine (Tokyo, Japan)   59 ( 2 )   163 - 167   2019年9月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.2169/internalmedicine.3481-19

    PubMed

    researchmap

  • Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. 査読 国際誌

    Nishii K, Hotta K, Ninomiya K, Kato Y, Ichihara E, Ohashi K, Ninomiya T, Kubo T, Rai K, Tabata M, Maeda Y, Kiura K

    Respiratory investigation   57 ( 5 )   460 - 465   2019年9月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.resinv.2019.04.004

    PubMed

    researchmap

  • Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation. 査読 国際誌

    Yoshitaka Iwamoto, Eiki Ichihara, Naofumi Hara, Takamasa Nakasuka, Chihiro Ando, Takahiro Umeno, Atsuko Hirabae, Yoshinobu Maeda, Katsuyuki Kiura

    Japanese journal of clinical oncology   49 ( 8 )   786 - 788   2019年8月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Exon 18 delE709_T710insD is an extremely rare mutation in epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC); the efficacy of EGFR tyrosine kinase inhibitors against this mutation remains unclear. In this case report, we report a case of NSCLC harboring EGFR exon 18 delE709_T710insD that was not detected by a commercially available assay, but was detected by a next-generation sequencing cancer panel. A 56-year old female patient with advanced NSCLC was diagnosed as EGFR-mutation-negative using the PNAClamp method. ALK rearrangement was also absent and she received cytotoxic chemotherapies. Clinical characteristics, including adenocarcinoma histology and no history of smoking, implied the presence of a driver mutation, so a next-generation-sequencing Oncomine® Cancer Research Panel was conducted in the patient's clinical course and the EGFR exon 18 delE709_T710insD mutation was detected. The patient started afatinib as sixth-line treatment and her pulmonary lesion significantly decreased in size. Afatinib was continued for 7 months until disease progressed.

    DOI: 10.1093/jjco/hyz086

    PubMed

    researchmap

  • The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. 査読 国際誌

    Watanabe H, Kubo T, Ninomiya K, Kudo K, Minami D, Murakami E, Ochi N, Ninomiya T, Harada D, Yasugi M, Ichihara E, Ohashi K, Fujiwara K, Hotta K, Tabata M, Maeda Y, Kiura K

    Japanese journal of clinical oncology   49 ( 8 )   762 - 765   2019年8月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/jjco/hyz066

    PubMed

    researchmap

  • A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement. 査読 国際誌

    Harada D, Kozuki T, Nogami N, Bessho A, Hosokawa S, Fukamatsu N, Hotta K, Ohashi K, Kubo T, Yoshioka H, Yokoyama T, Sone N, Kuyama S, Kudo K, Yasugi M, Takigawa N, Oze I, Kiura K

    Asia-Pacific journal of clinical oncology   15 ( 4 )   250 - 256   2019年8月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/ajco.13147

    PubMed

    researchmap

  • Cause of pleuroparenchymal fibroelastosis following allogeneic hematopoietic stem cell transplantation. 査読 国際誌

    Higo H, Miyahara N, Taniguchi A, Maeda Y, Kiura K

    Respiratory investigation   57 ( 4 )   321 - 324   2019年7月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.resinv.2019.04.003

    PubMed

    researchmap

  • Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy. 査読

    Suzawa K, Soh J, Takahashi Y, Sato H, Shien K, Yamamoto H, Kanazawa S, Kiura K, Miyoshi S, Toyooka S

    Surgery today   49 ( 7 )   601 - 609   2019年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00595-019-1774-8

    PubMed

    researchmap

  • Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. 査読 国際誌

    Hirashima T, Satouchi M, Hida T, Nishio M, Kato T, Sakai H, Imamura F, Kiura K, Okamoto I, Kasahara K, Uchida H, Vowler SL, Mitsudomi T

    Cancer science   110 ( 9 )   2884 - 2893   2019年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.14120

    PubMed

    researchmap

  • Recent trends in the treatment of unresectable stage III non-small-cell lung cancer. 査読 国際誌

    Go Makimoto, Katsuyuki Hotta, Katsuyuki Kiura

    Respiratory investigation   57 ( 4 )   330 - 336   2019年7月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Approximately 20-25% of non-small-cell lung cancer (NSCLC) is diagnosed when the disease has progressed to clinical stage III. At this stage, and even if the cancer is considered unresectable, the treatment strategy should aim to achieve a cure. At the time of the initial diagnosis, it is necessary for medical oncologists to devise the best treatment strategy for each patient by composing a multidisciplinary treatment team including thoracic surgeons and radiation oncologists. In this review, we summarize prior pivotal clinical trials in unresectable clinical stage III NSCLC. Furthermore, we review very recent clinical trials evaluating the efficacy of immune checkpoint inhibitors in the treatment of NSCLC.

    DOI: 10.1016/j.resinv.2019.03.004

    PubMed

    researchmap

  • Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib. 査読

    Go Makimoto, Kadoaki Ohashi, Satoru Senoo, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

    Internal medicine (Tokyo, Japan)   58 ( 11 )   1625 - 1627   2019年6月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. A 69-year-old non-smoking woman was diagnosed with advanced NSCLC harboring an EGFR exon19 deletion and T790M. She was treated with osimertinib for two years but eventually acquired resistance. After 1.5 years of salvage chemotherapies, osimertinib was re-administered. She has been effectively and safely treated with osimertinib readministration for over 10 months. A prospective study is warranted to evaluate the efficacy and safety of osimertinib readministration in NSCLC with EGFR mutations.

    DOI: 10.2169/internalmedicine.2152-18

    PubMed

    researchmap

  • Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. 査読 国際誌

    Ichihara E, Hotta K, Ninomiya K, Kubo T, Ohashi K, Rai K, Tanaka H, Tabata M, Maeda Y, Kiura K

    Lung cancer (Amsterdam, Netherlands)   132   54 - 58   2019年6月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.lungcan.2019.02.021

    PubMed

    researchmap

  • Successful Treatment of Metastatic Urothelial Carcinoma after Accurate Diagnosis by Immunohistochemistry. 査読

    Makimoto G, Nishimori H, Kondo R, Yanai H, Sugimoto M, Oda N, Kubo T, Hotta K, Tabata M, Kiura K, Maeda Y

    Acta medica Okayama   73 ( 3 )   279 - 284   2019年6月

     詳細を見る

    記述言語:英語  

    DOI: 10.18926/AMO/56873

    PubMed

    researchmap

  • Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. 査読 国際誌

    Higo H, Kubo T, Makimoto S, Makimoto G, Ihara H, Masaoka Y, Ninomiya T, Ichihara E, Ohashi K, Sato A, Hotta K, Tabata M, Takigawa N, Maeda Y, Kiura K

    Japanese journal of clinical oncology   49 ( 5 )   458 - 464   2019年5月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/jjco/hyz016

    PubMed

    researchmap

  • Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. 査読

    Sugawara S, Nakagawa K, Yamamoto N, Nokihara H, Ohe Y, Nishio M, Takahashi T, Goto K, Maemondo M, Ichinose Y, Seto T, Sakai H, Gemma A, Imamura F, Shingyoji M, Saka H, Inoue A, Takeda K, Okamoto I, Kiura K, Morita S, Tamura T

    International journal of clinical oncology   24 ( 5 )   485 - 493   2019年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10147-019-01396-z

    PubMed

    researchmap

  • Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. 査読

    Satoru Senoo, Kiichiro Ninomiya, Katsuyuki Hotta, Katsuyuki Kiura

    International journal of clinical oncology   24 ( 5 )   461 - 467   2019年5月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Squamous cell carcinoma of the lung is associated with smoking in its development and comprises about 20-30% of all lung cancers. Its treatment strategy had been limited for the past decades, inevitably resulting in the poor outcome. However in the 2010s, it has dramatically changed mainly with the recent clinical introduction of immune checkpoint inhibitors. In this review, we will introduce various clinical studies involving squamous cell carcinoma of the lung.

    DOI: 10.1007/s10147-019-01424-y

    PubMed

    researchmap

  • Randomized phase II study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in advanced non-small cell lung cancer: The OLCSG1406 trial.

    Go Makimoto, Katsuyuki Hotta, Isao Oze, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Kadoaki Ohashi, Eiki Ichihara, Kammei Rai, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    JOURNAL OF CLINICAL ONCOLOGY   37 ( 15 )   2019年5月

     詳細を見る

    担当区分:最終著者   記述言語:英語   出版者・発行元:AMER SOC CLINICAL ONCOLOGY  

    DOI: 10.1200/JCO.2019.37.15_suppl.e23105

    Web of Science

    researchmap

  • Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab. 査読

    Senoo S, Ninomiya T, Makimoto G, Nishii K, Kano H, Watanabe H, Hata Y, Kubo T, Tanaka T, Hotta K, Maeda Y, Kiura K

    Internal medicine (Tokyo, Japan)   58 ( 7 )   985 - 989   2019年4月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.2169/internalmedicine.0890-18

    PubMed

    researchmap

  • Requirement for neuropeptide Y in the development of type 2 responses and allergen-induced airway hyperresponsiveness and inflammation. 査読 国際誌

    Oda N, Miyahara N, Taniguchi A, Morichika D, Senoo S, Fujii U, Itano J, Gion Y, Kiura K, Kanehiro A, Maeda Y

    American journal of physiology. Lung cellular and molecular physiology   316 ( 3 )   L407 - L417   2019年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1152/ajplung.00386.2018

    PubMed

    researchmap

  • Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. 査読 国際誌

    Ninomiya T, Ishikawa N, Inoue K, Kubo T, Yasugi M, Shibayama T, Maeda T, Fujitaka K, Kodani M, Yokoyama T, Kuyama S, Ochi N, Ueda Y, Miyoshi S, Kozuki T, Amano Y, Kubota T, Sugimoto K, Bessho A, Ishii T, Watanabe K, Oze I, Hotta K, Kiura K

    Clinical lung cancer   20 ( 2 )   134 - 138   2019年3月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.cllc.2018.10.008

    PubMed

    researchmap

  • Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival. 査読 国際誌

    Tanaka S, Miyoshi K, Higo H, Kurosaki T, Otani S, Sugimoto S, Yamane M, Kiura K, Toyooka S, Oto T

    Respiratory investigation   57 ( 2 )   165 - 171   2019年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.resinv.2018.12.002

    PubMed

    researchmap

  • A retinoid X receptor partial agonist attenuates pulmonary emphysema and airway inflammation. 査読 国際誌

    Morichika D, Miyahara N, Fujii U, Taniguchi A, Oda N, Senoo S, Kataoka M, Tanimoto M, Kakuta H, Kiura K, Maeda Y, Kanehiro A

    Respiratory research   20 ( 1 )   2 - 2   2019年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/s12931-018-0963-0

    PubMed

    researchmap

  • Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. 査読

    Katsuyuki Hotta, Kiichiro Ninomiya, Eiki Ichihara, Katsuyuki Kiura

    International journal of clinical oncology   24 ( 1 )   41 - 45   2019年1月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. This review reports that the significance of a re-biopsy varies depending on the clinical situation.

    DOI: 10.1007/s10147-018-1344-x

    PubMed

    researchmap

  • Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review. 査読 国際誌

    Makimoto G, Ohashi K, Taniguchi K, Soh J, Taniguchi A, Miyahara N, Toyooka S, Yoshino T, Maeda Y, Kiura K

    Respiratory medicine case reports   28   100938 - 100938   2019年

     詳細を見る

    担当区分:最終著者   記述言語:英語  

    DOI: 10.1016/j.rmcr.2019.100938

    PubMed

    researchmap

  • A case of axillary lymphadenitis caused by Mycobacterium intracellulare in an immunocompetent patient. 査読 国際誌

    Itano J, Ohashi K, Senoo S, Oda N, Nishii K, Taniguchi A, Miyahara N, Maeda Y, Kiura K

    Respiratory medicine case reports   28   100947 - 100947   2019年

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.rmcr.2019.100947

    PubMed

    researchmap

  • A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403 査読 国際誌

    Naohiro Oda, Kastuyuki Hotta, Kiichiro Ninomiya, Daisuke Minami, Eiki Ichihara, Toshi Murakami, Toshihide Yokoyama, Hirohisa Ichikawa, Kenichi Chikamori, Nagio Takigawa, Nobuaki Ochi, Shingo Harita, Yoshinobu Maeda, Katsuyuki Kiura

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   82 ( 6 )   1031 - 1038   2018年12月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    PurposeThe aim of this study was to evaluate the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) readministration using afatinib in patients with non-small-cell lung cancer (NSCLC) with a sensitive non-T790M EGFR mutation who had received cytotoxic chemotherapy after acquiring resistance to EGFR-TKIs.MethodsEligible patients had EGFR-mutant tumors resistant to first- or second-generation EGFR-TKIs and an EGFR-TKI-free period with cytotoxic agents. Confirmation of absence of the T790M mutation was required before registration. Afatinib (40mg/body) was administered daily. The primary endpoint was progression-free survival (PFS). We assumed estimated and threshold PFS times of 3.3 and 1 months, with an of 0.05 and of 0.1, respectively.ResultsTwelve patients were enrolled from December 2014 to May 2017. The objective response rate and disease control rate were 17% and 84%, respectively. The median PFS time was 4.2 months (95% confidence interval [CI] 2.0-5.8), which met the pre-defined primary endpoint. The median overall survival was 11.6 months (95% CI 9.2-not reached). Grade 3 or worse adverse events included diarrhea (25%), elevated creatinine levels (8%), and hypokalemia (8%), without any treatment-related deaths.ConclusionEGFR-TKI readministration with afatinib for sensitive EGFR-mutant NSCLC without T790M after resistance to a first- or second-generation EGFR-TKI yielded modest activity with tolerable toxicity. It might be one of the treatment options in patients who do not possess T790M tumors, although further studies in this patient setting are warranted.

    DOI: 10.1007/s00280-018-3694-5

    Web of Science

    PubMed

    researchmap

  • Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors. 査読 国際誌

    Kubo T, Ninomiya T, Hotta K, Kozuki T, Toyooka S, Okada H, Fujiwara T, Udono H, Kiura K

    Clinical lung cancer   19 ( 6 )   e861 - e864   2018年11月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.cllc.2018.07.010

    PubMed

    researchmap

  • Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab. 査読 国際誌

    Oda N, Miyahara N, Senoo S, Itano J, Taniguchi A, Morichika D, Fujii U, Maeda Y, Kiura K, Kanehiro A

    Allergology international : official journal of the Japanese Society of Allergology   67 ( 4 )   521 - 523   2018年10月

     詳細を見る

  • Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. 査読 国際誌

    Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K

    Cancer science   109 ( 10 )   3149 - 3158   2018年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.13752

    PubMed

    researchmap

  • Dose-Volume Parameters Predict Radiation Pneumonitis after Surgery with Induction Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer. 査読

    Ogata T, Katsui K, Yoshio K, Ihara H, Katayama N, Soh J, Kuroda M, Kiura K, Maeda Y, Toyooka S, Kanazawa S

    Acta medica Okayama   72 ( 5 )   507 - 513   2018年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.18926/AMO/56249

    PubMed

    researchmap

  • Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. 査読 国際誌

    Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M, Kim SW, Kiura K, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K

    Cancer science   109 ( 9 )   2852 - 2862   2018年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.13724

    PubMed

    researchmap

  • ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer. 査読 国際誌

    Azuma K, Nishio M, Hayashi H, Kiura K, Satouchi M, Sugawara S, Hida T, Iwamoto Y, Inoue A, Takeda K, Ikeda S, Nakagawa T, Takeda K, Asahina S, Komatsu K, Morita S, Fukuoka M, Nakagawa K

    Cancer science   109 ( 8 )   2532 - 2538   2018年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.13651

    PubMed

    researchmap

  • Needle wash solution cultures following EBUS-TBNA with or without endobronchial intubation. 国際誌

    Daisuke Minami, Nagio Takigawa, Masahide Oki, Hideo Saka, Takuo Shibayama, Katsuyuki Kiura

    Respiratory investigation   56 ( 4 )   356 - 360   2018年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive procedure with a high diagnostic yield in lesions adjacent to the airways. However, complications associated with EBUS-TBNA, such as mediastinitis, have recently been reported. Oral bacteria contamination in punctured lymph nodes can cause severe infections. In the current study, we investigated whether endobronchial intubation using EBUS-TBNA can prevent oral bacterial contamination of punctured lymph nodes. METHODS: We retrospectively evaluated 80 patients (102 lymph nodes) who had undergone EBUS-TBNA and divided them two groups: Group A comprised 60 patients who had undergone EBUS-TBNA with endobronchial intubation and Group B consisted of 20 patients who had undergone EBUS-TBNA without endobronchial intubation. The patients' medical records were examined and the two groups were compared using the unpaired Student's t-test. RESULTS: EBUS-TBNA needle wash cultures were positive in only two Group A cases (3.3%), but in all 20 Group B cases (100%) (P < 0.05). Except for one case of Mycobacterium tuberculosis, all bacterial isolates yielded typical oropharyngeal commensal flora. Fever (≥ 38.0 °C) was observed in six Group A cases (10%) and two Group B cases (10%; P = 0.526). This was treated by cooling, a single administration of non-steroidal anti-inflammatory drugs, and/or antibiotic therapy. Fever was not associated with any clinical features, including malignancy in punctured lesions, number of punctures, echo features, simultaneous peripheral biopsy, additional oral prophylactic antibiotics, or positive needle wash cultures. CONCLUSIONS: Endobronchial intubation may prevent contamination by oropharyngeal commensal bacteria.

    DOI: 10.1016/j.resinv.2018.03.006

    PubMed

    researchmap

  • Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. 査読 国際誌

    Ichihara E, Hotta K, Kubo T, Higashionna T, Ninomiya K, Ohashi K, Tabata M, Maeda Y, Kiura K

    Oncotarget   9 ( 50 )   29525 - 29531   2018年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.18632/oncotarget.25705

    PubMed

    researchmap

  • Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol. 査読

    Makimoto G, Ichihara E, Hotta K, Ninomiya K, Oze I, Minami D, Ninomiya T, Kubo T, Ohashi K, Tabata M, Maeda Y, Kiura K

    Acta medica Okayama   72 ( 3 )   319 - 323   2018年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.18926/AMO/56080

    PubMed

    researchmap

  • Is Surgery after Chemoradiotherapy Feasible in Lung Cancer Patients with Superior Vena Cava Invasion? 査読

    Sato H, Soh J, Hotta K, Katsui K, Kanazawa S, Kiura K, Toyooka S

    Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia   24 ( 3 )   131 - 138   2018年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.5761/atcs.oa.18-00027

    PubMed

    researchmap

  • フェンタニルとミダゾラム併用による気管挿管下での気管支鏡検査の苦痛度評価

    南 大輔, 瀧川 奈義夫, 二宮 崇, 久保 寿夫, 市原 英基, 大橋 圭明, 堀田 勝幸, 宮原 信明, 柴山 卓夫, 田端 雅弘, 木浦 勝行

    気管支学   40 ( Suppl. )   S189 - S189   2018年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本呼吸器内視鏡学会  

    researchmap

  • Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. 査読 国際誌

    Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K

    Clinical lung cancer   19 ( 3 )   213 - 220.e4   2018年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Despite the likelihood of an initial response to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non-small-cell lung cancer (NSCLC) patients develop disease progression. Antiangiogenic agents in combination with an EGFR TKI might provide additional benefit in patients with EGFR-mutant NSCLC. In this article we report safety, exposure, and progression-free survival (PFS) results for part A (phase Ib) of RELAY, a randomized, double-blind, phase Ib/III study investigating safety and efficacy of erlotinib (EGFR TKI) with ramucirumab (anti-vascular endothelial growth factor receptor-2 antibody) or placebo in first-line EGFR-mutant stage IV NSCLC. PATIENTS AND METHODS: Eligible patients had untreated stage IV NSCLC, Eastern Cooperative Oncology Group performance status of 0 to 1, and activating EGFR mutation (exon 19 deletion or exon 21 L858R substitution). Patients received ramucirumab 10 mg/kg on day 1 of a repeating 14-day cycle and erlotinib 150 mg/d. Treatment continued until disease progression or unacceptable toxicity. The primary objective was to assess safety and tolerability, in terms of dose-limiting toxicities (DLTs), during the first 2 cycles. RESULTS: Fourteen patients were treated and 12 were evaluable for DLTs. One patient experienced a DLT of Grade 3 elevated alanine aminotransferase during the DLT assessment period. Adverse events were reported in all patients, but were generally mild and manageable. The most common Grade 3 adverse events were hypertension, rash, and diarrhea. No serious or Grade 4 to 5 events occurred. Median PFS was 17.1 months (95% confidence interval, 8.8-not reached). Five patients continue receiving study treatment. CONCLUSION: Ramucirumab with erlotinib showed no unexpected toxicities and encouraging clinical activity in part A. Phase III enrollment has been initiated, maintaining ramucirumab 10 mg/kg every 2 weeks with erlotinib 150 mg/d.

    DOI: 10.1016/j.cllc.2017.11.003

    PubMed

    researchmap

  • Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples. 査読 国際誌

    Kiura K, Yoh K, Katakami N, Nogami N, Kasahara K, Takahashi T, Okamoto I, Cantarini M, Hodge R, Uchida H

    Cancer science   109 ( 4 )   1177 - 1184   2018年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.13511

    PubMed

    researchmap

  • Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. 査読 国際誌

    Kiura K, Imamura F, Kagamu H, Matsumoto S, Hida T, Nakagawa K, Satouchi M, Okamoto I, Takenoyama M, Fujisaka Y, Kurata T, Ito M, Tokushige K, Hatano B, Nishio M

    Japanese journal of clinical oncology   48 ( 4 )   367 - 375   2018年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/jjco/hyy016

    PubMed

    researchmap

  • Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. 査読 国際誌

    Makimoto G, Kubo T, Oze I, Ohashi K, Hotta K, Tabata M, Soh J, Toyooka S, Katsui K, Takigawa N, Tanimoto M, Kiura K

    Japanese journal of clinical oncology   48 ( 3 )   287 - 290   2018年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/jjco/hyy003

    PubMed

    researchmap

  • A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. 査読 国際誌

    Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, Kuyama S, Kudo K, Bessho A, Fukamatsu N, Fujimoto N, Aoe K, Shibayama T, Sugimoto K, Takigawa N, Hotta K, Kiura K

    Lung cancer (Amsterdam, Netherlands)   115   103 - 108   2018年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.lungcan.2017.11.025

    PubMed

    researchmap

  • MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. 査読 国際誌

    Ninomiya K, Ohashi K, Makimoto G, Tomida S, Higo H, Kayatani H, Ninomiya T, Kubo T, Ichihara E, Hotta K, Tabata M, Maeda Y, Kiura K

    Scientific reports   8 ( 1 )   1955 - 1955   2018年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41598-018-20326-z

    PubMed

    researchmap

  • A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors. 査読 国際誌

    Sasaki T, Kato Y, Sato A, Usui N, Baba E, Takano T, Susumu N, Ohnishi K, Nishimoto H, Kiura K

    Journal of pharmaceutical health care and sciences   4   2 - 2   2018年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Clinical practice guidelines should be user-friendly and confirming their penetration rate and compliance are critical. Methods: We conducted a nationwide web-based questionnaire survey among pharmacists regarding the 2013 guidelines for the appropriate use of granulocyte-colony stimulating factors (G-CSFs) (version 2, published by the Japan Society of Clinical Oncology [JSCO]) between August 24 and September 6, 2015. Results: A total of 301 pharmacists responded; 96.0% belonged to hospitals and were board-certified pharmacists in oncology pharmacy (n = 133) and palliative pharmacy (n = 78). In addition, 61.5% of respondents (n = 185) worked for designated cancer care hospitals. The observation that 75.7% of respondents knew that the JSCO guidelines are available on the internet indicated that several pharmacists used this guideline. A high degree of usability by pharmacists was also demonstrated, as 98.0% and 51.5% of respondents, respectively, agreed with the statements "it is useful for the work of pharmacists" and "it is referred to in the actual work of pharmacists". However, more than half of the respondents (58.4%) agreed with the phrase "there are differences from the actual work of pharmacists". Conclusions: Their responses indicated that the respondents used the G-CSF guidelines and viewed them positively; however, the observation that about half of the respondents reported feeling that the guidelines do not match their current practice requires additional follow-up in future studies. The use of these guidelines should be routinely assessed in order to introduce novel cancer chemotherapy regimens and long-acting G-CSF in clinical practice.

    DOI: 10.1186/s40780-018-0098-y

    PubMed

    researchmap

  • EGFR G719A遺伝子変異を有する肺腺癌に対してニボルマブが奏効した1例

    高瀬 了輔, 板野 純子, 西井 和也, 二宮 崇, 市原 英基, 大橋 圭明, 堀田 勝幸, 木浦 勝行, 久保 寿夫, 田端 雅弘

    肺癌   57 ( 7 )   903 - 903   2017年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E. 査読 国際誌

    Yamamoto H, Toyooka S, Ninomiya T, Matsumoto S, Kanai M, Tomida S, Kiura K, Muto M, Suzawa K, Desmeules P, Kris MG, Li BT, Ladanyi M

    The oncologist   23 ( 2 )   150 - 154   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1634/theoncologist.2017-0345

    PubMed

    researchmap

  • EGFR遺伝子変異陽性非小細胞肺癌に対するafatinib+bevacizumab併用療法の第I相試験

    別所 昭宏, 深松 伸明, 野上 尚之, 久山 彰一, 大橋 圭明, 藤本 伸一, 杉本 啓介, 瀧川 奈義夫, 二宮 崇, 木浦 勝行

    日本癌治療学会学術集会抄録集   55回   O25 - 6   2017年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • EBUS-TBNA後の発熱および穿刺針洗浄培養における挿管チューブの有用性

    南 大輔, 瀧川 奈義夫, 沖 昌英, 坂 英雄, 二宮 崇, 久保 寿夫, 市原 英基, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 柴山 卓夫, 田端 雅弘, 木浦 勝行

    肺癌   57 ( 5 )   453 - 453   2017年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 肺がん新治療の展望 HER2異常肺癌に対する治療戦略

    豊岡 伸一, 諏澤 憲, 二宮 崇, 山本 寛斉, 枝園 和彦, 宗 淳一, 冨田 秀太, 木浦 勝行

    日本癌学会総会記事   76回   SST6 - 3   2017年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • T790M遺伝子変異検索における再・再生検の意義

    市原 英基, 堀田 勝幸, 二宮 崇, 久保 寿夫, 東恩納 司, 大橋 圭明, 佐藤 晃子, 田端 雅弘, 木浦 勝行

    肺癌   57 ( 5 )   420 - 420   2017年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • Interstitial lung abnormalitiesを有する局所進行肺癌に対する放射線化学療法の検討

    肥後 寿夫, 久保 寿夫, 槇本 怜子, 井原 弘貴, 正岡 佳久, 二宮 崇, 市原 英基, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 田端 雅弘, 瀧川 奈義夫, 木浦 勝行

    肺癌   57 ( 5 )   499 - 499   2017年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo. 査読

    Kudo K, Ohashi K, Makimoto G, Higo H, Kato Y, Kayatani H, Kurata Y, Takami Y, Minami D, Ninomiya T, Kubo T, Ichihara E, Sato A, Hotta K, Yoshino T, Tanimoto M, Kiura K

    Molecular oncology   11 ( 6 )   670 - 681   2017年6月

  • Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease. 査読 国際誌

    Oda N, Miyahara N, Ichikawa H, Tanimoto Y, Kajimoto K, Sakugawa M, Kawai H, Taniguchi A, Morichika D, Tanimoto M, Kanehiro A, Kiura K

    International journal of chronic obstructive pulmonary disease   12   1119 - 1124   2017年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.2147/COPD.S133071

    PubMed

    researchmap

  • 肺多形癌に対してnivolumabを投与中にニューモシスチス肺炎を発症した1例

    小柳 太作, 堀田 勝幸, 妹尾 賢, 狩野 裕久, 西井 和也, 秦 雄介, 渡邉 洋美, 二宮 崇, 大橋 圭明, 市原 英基, 佐藤 晃子, 木浦 勝行, 久保 寿夫, 田端 雅弘, 谷本 光音

    肺癌   56 ( 7 )   1087 - 1088   2016年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • オシメルチニブ投与中に発症したうっ血性心不全の1例

    松尾 逸平, 渡邉 洋美, 市原 英基, 狩野 裕久, 妹尾 賢, 西井 和也, 秦 雄介, 二宮 崇, 久保 寿夫, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    肺癌   56 ( 7 )   1088 - 1088   2016年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 肺多形癌に対してnivolumabを投与し、抗腫瘍効果が得られた1例

    妹尾 賢, 狩野 裕久, 西井 和也, 秦 雄介, 渡邉 洋美, 二宮 崇, 久保 寿夫, 大橋 圭明, 市原 英基, 佐藤 晃子, 堀田 勝幸, 田端 雅弘, 谷本 光音, 木浦 勝行

    肺癌   56 ( 6 )   859 - 859   2016年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 脳転移を有する非小細胞肺がんに対するニボルマブの使用経験

    渡邉 洋美, 久保 寿夫, 狩野 裕久, 妹尾 賢, 西井 和也, 秦 雄介, 二宮 崇, 市原 英基, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 田端 雅弘, 谷本 光音, 木浦 勝行

    肺癌   56 ( 6 )   800 - 800   2016年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 非小細胞肺癌に対するre-biopsy 気管支鏡検査とCTガイド下生検との比較

    狩野 裕久, 久保 寿夫, 妹尾 賢, 西井 和也, 秦 雄介, 渡邉 洋美, 二宮 崇, 市原 英基, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 田端 雅弘, 谷本 光音, 木浦 勝行

    肺癌   56 ( 6 )   512 - 512   2016年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 挿管チューブを使用したEBUS-TBNA後の発熱および穿刺針洗浄培養の後方視的検討

    南 大輔, 瀧川 奈義夫, 二宮 崇, 久保 寿夫, 大橋 圭明, 堀田 勝幸, 柴山 卓夫, 宮原 信明, 田端 雅弘, 谷本 光音, 木浦 勝行

    肺癌   56 ( 6 )   511 - 511   2016年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 肺 肺がんのトランスレーショナル・リサーチ EGFR遺伝子変異陽性NSCLCに対するGefitinib治療中の肝障害発現における過体重の影響

    小田 尚廣, 堀田 勝幸, 吉岡 弘鎮, 工藤 健一郎, 市原 英基, 加藤 有加, 二宮 貴一朗, 二宮 崇, 久保 寿夫, 大橋 圭明, 佐藤 晃子, 瀧川 奈義夫, 田端 雅弘, 谷本 光音, 木浦 勝行

    日本癌治療学会学術集会抄録集   54回   WS59 - 2   2016年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • Common variable immunodeficiency患者に発症したEBウイルス関連多発平滑筋腫瘍の1例

    妹尾 賢, 田端 雅弘, 狩野 裕久, 西井 和也, 秦 雄介, 渡邉 洋美, 二宮 崇, 久保 寿夫, 大橋 圭明, 市原 英基, 佐藤 晃子, 堀田 勝幸, 木浦 勝行, 谷本 光音

    日本癌治療学会学術集会抄録集   54回   P62 - 10   2016年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • 右肺門部腫瘤影の一例

    秦 雄介, 二宮 崇, 渡邉 洋美, 狩野 裕久, 西井 和也, 妹尾 賢, 加藤 有加, 谷口 暁彦, 南 大輔, 久保 寿夫, 大橋 圭明, 堀田 勝幸, 宮原 信明, 田端 雅弘, 金廣 有彦, 谷本 光音, 木浦 勝行

    岡山医学会雑誌   128 ( 2 )   155 - 156   2016年8月

  • Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial 査読 国際誌

    Koichi Goto, Yuichiro Ohe, Taro Shibata, Takashi Seto, Toshiaki Takahashi, Kazuhiko Nakagawa, Hiroshi Tanaka, Koji Takeda, Makoto Nishio, Kiyoshi Mori, Miyako Satouchi, Toyoaki Hida, Naruo Yoshimura, Toshiyuki Kozuki, Fumio Imamura, Katsuyuki Kiura, Hiroaki Okamoto, Toshiyuki Sawa, Tomohide Tamura

    LANCET ONCOLOGY   17 ( 8 )   1147 - 1157   2016年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE INC  

    Background Etoposide and irinotecan are key drugs in the treatment of small-cell lung cancer. We did this study to investigate whether combined chemotherapy with cisplatin, etoposide, and irinotecan was superior to topotecan monotherapy as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer.
    Methods We did this open-label, multicentre, randomised phase 3 trial at 29 institutions in Japan. Patients with small-cell lung cancer that responded to first-line treatment but showed evidence of disease relapse or progression at least 90 days after completion of the first-line treatment were eligible to participate. Enrolled patients were randomly assigned (1: 1) to receive combination chemotherapy with cisplatin plus etoposide plus irinotecan or topotecan alone. Randomisation was done via the minimisation method with biased-coin balancing for Eastern Cooperative Oncology Group performance status, disease stage at enrolment, and institution. Combination chemotherapy consisted of five 2-week courses of intravenous cisplatin 25 mg/m(2) on days 1 and 8, intravenous etoposide 60 mg/m(2) on days 1-3, and intravenous irinotecan 90 mg/m(2) on day 8, with granulocyte colony-stimulating factor given by hypodermic injection every day starting from day 9 of the first course (except on the days anticancer drugs were given). Topotecan therapy consisted of four courses of intravenous topotecan 1.0 mg/m(2) on days 1-5, every 3 weeks. The primary endpoint was overall survival in the intention-to-treat population, which was analysed with a one-sided a of 5%, and safety was assessed in all patients who received at least one dose of study drug. The trial is registered with University Hospital Medical Information Network Clinical Trials Registry, number UMIN000000828.
    Findings Between Sept 20, 2007, and Nov 30, 2012, 180 patients were enrolled, with 90 assigned to each treatment group. The median follow-up for censored patients was 22.7 months (IQR 20.0-35.3). Overall survival was significantly longer in the combination chemotherapy group (median 18.2 months, 95% CI 15.7-20.6) than in the topotecan group (12.5 months, 10.8-14.9; hazard ratio 0.67, 90% CI 0.51-0.88; p=0.0079). The most common grade 3 or 4 adverse events were neutropenia (75 [83%] patients in the combination chemotherapy group vs 77 [86%] patients in the topotecan group), anaemia (76 [84%] vs 25 [28%]), and leucopenia (72 [80%] vs 46 [51%]). Grade 3 or 4 febrile neutropenia was more common in the combination chemotherapy group than in the topotecan group (28 [31%] vs six [7%]), as was grade 3 or 4 thrombocytopenia (37 [41%] vs 25 [28%]). Serious adverse events were reported in four (4%) patients in the topotecan group and nine (10%) in the combination chemotherapy group. Two treatment-related deaths (one each of pneumonitis and pulmonary infection) occurred in the topotecan group and one (febrile neutropenia with sepsis) occurred in the combination chemotherapy group.
    Interpretation Combination chemotherapy with cisplatin plus etoposide plus irinotecan could be considered the standard second-line chemotherapy for selected patients with sensitive relapsed small-cell lung cancer.

    DOI: 10.1016/S1470-2045(16)30104-8

    Web of Science

    PubMed

    researchmap

  • Activating alternative receptor tyrosine kinases induced alectinib-resistance in ALK rearranged non-small cell lung cancer cells 査読

    Isozaki Hideko, Ichihara Eiki, Yasugi Masayuki, Takigawa Nagio, Ohashi Kadoaki, Kubo Toshio, Ninomiya Takashi, Ochi Nobuaki, Minami Daisuke, Kudo Kenichiro, Kato Yuka, Kayatani Hiroe, Tamura Tomoki, Ninonniya Kiichiro, Higo Toshio, Makimoto Tsuyoshi, Sato Akiko, Hotta Katsuyuki, Matsumoto Kunio, Sendo Toshiaki, Tanimoto Mitsune, Kiura Katsuyuki

    CANCER RESEARCH   76   2016年7月

     詳細を見る

  • Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on F-18-fluorodeoxyglucose positron emission tomography/computed tomography 査読

    Daisuke Minami, Nagio Takigawa, Naohiro Oda, Takashi Ninomiya, Toshio Kubo, Kadoaki Ohashi, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Mitsumasa Kaji, Mitsune Tanimoto, Katsuyuki Kiura

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   46 ( 6 )   529 - 533   2016年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OXFORD UNIV PRESS  

    Endobronchial ultrasound-guided transbronchial needle aspiration is of diagnostic value in hilar/mediastinal (N1/N2) lymph node staging. We assessed the utility of endobronchial ultrasound-guided transbronchial needle aspiration in lung cancer patients with N1/N2 lymph nodes detected on F-18-fluorodeoxyglucose positron emission tomography/computed tomography.
    Fifty lung cancer patients with N1/N2 disease on F-18-fluorodeoxyglucose positron emission tomography/computed tomography underwent endobronchial ultrasound-guided transbronchial needle aspiration for pathological lymph nodes between November 2012 and April 2015. The diagnostic performance of endobronchial ultrasound-guided transbronchial needle aspiration, lymph node site and size, number of needle passes and complications were evaluated retrospectively from patients' medical records. Malignancy was defined as a maximum standardized uptake value (SUVmax) &gt; 2.5.
    The median longest diameter of the 61 lymph nodes (29 subcarinal, 21 right lower paratracheal, 6 left lower paratracheal, 4 right hilar and 1 upper paratracheal) was 23.4 mm (range: 10.4-45.7); the median number of needle passes was 2 (range: 1-5). There were no severe complications. A definitive diagnosis was made by endobronchial ultrasound-guided transbronchial needle aspiration in 39 patients (31 adenocarcinomas, 3 small-cell carcinomas, 2 squamous-cell carcinomas, 3 large-cell neuroendocrine carcinomas). In the remaining 11 patients, the diagnosis was indefinite: insufficient endobronchial ultrasound-guided transbronchial needle aspiration material was collected in two patients and non-specific lymphadenopathy was confirmed by endobronchial ultrasound-guided transbronchial needle aspiration or thoracotomy in the other nine patients. The mean lymph node SUVmax was 7.09 (range: 2.90-26.9) and was significantly higher in true-positive than in false-positive nodes (P &lt; 0.05, t-test). Non-specific lymphadenopathy was diagnosed by expert visual interpretation of F-18-fluorodeoxyglucose positron emission tomography/computed tomography images in five of the nine patients.
    Endobronchial ultrasound-guided transbronchial needle aspiration accurately diagnoses N1/N2 disease detected on F-18-fluorodeoxyglucose positron emission tomography/computed tomography.

    DOI: 10.1093/jjco/hyw023

    Web of Science

    researchmap

  • 呼吸器内視鏡の新技術 BIOEVALUATORを用いた迅速細胞診断を併用したEBUS-TBNAの組織診断

    南 大輔, 瀧川 奈義夫, 二宮 崇, 久保 寿夫, 大橋 圭明, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅彦, 谷本 光音, 木浦 勝行

    気管支学   38 ( Suppl. )   S176 - S176   2016年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本呼吸器内視鏡学会  

    researchmap

  • RebiopsyにおいてEBUS-TBNAが有用であった3症例

    狩野 裕久, 南 大輔, 妹尾 賢, 西井 和也, 秦 雄介, 渡邉 洋美, 加藤 有加, 谷口 暁彦, 二宮 崇, 久保 寿夫, 大橋 圭明, 堀田 勝幸, 宮原 信明, 田端 雅弘, 金廣 有彦, 谷本 光音, 木浦 勝行

    気管支学   38 ( Suppl. )   S263 - S263   2016年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本呼吸器内視鏡学会  

    researchmap

  • フェンタニルとミダゾラム併用による気管支鏡検査の苦痛度評価

    南 大輔, 瀧川 奈義夫, 二宮 崇, 久保 寿夫, 大橋 圭明, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    気管支学   38 ( Suppl. )   S245 - S245   2016年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本呼吸器内視鏡学会  

    researchmap

  • 肺クリプトコッカス症診断における迅速細胞診を用いた気管支鏡検査の有用性

    森近 大介, 南 大輔, 宮原 信明, 谷口 暁彦, 二宮 崇, 久保 寿夫, 大橋 圭明, 堀田 勝幸, 田端 雅弘, 金廣 有彦, 谷本 光音, 木浦 勝行

    気管支学   38 ( Suppl. )   S222 - S222   2016年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本呼吸器内視鏡学会  

    researchmap

  • 自己免疫疾患合併肺癌の検討

    狩野 裕久, 久保 寿夫, 秦 雄介, 渡邉 洋美, 加藤 有加, 南 大輔, 二宮 崇, 大橋 圭明, 堀田 勝幸, 田端 雅弘, 谷本 光音, 木浦 勝行

    日本呼吸器学会誌   5 ( 増刊 )   245 - 245   2016年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • PET-CTで縦隔・肺門リンパ節陽性肺癌に対するEBUS-TBNAの有用性

    南 大輔, 瀧川 奈義夫, 槇本 剛, 狩野 裕久, 秦 雄介, 渡邉 洋美, 中西 将元, 加藤 有加, 二宮 崇, 久保 寿夫, 大橋 圭明, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    日本呼吸器学会誌   5 ( 増刊 )   187 - 187   2016年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • ボリュームアナライザーSYNAPSE VINCENTを用いたガイドシース併用気管支腔内超音波断層法の肺癌診断への導入効果

    南 大輔, 瀧川 奈義夫, 槇本 剛, 狩野 裕久, 秦 雄介, 渡邊 洋美, 中西 将元, 二宮 崇, 久保 寿夫, 大橋 圭明, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    気管支学   38 ( 2 )   153 - 153   2016年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本呼吸器内視鏡学会  

    researchmap

  • 放射線化学療法後に外科手術を行った局所進行非小細胞肺癌症例の長期フォローアップ解析

    槇本 剛, 久保 寿夫, 南 大輔, 大橋 圭明, 堀田 勝幸, 田端 雅弘, 豊岡 伸一, 勝井 邦彰, 谷本 光音, 木浦 勝行

    日本内科学会雑誌   105 ( Suppl. )   192 - 192   2016年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内科学会  

    researchmap

  • Pharmacokinetics of amrubicin in lung cancer patients with impaired hepatic function. 査読

    Shinishiro Ryuge, Noriyuki Masuda, Nobuyuji Yamamoto, Toshiaki Takashi, Haruyasu Murakami, Koji Takeda, Haruko Daga, Kimio Yonesaka, Hiroshi Tsukuda, Kazuhiko Nakagawa, Kaoru Yanaka, Katsuyuki Kiura, Nagio Takigawa, Yoyoaki Hida, Takashi Seto, Masanori Yokoba, Shinzoh Kudoh, Takeshi Takagaki, Kazushige Shono, Hideo Kitagawa, Takeshi Kurihara, Masahiro Fukuoka

    Cnacer treatment and research communications   981 - 987   2016年

     詳細を見る

  • Lobe-specific nodal dissection for clinical stage I-II non-small cell lung cancer: Japanese multi-institutional retrospective study using a propensity score analysis. 査読 国際誌

    Hishida T, Miyaoka E, Yokoi K, Tsuboi M, Asamura H, Kiura K, Takahashi K, Dosaka-Akita H, Kobayashi H, Date H, Tada H, Okumura M, Yoshino I, Japanese Join, Committee of Lung, Cancer Registry

    J Thorac Oncol,   11 ( 9 )   1529 - 1537   2016年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.jtho.2016.05.014

    PubMed

    researchmap

  • III期肺腺癌に対する化学療法併用根治的外科切除から15年後に発症した放射線誘発軟部肉腫の1例

    中野 靖浩, 豊田 容輔, 大橋 圭明, 小田 尚廣, 槇本 剛, 久保 寿夫, 木浦 勝行, 谷本 光音, 山口 隆廣, 柳井 広之

    肺癌   55 ( 7 )   1128 - 1128   2015年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 肺類上皮血管内皮腫の1例

    田中 晶平, 小田 尚廣, 佐藤 晃子, 宮原 信明, 狩野 裕久, 中西 将元, 秦 雄介, 槇本 剛, 久保 寿夫, 大橋 圭明, 二宮 崇, 堀田 勝幸, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行, 牧 佑歩, 宗 淳一, 豊岡 伸一, 三好 新一郎

    肺癌   55 ( 7 )   1127 - 1127   2015年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 薬疹、薬剤性肺炎を治療経過で認めた胸腺癌にnab-paclitaxel単剤療法が有用であった1例

    河合 三津保, 南 大輔, 槇本 剛, 中西 将元, 小田 尚廣, 豊田 容輔, 肥後 寿夫, 二宮 崇, 久保 寿夫, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    肺癌   55 ( 7 )   1126 - 1126   2015年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • Fever after lung radiofrequency ablation: Prospective evaluation of its incidence and associated factors. 査読 国際誌

    Masaoka Y, Hiraki T, Gobara H, Iguchi T, Fujiwara H, Matsui Y, Toyooka S, Soh J, Kiura K, Kanazawa S

    European journal of radiology   84 ( 11 )   2202 - 2209   2015年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.ejrad.2015.07.009

    PubMed

    researchmap

  • 当院における進行非小細胞肺癌患者に対するrebiopsyの検討

    狩野 裕久, 久保 寿夫, 南 大輔, 中西 将元, 槇本 剛, 秦 雄介, 渡邉 洋美, 加藤 有加, 二宮 崇, 大橋 圭明, 堀田 勝幸, 田端 雅弘, 谷本 光音, 木浦 勝行

    肺癌   55 ( 5 )   457 - 457   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • T790M変異を含むEGFR遺伝子変異を有する非小細胞肺癌細胞株に対するTAE226の抗腫瘍効果

    山本 寛斉, 阪口 政清, 宗 淳一, 佃 和憲, 木浦 勝行, 猶本 良夫, 三好 新一郎, 豊岡 伸一

    日本癌学会総会記事   74回   P - 2193   2015年10月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • EGFR-TKIによるクリゾチニブ耐性ROS1融合遺伝子陽性非小細胞肺癌細胞株の耐性克服

    加藤 有加, 大橋 圭明, 市原 英基, 工藤 健一郎, 磯崎 英子, 南 大輔, 久保 寿夫, 佐藤 晃子, 堀田 勝幸, 田端 雅弘, 瀧川 奈義夫, 谷本 光音, 木浦 勝行

    日本癌学会総会記事   74回   E - 1179   2015年10月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 鉄誘発ラット悪性中皮腫モデルにおけるTBXAS1遺伝子発現の抑制

    南 大輔, 瀧川 奈義夫, 加藤 有加, 工藤 健一郎, 磯崎 英子, 二宮 崇, 久保 寿夫, 大橋 圭明, 堀田 勝幸, 豊岡 伸一, 谷本 光音, 木浦 勝行

    日本癌学会総会記事   74回   P - 1040   2015年10月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 当院呼吸器内科おけるペグフィルグラスチムの使用経験

    渡邉 洋美, 久保 寿夫, 中西 将元, 槇本 剛, 秦 雄介, 狩野 裕久, 加藤 有加, 南 大輔, 二宮 崇, 大橋 圭明, 堀田 勝幸, 田端 雅弘, 谷本 光音, 木浦 勝行

    肺癌   55 ( 5 )   711 - 711   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 鉄誘発ラット悪性中皮腫モデルにおけるTBXAS1遺伝子発現の抑制

    南 大輔, 瀧川 奈義夫, 工藤 健一郎, 加藤 有加, 磯崎 英子, 原田 大二郎, 越智 宣明, 二宮 崇, 久保 寿夫, 大橋 圭明, 堀田 勝幸, 田端 雅弘, 豊岡 伸一, 谷本 光音, 木浦 勝行

    肺癌   55 ( 5 )   502 - 502   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3 査読 国際誌

    Terufumi Kato, Hiroshige Yoshioka, Isamu Okamoto, Akira Yokoyama, Toyoaki Hida, Takashi Seto, Katsuyuki Kiura, Dan Massey, Yoko Seki, Nobuyuki Yamamoto

    CANCER SCIENCE   106 ( 9 )   1202 - 1211   2015年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    In LUX-Lung 3, afatinib significantly improved progression-free survival (PFS) versus cisplatin/pemetrexed in EGFR mutation-positive lung adenocarcinoma patients and overall survival (OS) in Del19 patients. Preplanned analyses in Japanese patients from LUX-Lung 3 were performed. Patients were randomized 2: 1 to afatinib or cisplatin/pemetrexed, stratified by mutation type (Del19/L858R/Other). Primary endpoint was PFS (independent review). Secondary endpoints included OS, objective response, and safety. Median PFS (data cut-off: February 2012) for afatinib versus cisplatin/pemetrexed was 13.8 vs 6.9 months (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.20-0.70; P = 0.0014) in all Japanese patients (N = 83), with more pronounced improvements in those with common mutations (Del19/L858R; HR, 0.28; 95% CI, 0.15-0.52; P &lt; 0.0001) and Del19 mutations (HR, 0.16; 95% CI, 0.06-0.39; P &lt; 0.0001). PFS was also improved in L858R patients (HR, 0.50; 95% CI, 0.20-1.25; P = 0.1309). Median OS (data cut-off: November 2013) with afatinib versus cisplatin/pemetrexed was 46.9 vs 35.8 months (HR, 0.75; 95% CI, 0.40-1.43; P = 0.3791) in all Japanese patients, with greater benefit in patients with common mutations (HR, 0.57; 95% CI, 0.29-1.12; P = 0.0966) and Del19 mutations (HR, 0.34; 95% CI, 0.13-0.87; P = 0.0181); OS was not significantly different in L858R patients (HR, 1.13; 95% CI, 0.40-3.21; P = 0.8212). Following study treatment discontinuation, most patients (93.5%) received subsequent anticancer therapy. The most common treatment-related adverse events were diarrhea, rash/acne, nail effects and stomatitis with afatinib and nausea, decreased appetite, neutropenia, and leukopenia with cisplatin/pemetrexed. Afatinib significantly improved PFS versus cisplatin/pemetrexed in Japanese EGFR mutation-positive lung adenocarcinoma patients and OS in Del19 but not L858R patients (www.clinicaltrials.gov; NCT00949650).

    DOI: 10.1111/cas.12723

    Web of Science

    PubMed

    researchmap

  • Intravascular lymphomaの肺病変に関する検討

    二宮 貴一朗, 藤原 英晃, 前田 嘉信, 高田 尚良, 吉野 正, 木浦 勝行, 谷本 光音

    日本リンパ網内系学会会誌   55   100 - 100   2015年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本リンパ網内系学会  

    researchmap

  • Crizotinib to overcome alectinib-resistance in non-small cell lung cancer (NSCLC) harboring EML4-ALK. 査読

    Isozaki Hideko, Ichihara Eiki, Takigawa Nagio, Sendo Toshiaki, Tanimoto Mitsune, Kiura Katsuyuki

    JOURNAL OF CLINICAL ONCOLOGY   33 ( 15 )   2015年5月

     詳細を見る

    記述言語:英語  

    Web of Science

    researchmap

  • PET-CTにて縦隔・肺門リンパ節転移陽性の肺癌症例における超音波気管支鏡ガイド下針生検の有用性

    南 大輔, 瀧川 奈義夫, 小田 尚廣, 槇本 剛, 二宮 貴一朗, 豊田 容輔, 肥後 寿夫, 久保 寿夫, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    気管支学   37 ( 3 )   345 - 345   2015年5月

  • 腎移植後の免疫抑制療法に合併した肺クリプトコッカス症の診断にEBUS-GSが有用であった1例

    槇本 剛, 南 大輔, 宮原 信明, 久保 寿夫, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    気管支学   37 ( 3 )   345 - 345   2015年5月

  • ガイドシース併用気管支腔内超音波断層法による経気管支肺生検で確定診断された悪性リンパ腫の2例

    肥後 寿夫, 南 大輔, 小田 尚廣, 豊田 容輔, 二宮 貴一朗, 槇本 剛, 谷口 暁彦, 久保 寿夫, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 田端 雅弘, 金廣 有彦, 谷本 光音, 木浦 勝行

    気管支学   37 ( Suppl. )   S287 - S287   2015年5月

  • PET-CTにて縦隔、肺門リンパ節転移偽陽性の肺癌症例における超音波気管支鏡ガイド下針生検の有用性

    南 大輔, 瀧川 奈義夫, 小田 尚廣, 槇本 剛, 二宮 貴一朗, 豊田 容輔, 肥後 寿夫, 久保 寿夫, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    気管支学   37 ( Suppl. )   S193 - S193   2015年5月

  • 気管支鏡検査における迅速細胞診の進歩と問題点 BIOEVALUATORを用いた迅速細胞診断を併用した超音波気管支鏡ガイド下針生検の有用性

    南 大輔, 瀧川 奈義夫, 槇本 剛, 小田 尚廣, 豊田 容輔, 二宮 貴一朗, 肥後 寿夫, 久保 寿夫, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    気管支学   37 ( Suppl. )   S151 - S151   2015年5月

  • Lower lobe origin is a poor prognostic factor in locally advanced non-small-cell lung cancer patients treated with induction chemoradiotherapy. 査読 国際誌

    Shien K, Toyooka S, Soh J, Hotta K, Katsui K, Oto T, Kanazawa S, Kiura K, Date H, Miyoshi S

    Molecular and clinical oncology   3 ( 3 )   706 - 712   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/mco.2015.509

    PubMed

    researchmap

  • Percutaneous radiofrequency ablation of lung cancer presenting as ground-glass opacity. 査読 国際誌

    Iguchi T, Hiraki T, Gobara H, Fujiwara H, Matsui Y, Soh J, Toyooka S, Kiura K, Kanazawa S

    Cardiovascular and interventional radiology   38 ( 2 )   409 - 415   2015年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00270-014-0926-x

    PubMed

    researchmap

  • BIOEVALUATORを用いた迅速細胞診断を併用したEBUS-TBNAの有用性

    槇本 剛, 南 大輔, 瀧川 奈義夫, 二宮 貴一朗, 小田 尚廣, 豊田 容輔, 肥後 寿夫, 久保 寿夫, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    日本呼吸器学会誌   4 ( 増刊 )   216 - 216   2015年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • EGFR遺伝子変異を有する進行肺非小細胞癌に対する初回治療として、ゲフィチニブ、ベバシズマブ併用療法を行う第II相試験 岡山肺癌治療研究会OLCSG1001

    二宮 貴一朗, 工藤 健一郎, 加藤 有加, 市原 英基, 野上 尚之, 久山 彰一, 田端 雅弘, 久保 寿夫, 谷本 光音, 木浦 勝行, 岡山肺癌治療研究会

    日本内科学会雑誌   104 ( Suppl. )   191 - 191   2015年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内科学会  

    researchmap

  • A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501. 査読 国際誌

    Nogami N, Takigawa N, Hotta K, Segawa Y, Kato Y, Kozuki T, Oze I, Kishino D, Aoe K, Ueoka H, Kuyama S, Harita S, Okada T, Hosokawa S, Inoue K, Gemba K, Shibayama T, Tabata M, Takemoto M, Kanazawa S, Tanimoto M, Kiura K

    Lung cancer (Amsterdam, Netherlands)   87 ( 2 )   141 - 147   2015年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.lungcan.2014.11.001

    PubMed

    researchmap

  • [Appropriate use of granulocyte-colony stimulating factor].

    Kadoaki Ohashi, Katsuyuki Kiura

    Nihon rinsho. Japanese journal of clinical medicine   73 Suppl 2   336 - 40   2015年2月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    PubMed

    researchmap

  • Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines 査読 国際誌

    Hiromichi Yamane, Hideko Isozaki, Masami Takeyama, Nobuaki Ochi, Kenichiro Kudo, Yoshihiro Honda, Tomoko Yamagishi, Toshio Kubo, Katsuyuki Kiura, Nagio Takigawa

    AMERICAN JOURNAL OF CANCER RESEARCH   5 ( 4 )   1553 - 1557   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:E-CENTURY PUBLISHING CORP  

    Introduction: Programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) play a major role in suppressing the immune system during the formation of the PD-1/PD-L1 pathway, which transmits an inhibitory signal to reduce T cell activity. PD-L1 is often expressed in various malignant tumors. In contrast, PD-1 is generally observed in activated lymphocytes and myeloid-derived dendritic cells. Of the malignant cells, only Jurkat cells under special conditions and angioimmunoblastic T-cell lymphoma tissue cells express PD-1 on their surface. Methods: To clarify whether the PD-1/PD-L1 pathway participates in the immunotolerance of small-cell lung cancer (SCLC) cells, we examined the expressions of PD-1 and PD-L1 on the cell surface of SCLC cell lines using flow cytometry and reverse transcription polymerase chain reaction. Results: Among the four SCLC cell lines examined, only SBC-3 expressed both PD-1 and PD-L1. Conclusions: We demonstrated that both PD-1 and PD-L1 molecules were co-expressed on the surface of SCLC cells. Although the biological implications of this remain unclear, we speculate that PD-1 and its ligand on the SCLC cells may participate in the growth inhibition of tumor cells as reported in cytotoxic T cells.

    Web of Science

    PubMed

    researchmap

  • TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells. 査読 国際誌

    Otani H, Yamamoto H, Takaoka M, Sakaguchi M, Soh J, Jida M, Ueno T, Kubo T, Asano H, Tsukuda K, Kiura K, Hatakeyama S, Kawahara E, Naomoto Y, Miyoshi S, Toyooka S

    PloS one   10 ( 6 )   e0129838   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1371/journal.pone.0129838

    PubMed

    researchmap

  • Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer. 査読 国際誌

    Kurata Y, Miyauchi N, Suno M, Ito T, Sendo T, Kiura K

    Journal of pharmaceutical health care and sciences   1   8 - 8   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/s40780-014-0008-x

    PubMed

    researchmap

  • A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0801 査読 国際誌

    Keisuke Aoe, Nagio Takigawa, Katsuyuki Hotta, Tadashi Maeda, Daizo Kishino, Naoyuki Nogami, Masahiro Tabata, Shingo Harita, Toshiaki Okada, Toshio Kubo, Shinobu Hosokawa, Keiichi Fujiwara, Kenichi Gemba, Masayuki Yasugi, Toshiyuki Kozuki, Yuka Kato, Kuniaki Katsui, Susumu Kanazawa, Hiroshi Ueoka, Mitsune Tanimoto, Katsuyuki Kiura

    EUROPEAN JOURNAL OF CANCER   50 ( 16 )   2783 - 2790   2014年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCI LTD  

    Background: Although thoracic irradiation (TRT) is a standard treatment for elderly patients with locally advanced non-small-cell lung cancer (LA-NSCLC), treatment outcomes are poor. We previously reported a phase I trial combining S-1, an oral 5-fluorouracil derivative, and thoracic radiation, which yielded safe and effective outcomes.
    Methods: In this phase II trial, 30 patients aged 76 years or older with LA-NSCLC received S-1 (80 mg/m(2) on days 1-14 and 29-42) and TRT (60 Gy). The primary end-point was the response rate.
    Results: The median age and pre-treatment Charlson score were 79 years and 1, respectively. The mean proportions of the actual doses of S-1 and TRT delivered relative to the planned doses were 95% and 98%, respectively. Partial responses were observed in 19 patients (63%; 95% confidence interval: 45-82%), which did not attain the end-point. At a median follow-up time of 23.7 months, the median progression-free survival and median survival times were 13.0 months and 27.9 months, respectively. No difference in efficacy was observed upon stratification by tumour histology. Toxicities were generally mild, except for grade 3 or greater febrile neutropenia and pneumonitis in 7% and 10% of patients, respectively. No patient developed severe oesophagitis.
    Conclusions: Although the primary end-point was not met, concurrent S-1 chemotherapy and radiotherapy yielded favourable survival data. Also, the combined treatment was well-tolerated in elderly patients with LA-NSCLC. (c) 2014 Elsevier Ltd. All rights reserved.

    DOI: 10.1016/j.ejca.2014.07.024

    Web of Science

    PubMed

    researchmap

  • ガイドシース併用気管支腔内超音波断層法の肺癌診断への導入効果

    南 大輔, 瀧川 奈義夫, 二宮 貴一朗, 小田 尚廣, 豊田 容輔, 槙本 剛, 肥後 寿夫, 久保 寿夫, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    肺癌   54 ( 5 )   534 - 534   2014年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • Novel germline G660D mutation in HER2 gene detected by whole-exome sequencing can predispose a patient to developing familial lung adenocarcinoma 査読

    Hiromasa Yamamoto, Koichiro Higasa, Masakiyo Sakaguchi, Kazuhiko Shien, Junichi Soh, Koichi Ichimura, Masashi Furukawa, Shinsuke Hashida, Kazunori Tsukuda, Nagio Takigawa, Keitaro Matsuo, Katsuyuki Kiura, Sinichiro Miyoshi, Fumihiko Matsuda, Shinichi Toyooka

    CANCER RESEARCH   74 ( 19 )   2014年10月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2014-LB-291

    Web of Science

    researchmap

  • ALK inactivation induced acquired resistance to alectinib in lung cancer harboring EML4-ALK fusion gene 査読

    Hideko Isozaki, Eiki Ichihara, Masayuki Yasugi, Ochi Nobuaki, Katsuyuki Hotta, Nagio Takigawa, Toshiaki Sendo, Mitsune Tanimoto, Katsuyuki Kiura

    CANCER RESEARCH   74 ( 19 )   2014年10月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2014-3721

    Web of Science

    researchmap

  • 家族性・孤発性肺腺癌におけるHER2膜貫通領域の新規遺伝子変異(Novel functional mutations in the transmembrane domain of HER2 gene in familial and sporadic lung adenocarcinomas)

    山本 寛斉, 日笠 幸一郎, 阪口 政清, 枝園 和彦, 宗 淳一, 市村 浩一, 佃 和憲, 瀧川 奈義夫, 松尾 恵太郎, 木浦 勝行, 三好 新一郎, 松田 文彦, 豊岡 伸一

    日本癌学会総会記事   73回   E - 2012   2014年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • ACTH産生胸腺神経内分泌腫瘍に合併したニューモシスチス肺炎の1例

    枝木 久典, 南 大輔, 二宮 貴一朗, 小田 尚廣, 豊田 容輔, 槇本 剛, 肥後 寿夫, 久保 寿夫, 大橋 圭明, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行, 小松原 基志, 稲垣 兼一

    肺癌   54 ( 4 )   260 - 260   2014年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • [Lung cancer: progress in diagnosis and treatments. Topics: III. Treatment; 4. Treatment of small cell lung cancer]. 査読

    Kubo T, Kiura K

    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine   103 ( 6 )   1322 - 1329   2014年6月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.2169/naika.103.1322

    PubMed

    researchmap

  • 【肺癌の治療2014〜2016】限局型小細胞肺癌の治療

    大橋 圭明, 木浦 勝行

    コンセンサス癌治療   13 ( 2 )   102 - 107   2014年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)へるす出版  

    researchmap

  • 超音波気管支鏡ガイド下針生検(EBUS-TBNA)におけるBIOEVALUATORを使用した迅速細胞診断の効果

    二宮 貴一朗, 南 大輔, 瀧川 奈義夫, 森近 大介, 後藤田 裕子, 萱谷 紘枝, 田村 朋季, 久保 寿夫, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    気管支学   36 ( Suppl. )   S136 - S136   2014年3月

  • 気管支鏡検査で診断し外科的切除を行った肺原発悪性黒色腫の1例

    萱谷 紘枝, 南 大輔, 渡邉 元嗣, 山本 寛斉, 宗 淳一, 久保 寿夫, 堀田 勝幸, 田端 雅弘, 豊岡 伸一, 三好 新一郎, 谷本 光音, 木浦 勝行

    気管支学   36 ( 2 )   208 - 208   2014年3月

  • Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer 査読

    Nobuaki Ochi, Nagio Takigawa, Daijiro Harada, Masayuki Yasugi, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    Experimental cell research   322 ( 1 )   168 - 177   2014年3月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier  

    To study epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance mechanisms, we established a novel gefitinib-resistant lung cancer cell line derived from an EGFR-mutant non-small cell lung cancer cell line (PC-9) pretreated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (designated PC9-GR). We found that gefitinib substantially suppressed the EGFR signaling pathway, whereas ERK was reactivated after several hours in PC9-GR but not in PC-9. The combination of gefitinib with ERK inhibition (by U0126) restored gefitinib susceptibility in PC9-GR, but PI3K-Akt inhibition with LY294002 did not. Although the levels of phosphorylated Src were up-regulated simultaneously with ERK reactivation, neither ERK suppression using U0126 nor an ERK-specific siRNA induced Src phosphorylation. Furthermore, dual inhibition of EGFR and Src restored gefitinib sensitivity in PC9-GR in vitro and in vivo. In conclusion, our results indicate that Src-mediated ERK reactivation may play a role in a novel gefitinib resistance mechanism, and that the combined use of gefitinib with a Src inhibitor may be a potent strategy to overcome this resistance.

    DOI: 10.1016/j.yexcr.2014.01.007

    PubMed

    researchmap

  • 超音波気管支鏡ガイド下針生検(EBUS-TBNA)におけるBIOEVALUATORを使用した迅速細胞診断の有用性

    南 大輔, 瀧川 奈義夫, 森近 大介, 二宮 貴一朗, 後藤田 裕子, 萱谷 紘江, 田村 朋季, 久保 寿夫, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    気管支学   36 ( 2 )   205 - 205   2014年3月

  • 肺癌診断におけるガイドシース併用気管支腔内超音波断層法の導入効果

    南 大輔, 瀧川 奈義夫, 二宮 貴一朗, 森近 大介, 後藤田 裕子, 萱谷 紘枝, 田村 朋季, 久保 寿夫, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    気管支学   36 ( Suppl. )   S149 - S149   2014年3月

  • 37.フッ化水素の誤吸入による急性肺障害の1例(第22回 日本呼吸器内視鏡学会中国四国支部会)

    谷本 安, 田中 寿明, 久保 寿夫, 早稲田 公一, 小野 勝一郎, 濱田 昇, 木村 五郎, 木浦 勝行, 片岡 幹男, 谷本 光音, 宗田 良

    気管支学   36 ( 2 )   213 - 213   2014年

     詳細を見る

    記述言語:日本語   出版者・発行元:特定非営利活動法人 日本呼吸器内視鏡学会  

    DOI: 10.18907/jjsre.36.2_213_1

    CiNii Article

    researchmap

  • EGFR遺伝子変異陽性肺癌に悪性リンパ腫を合併した1例

    二宮 貴一朗, 市原 英基, 萱谷 紘枝, 後藤田 裕子, 森近 大介, 田村 朋季, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 谷本 安, 金廣 有彦, 木浦 勝行, 谷本 光音

    肺癌   53 ( 7 )   911 - 911   2013年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • Usefulness of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in Distinguishing Sarcoidosis from Recurrent Cancer in Patients with Lymphadenopathy after Surgery 査読 国際誌

    Daisuke Minami, Nagio Takigawa, Hiromi Hayakawa, Makoto Mizuta, Kenichiro Kudo, Kozi Uchida, Eiki Ichihara, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   43 ( 11 )   1110 - 1114   2013年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OXFORD UNIV PRESS  

    Objective: Endobronchial ultrasound-guided transbronchial needle aspiration is a new minimally invasive test for investigating mediastinal and hilar lymphadenopathy. It is sometimes difficult to distinguish between a recurrent malignant lymph node and lymphadenopathy due to sarcoidosis in patients who develop lymphadenopathy after surgery for a malignant tumor.
    Methods: Between December 2009 and October 2012, we performed endobronchial ultrasound- guided transbronchial needle aspiration in 13 selected patients with a suspected recurrence in the mediastinum and/or hilum of the lung after surgical resection of a malignant tumor. We examined their medical records to obtain information on the diagnosis, the sizes of lymph nodes, the number of needle passes and other complications.
    Results: Definitive diagnoses were made using endobronchial ultrasound-guided transbronchial needle aspiration in 10 patients (three lung adenocarcinomas, one prostate carcinoma, one renal cell carcinoma, one neuroendocrine tumor and four sarcoidosis). Pathological specimens showing non-caseating granulomas led to the diagnosis of sarcoidosis in four patients; their previous malignancies had been papillary adenocarcinoma of the thyroid, carcinoma of the gingiva, thymoma and bladder cancer, but no recurrences were observed. The median of the longest diameter in 15 lymph nodes was 22 mm (range 13-35), and the median number of needle passes was two times (range 1-5) without severe complications.
    Conclusions: Endobronchial ultrasound-guided transbronchial needle aspiration might be useful in differentiating between benign lymphadenopathy, including sarcoidosis, and cancer recurrence in patients with mediastinal or hilar lymphadenopathy after surgical resection of a malignant tumor.

    DOI: 10.1093/jjco/hyt123

    Web of Science

    PubMed

    researchmap

  • Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer. 査読 国際誌

    Okamoto I, Aoe K, Kato T, Hosomi Y, Yokoyama A, Imamura F, Kiura K, Hirashima T, Nishio M, Nogami N, Okamoto H, Saka H, Yamamoto N, Yoshizuka N, Sekiguchi R, Kiyosawa K, Nakagawa K, Tamura T

    Investigational new drugs   31 ( 5 )   1275 - 1282   2013年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10637-013-9941-z

    PubMed

    researchmap

  • Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers. 査読 国際誌

    Saito K, Takigawa N, Ohtani N, Iioka H, Tomita Y, Ueda R, Fukuoka J, Kuwahara K, Ichihara E, Kiura K, Kondo E

    Molecular cancer therapeutics   12 ( 8 )   1616 - 1628   2013年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1158/1535-7163.MCT-12-1239

    PubMed

    researchmap

  • CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. 査読 国際誌

    Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, Ohe Y, Nogami N, Takeuchi K, Shimada T, Tanaka T, Tamura T

    The Lancet. Oncology   14 ( 7 )   590 - 598   2013年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/S1470-2045(13)70142-6

    PubMed

    researchmap

  • Switching oncogene signaling in a highly selective ALK tyrosine kinase inhibitor CH5424802 resistant cells 査読

    Isozaki Hideko, Ichihara Eiki, Yasugi Masayuki, Ninomiya Takashi, Honda Yoshihiro, Murakami Toshi, Minami Daisuke, Kato Yuka, Kudo Kenitiro, Sato Akiko, Hotta Katsuyuki, Takigawa Nagio, Sendo Toshiaki, Tanimoto Mitsune, Kiura Katsuyuki

    CANCER RESEARCH   73 ( 8 )   2013年4月

     詳細を見る

  • 縦隔リンパ節転移のみで術後再発した腎細胞癌にEBUS-TBNAが有用であった1例

    後藤田 裕子, 佐藤 晃子, 南 大輔, 市原 英基, 宮原 信明, 谷本 安, 金廣 有彦, 木浦 勝行

    気管支学   35 ( 5 )   525 - 529   2013年

     詳細を見る

    記述言語:日本語   出版者・発行元:特定非営利活動法人 日本呼吸器内視鏡学会  

    背景.腎細胞癌の転移部位として肺は代表的な好発部位であるが,縦隔リンパ節転移のみを来す再発形式は比較的稀である. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)は,縦隔リンパ節転移の診断を低侵襲かつ高精度に行う方法の1つとされている.今回我々は,縦隔リンパ節転移のみという再発形式をとった術後腎細胞癌を, EBUS-TBNAを用いて診断した1例を経験した.症例. 75歳の男性. 2010年10月,左腎細胞癌に対して左腎臓全摘出術を施行された. 2012年8月のCTで気管分岐下リンパ節の腫大を指摘され,同部位はfluorodeoxyglucose-positron emission tomography (FDG-PET)にて異常集積を認めた. EBUS-TBNAにより組織採取し,免疫組織学的検査にて腎細胞癌縦隔リンパ節転移と診断された.結論.腎細胞癌術後に稀ながら縦隔リンパ節転移のみを来す可能性があることを念頭に置き, EBUS-TBNAはそれを安全かつ,適切に診断するのに有用である.

    DOI: 10.18907/jjsre.35.5_525

    CiNii Article

    researchmap

  • A Definite Case of L-carbocisteine-induced Pneumonia with CATCH22 Syndrome 査読

    Kenichiro Kudo, Eiki Ichihara, Akiko Hisamoto, Katsuyuki Hotta, Nobuaki Miyahara, Yasushi Tanimoto, Sadaharu Akagi, Katsuya Kato, Mitsune Tanimoto, Katsuyuki Kiura

    INTERNAL MEDICINE   52 ( 1 )   97 - 100   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JAPAN SOC INTERNAL MEDICINE  

    A 32-year-old male with CATCH22 syndrome presented with a high fever and productive cough after taking drugs for acute bronchitis, including L-carbocisteine. Chest radiography revealed ground-glass opacities in the bilateral lung fields. He had a history of similar pneumonia. Under the assumption of drug-induced pneumonia, or bacterial or viral pneumonia, all drugs including L-carbocisteine were discontinued, and antibiotics were started. A drug-induced lymphocyte stimulation test was positive only for L-carbocisteine. The only drug in common between this and the previous episode of pneumonia was L-carbocisteine. We thus concluded that this was a definite case of L-carbocisteine-induced pneumonia in a patient with CATCH22 syndrome.

    DOI: 10.2169/internalmedicine.52.7882

    Web of Science

    PubMed

    researchmap

  • Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation 査読 国際誌

    Hiromichi Yamane, Nobuaki Ochi, Masayuki Yasugi, Takayuki Tabayashi, Tomoko Yamagishi, Yasumasa Monobe, Akiko Hisamoto, Katsuyuki Kiura, Nagio Takigawa

    ONCOTARGETS AND THERAPY   6   155 - 160   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:DOVE MEDICAL PRESS LTD  

    72-year-old woman was referred to our hospital with Stage IV non-small-cell lung cancer (NSCLC). Chest computed tomography revealed a mass in the upper lobe of the right lung, with pleural effusion. Cytologic examination identified adenocarcinoma cells in the right pleural effusion. Furthermore, both a deletion mutation in exon 19 and a threonine-methionine substitution mutation at position 790 in exon 20 (T790M) were detected in the epidermal growth factor receptors (EGFR) in the malignant cells. As systemic chemotherapy consisting of carboplatin and pemetrexed or erlotinib proved ineffective, docetaxel monotherapy was initiated as a third-line treatment. Following salvage chemotherapy, her Eastern Cooperative Oncology Group performance status improved from 3 to 1, with tumor regression over 5 months. To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors.

    DOI: 10.2147/OTT.S41797

    Web of Science

    PubMed

    researchmap

  • O27-1 気道過敏性とアレルギー性気道炎症における終末糖化産物受容体(RAGE)の重要性(O27 喘息モデル1,口演,第63回日本アレルギー学会秋季学術大会)

    谷口 暁彦, 宮原 信明, 金廣 有彦, 早稲田 公一, 栗本 悦子, 藤井 詩子, 谷本 安, 片岡 幹男, 木浦 勝行, 山本 靖彦, 山本 博, 谷本 光音

    アレルギー   62 ( 9 )   1352 - 1352   2013年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本アレルギー学会  

    DOI: 10.15036/arerugi.62.1352_3

    CiNii Article

    researchmap

  • MS11-1 成人喘息における鼻炎と副鼻腔炎の合併に関する臨床的検討(MS11 One Airway, One Disease,ミニシンポジウム,第63回日本アレルギー学会秋季学術大会)

    谷本 安, 早稲田 公一, 藤井 詩子, 谷口 暁彦, 古賀 光, 宮原 信明, 木浦 勝行, 岡野 光博, 岡田 千春, 片岡 幹男, 宗田 良, 谷本 光音

    アレルギー   62 ( 9 )   1299 - 1299   2013年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本アレルギー学会  

    DOI: 10.15036/arerugi.62.1299_2

    CiNii Article

    researchmap

  • P/O-025 成人喘息に合併する副鼻腔炎の臨床的検討(成人喘息(病態・評価)2,一般演題,第25回日本アレルギー学会春季臨床大会)

    谷本 安, 能島 大輔, 早稲田 公一, 藤井 詩子, 谷口 暁彦, 栗本 悦子, 古賀 光, 宮原 信明, 木浦 勝行, 岡野 光博, 岡田 千春, 片岡 幹男, 宗田 良, 谷本 光音

    アレルギー   62 ( 3 )   393 - 393   2013年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本アレルギー学会  

    DOI: 10.15036/arerugi.62.393_1

    CiNii Article

    researchmap

  • O5-6 超音波気管支鏡ガイド下針生検における迅速細胞診断の有用性(EBUS-1,一般演題口演,第36回日本呼吸器内視鏡学会学術集会)

    南 大輔, 瀧川 奈義夫, 後藤田 裕子, 萱谷 紘枝, 谷口 暁彦, 市原 英基, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 谷本 安, 田端 雅弘, 金廣 有彦, 谷本 光音, 木浦 勝行

    気管支学   35   S152   2013年

     詳細を見る

    記述言語:日本語   出版者・発行元:特定非営利活動法人 日本呼吸器内視鏡学会  

    DOI: 10.18907/jjsre.35.Special_S152_3

    CiNii Article

    researchmap

  • P1-4-4 超音波気管支鏡ガイド下針生検によるサルコイドーシスの組織診断の検討(EBUS-1,一般演題ポスター,第36回日本呼吸器内視鏡学会学術集会)

    工藤 健一郎, 南 大輔, 瀧川 奈義夫, 後藤田 裕子, 萱谷 紘枝, 谷口 暁彦, 堀田 勝幸, 市原 英基, 佐藤 晃子, 宮原 信明, 谷本 安, 田端 雅弘, 金廣 有彦, 片岡 幹男, 谷本 光音, 木浦 勝行

    気管支学   35   S198   2013年

     詳細を見る

    記述言語:日本語   出版者・発行元:特定非営利活動法人 日本呼吸器内視鏡学会  

    DOI: 10.18907/jjsre.35.Special_S198_1

    CiNii Article

    researchmap

  • 1.極細径気管支内視鏡検査にて右肺末梢性動静脈奇形(AVM)を観察しえた1例(第21回 日本呼吸器内視鏡学会中国四国支部会)

    久本 晃子, 後藤田 裕子, 宋 淳一, 豊岡 伸一, 市原 英基, 谷本 安, 宮原 伸明, 金廣 有彦, 谷本 光音, 木浦 勝行

    気管支学   35 ( 2 )   222 - 222   2013年

     詳細を見る

    記述言語:日本語   出版者・発行元:特定非営利活動法人 日本呼吸器内視鏡学会  

    DOI: 10.18907/jjsre.35.2_222_1

    CiNii Article

    researchmap

  • 23.無症状で経過している気管気管支巨大症(Mounier-Kuhn症候群)の1例(第21回 日本呼吸器内視鏡学会中国四国支部会)

    後藤田 裕子, 谷本 安, 南 大輔, 中村 香葉, 萱谷 紘枝, 田村 朋季, 内田 晃司, 市原 英基, 佐藤 晃子, 宮原 信明, 金廣 有彦, 木浦 勝行, 谷本 光音

    気管支学   35 ( 2 )   227 - 227   2013年

     詳細を見る

    記述言語:日本語   出版者・発行元:特定非営利活動法人 日本呼吸器内視鏡学会  

    DOI: 10.18907/jjsre.35.2_227_3

    CiNii Article

    researchmap

  • 29.術後再発が疑われるリンパ節病変に対する超音波気管支鏡ガイド下針生検(EBUS-TBNA)の使用経験(第21回 日本呼吸器内視鏡学会中国四国支部会)

    南 大輔, 瀧川 奈義夫, 工藤 健一郎, 加藤 有加, 市原 英基, 佐藤 晃子, 堀田 勝幸, 宮原 信明, 谷本 安, 金廣 有彦, 田端 雅弘, 谷本 光音, 木浦 勝行

    気管支学   35 ( 2 )   228 - 229   2013年

     詳細を見る

    記述言語:日本語   出版者・発行元:特定非営利活動法人 日本呼吸器内視鏡学会  

    DOI: 10.18907/jjsre.35.2_228_4

    CiNii Article

    researchmap

  • [Bronchial asthma and allergic diseases]. 査読

    Miyahara N, Kiura K

    Nihon rinsho. Japanese journal of clinical medicine   70 Suppl 8   545 - 549   2012年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    PubMed

    researchmap

  • EGFR変異陽性非扁平非小細胞肺癌に対するpemetrexedの有用性

    上月 稔幸, 山本 将一朗, 北島 寛元, 野上 尚之, 木浦 勝行, 谷本 光音, 新海 哲

    肺癌   52 ( 5 )   754 - 754   2012年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • Induction chemoradiotherapy followed by surgical resection for clinical T3 or T4 locally advanced non-small cell lung cancer. 査読 国際誌

    Shien K, Toyooka S, Kiura K, Matsuo K, Soh J, Yamane M, Oto T, Takemoto M, Date H, Miyoshi S

    Annals of surgical oncology   19 ( 8 )   2685 - 2692   2012年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1245/s10434-012-2302-x

    PubMed

    researchmap

  • Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. 査読 国際誌

    Toyooka S, Kiura K, Takemoto M, Oto T, Takigawa N, Fujiwara T, Miyoshi S, Date H

    Interactive cardiovascular and thoracic surgery   14 ( 5 )   565 - 569   2012年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/icvts/ivs028

    PubMed

    researchmap

  • Cytotoxicity of activated natural killer cells and expression of adhesion molecules in small-cell lung cancer. 国際誌

    Tadashi Tsuchida, Hiromichi Yamane, Nobuaki Ochi, Takayuki Tabayashi, Akio Hiraki, Naoyuki Nogami, Nagio Takigawa, Katsuyuki Kiura, Mitsune Tanimoto

    Anticancer research   32 ( 3 )   887 - 92   2012年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND/AIM: Although small-cell lung cancer (SCLC) is sensitive to anticancer agents, most patients with SCLC experience relapse and die within two years. Here, we examined the relationship between natural killer (NK) cells and adhesion molecules on SCLC cell lines. MATERIALS AND METHODS: The expression levels of HLA class I, β2-microglobulin, Fas/Apo-1 receptor (FAS) and adhesion molecules on SCLC cell lines were examined by flow cytometry. The cytotoxicity of activated NK cells from SCLC patients was examined using (51)Cr-release assay. RESULTS: HLA class I antigen and β2-microglobulin expression levels in SCLC cell lines were lower than those in healthy volunteers. SCLC cell lines were susceptible to lysis by activated NK cells but this showed no correlation with expression levels of adhesion molecules. CONCLUSION: Target cell susceptibility to activated NK cells from five SCLC patients correlated with survival benefit; target cell susceptibility to activated NK cells may be a surrogate marker of outcome for patients with SCLC.

    PubMed

    researchmap

  • 当院におけるFDG-PET陽性縦隔リンパ節に対し縦隔鏡検査を施行した非小細胞肺癌症例の検討

    加藤 有加, 上月 稔幸, 野上 尚之, 新海 哲, 岡崎 幹生, 末久 弘, 澤田 茂樹, 山下 素弘, 井上 武, 西村 理恵子, 寺本 典弘, 木浦 勝行, 谷本 光音

    肺癌   52 ( 1 )   112 - 113   2012年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. 査読 国際誌

    Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S

    Lung cancer (Amsterdam, Netherlands)   75 ( 2 )   161 - 166   2012年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.lungcan.2011.04.022

    PubMed

    researchmap

  • MS2-1 アレルギー性気道炎症における終末糖化産物受容体(RAGE)の役割(MS2 動物モデル,ミニシンポジウム,第62回日本アレルギー学会秋季学術大会)

    谷口 暁彦, 宮原 信明, 金廣 有彦, 早稲田 公一, 栗本 悦子, 能島 大輔, 谷本 安, 片岡 幹男, 木浦 勝行, 山本 靖彦, 山本 博, 谷本 光音

    アレルギー   61 ( 9 )   1436 - 1436   2012年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本アレルギー学会  

    DOI: 10.15036/arerugi.61.1436_4

    CiNii Article

    researchmap

  • MS10-11 重症難治性喘息の臨床的特徴に関する検討(MS10 成人気管支喘息3 臨床,ミニシンポジウム,第24回日本アレルギー学会春季臨床大会)

    谷本 安, 能島 大輔, 早稲田 公一, 宮原 信明, 山中 隆夫, 平野 淳, 木村 五郎, 岡田 千春, 木浦 勝行, 片岡 幹男, 宗田 良, 谷本 光音

    アレルギー   61 ( 3 )   487 - 487   2012年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本アレルギー学会  

    DOI: 10.15036/arerugi.61.487_1

    CiNii Article

    researchmap

  • 46. 超音波ガイド下経気管支鏡針生検(EBUS-TBNA)による診断が可能であった結核性リンパ節炎の1例(第20回 日本呼吸器内視鏡学会中国四国支部会)

    工藤 健一郎, 南 大輔, 瀧川 奈義夫, 村上 斗司, 市原 英基, 久本 晃子, 堀田 勝幸, 宮原 信明, 赤木 滋, 谷本 安, 田端 雅弘, 金廣 有彦, 三宅 俊嗣, 西井 研治, 愼野 博史, 谷本 光音, 木浦 勝行

    気管支学   34 ( 4 )   405 - 405   2012年

     詳細を見る

    記述言語:日本語   出版者・発行元:特定非営利活動法人 日本呼吸器内視鏡学会  

    DOI: 10.18907/jjsre.34.4_405_4

    CiNii Article

    researchmap

  • 41. 気管支内視鏡検査にて診断が得られた節外性NK/T細胞リンパ腫(鼻型)の1例(第20回 日本呼吸器内視鏡学会中国四国支部会)

    加藤 有加, 久本 晃子, 田中 寿明, 市原 英基, 谷本 安, 宮原 信明, 堀田 勝幸, 田端 雅弘, 原田 大二郎, 塩手 康弘, 洲脇 俊充, 亀井 治人, 木浦 勝行

    気管支学   34 ( 4 )   404 - 404   2012年

     詳細を見る

    記述言語:日本語   出版者・発行元:特定非営利活動法人 日本呼吸器内視鏡学会  

    DOI: 10.18907/jjsre.34.4_404_3

    CiNii Article

    researchmap

  • P056 PR3-ANCA陽性のChurg-Strauss症候群の1例(好酸球性肺炎・過敏性肺臓炎,ポスターセッション,第24回日本アレルギー学会春季臨床大会)

    谷本 安, 谷口 暁彦, 栗本 悦子, 能島 大輔, 早稲田 公一, 古賀 光, 宮原 信明, 木浦 勝行, 片岡 幹男, 宗田 良, 谷本 光音

    アレルギー   61 ( 3 )   520 - 520   2012年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本アレルギー学会  

    DOI: 10.15036/arerugi.61.520_4

    CiNii Article

    researchmap

  • O48-2 エラスターゼにより惹起される肺気腫における終末糖化産物受容体(RAGE)の役割(動物モデル3,口演,第62回日本アレルギー学会秋季学術大会)

    早稲田 公一, 宮原 信明, 金廣 有彦, 谷口 暁彦, 栗本 悦子, 能島 大輔, 古賀 光, 谷本 安, 片岡 幹男, 木浦 勝行, 山本 博, 谷本 光音

    アレルギー   61 ( 9 )   1526 - 1526   2012年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本アレルギー学会  

    DOI: 10.15036/arerugi.61.1526_4

    CiNii Article

    researchmap

  • O80-2 成人喘息における鼻炎の合併と喘息コントロールに関する検討(鼻炎合併喘息4,口演,第62回日本アレルギー学会秋季学術大会)

    谷本 安, 谷口 暁彦, 栗本 悦子, 能島 大輔, 早稲田 公一, 古賀 光, 宮原 信明, 岡野 光博, 木浦 勝行, 片岡 幹男, 宗田 良, 谷本 光音

    アレルギー   61 ( 9 )   1574 - 1574   2012年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本アレルギー学会  

    DOI: 10.15036/arerugi.61.1574_2

    CiNii Article

    researchmap

  • W2-2 気管内チューブを用いたEBUS-TBNAの使用経験(EBUS-TBNA,ワークショップ2,第35回日本呼吸器内視鏡学会学術集会)

    南 大輔, 瀧川 奈義夫, 村上 斗司, 谷口 暁彦, 市原 英基, 久本 晃子, 堀田 勝幸, 宮原 信明, 谷本 安, 田端 雅彦, 金廣 有彦, 谷本 光音, 木浦 勝行

    気管支学   34   S123   2012年

     詳細を見る

    記述言語:日本語   出版者・発行元:特定非営利活動法人 日本呼吸器内視鏡学会  

    DOI: 10.18907/jjsre.34.Special_S123_2

    CiNii Article

    researchmap

  • Cavitary pulmonary involvement of diffuse large B-cell lymphoma transformed from extra nodal marginal zone B-cell lymphoma MALT type. 査読

    Yamane H, Ohsawa M, Shiote Y, Umemura S, Suwaki T, Shirakawa A, Kamei H, Takigawa N, Kiura K

    Clinical journal of gastroenterology   4 ( 6 )   401 - 406   2011年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s12328-011-0259-0

    PubMed

    researchmap

  • [A relapse of small-cell lung cancer ten years after concomitant chemoradiotherapy followed by high-dose chemotherapy with autologous peripheral blood stem cell transfusion].

    Akihiko Taniguchi, Nagio Takigawa, Katsuyuki Hotta, Tadashi Matsumura, Mitsune Tanimoto, Katsuyuki Kiura

    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society   49 ( 9 )   697 - 701   2011年9月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 57-year-old man had limited-disease small cell lung cancer in the left lower lobe of the lung. He was treated with chemotherapy with concurrent accelerated hyperfractionated thoracic radiation, followed by high-dose chemotherapy with autologous peripheral blood stem cell transplantation. He had obtained a complete response for 10 years until the tumor in the left lower lobe was detected by positron emission tomography. Bronchoscopic brushing cytology revealed small cell cancer, which was considered to be local relapse by staging work-up. He achieved a partial response with chemotherapy consisting of cisplatin and irinotecan. The progression-free survival rate at 5 years in limited-disease small cell lung cancer ranges from 10% to 25%. Although it was difficult to distinguish the relapse of lung cancer from second primary lung cancer, we considered this case as relapse because the tumor had the same cytology in the same lobe as the previous primary tumor. The residual cells refractory to concomitant chemoradiotherapy followed by high-dose chemotherapy with stem cell transplantation had survived and proliferated after 10 years.

    PubMed

    researchmap

  • 両側肺腺癌に対する術前放射線化学療法後両側の肺切除を行い、その後"たこつぼ心筋症"を発症した1例

    林 達朗, 豊岡 伸一, 宗 淳一, 古川 公之, 山根 正修, 大藤 剛宏, 三好 新一郎, 木浦 勝行

    肺癌   51 ( 4 )   312 - 312   2011年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • Molecular oncology of lung cancer. 査読

    Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, Oto T, Kiura K, Miyoshi S

    General thoracic and cardiovascular surgery   59 ( 8 )   527 - 537   2011年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s11748-010-0743-3

    PubMed

    researchmap

  • 高齢者非小細胞肺癌局所進展例に対するS-1併用化学放射線療法の第I相試験

    武本 充広, 吉尾 浩太郎, 山下 真子, 勝井 邦彰, 金澤 右, 瀧川 奈義夫, 木浦 勝行, 谷本 光音, 黒田 昌宏, 榮 勝美

    Japanese Journal of Radiology   29 ( Suppl.I )   71 - 71   2011年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本医学放射線学会  

    researchmap

  • 肺癌の分子標的治療 基礎から臨床へ EGFR-TKIの耐性機構とその克服

    豊岡 伸一, 宗 淳一, 大谷 弘樹, 小林 成行, 久保 孝文, 上野 剛, 青景 圭樹, 山根 正修, 大藤 剛宏, 木浦 勝行, 三好 新一郎

    肺癌   50 ( 5 )   450 - 450   2010年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 術前補助療法 進行非小細胞肺癌に対する導入化学放射線療法

    枝園 和彦, 豊岡 伸一, 武本 充広, 宗 淳一, 山根 正修, 大藤 剛宏, 堀田 勝幸, 頼 冠名, 瀧川 奈義夫, 田端 雅弘, 木浦 勝行, 三好 新一郎

    肺癌   50 ( 5 )   472 - 472   2010年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 当院におけるFDG-PET陽性縦隔リンパ節に対し縦隔鏡検査施行非小細胞肺癌症例の検討

    加藤 有加, 上月 稔幸, 野上 尚之, 岡崎 幹生, 末久 弘, 澤田 茂樹, 山下 素弘, 井上 武, 西村 理恵子, 寺本 典弘, 新海 哲, 木浦 勝行, 谷本 光音

    日本癌治療学会誌   45 ( 2 )   574 - 574   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • A Randomized Phase II Study of a Combination of Docetaxel and S-1 versus Docetaxel Monotherapy in Patients with Non-small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy Results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503 査読 国際誌

    Yoshihiko Segawa, Katsuyuki Kiura, Katsuyuki Hotta, Nagio Takigawa, Masahiro Tabata, Keitaro Matsuo, Hiroshige Yoshioka, Hidetoshi Hayashi, Haruyuki Kawai, Keisuke Aoe, Tadashi Maeda, Hiroshi Ueoka, Mitsune Tanimoto

    JOURNAL OF THORACIC ONCOLOGY   5 ( 9 )   1430 - 1434   2010年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Background: The survival impact of single-agent treatment with docetaxel, the standard regimen for relapsed patients with non-small cell lung cancer (NSCLC), remains modest We conducted a randomized phase II study to evaluate the efficacy and safety of the combination of docetaxel and S-I in the second-line setting
    Methods: Patients with relapse of NSCLC after first-line platinum-based chemotherapy were randomly assigned to docetaxel alone (60 mg/m(2), day I. q3 weeks, arm A) or a combination of docetaxel (40 mg/m(2). day 1. q3 weeks) and S-I (80 mg/m(2), days 1-15, arm B) The primary end point was response rate, whereas secondary endpoints included overall survival, progression-free survival, and toxicity
    Results: Between 2005 and 2008, a total of 60 patients were enrolled in the study The objective response rates were 20 7% and 16 1% in arms A and B. respectively (p = 0 81) Progression-free survival was comparable in the two arms (median 3 7 versus 3 4 months. p = 0 27), whereas overall survival time was longer in arm A (22 9 versus 8 7 months, p = 0 02) The major toxicity was myelosuppression with grade neutropenia in 89 7% of patients versus 64 5% in arms A and B. respectively
    Conclusions: This study suggests that docetaxel monotherapy should continue to be considered the standard for second-line chemotherapy against NSCLC

    DOI: 10.1097/JTO.0b013e3181e3248e

    Web of Science

    PubMed

    researchmap

  • micro RNA 7発現プラスミドによるEGFR依存性腫瘍におけるin vivoでの著明な抗腫瘍効果(Dramatic anti-proliferative effect of designed miR-7 expressing plasmid against EGFR oncogene addicted tumors)

    頼 冠名, 瀧川 奈義夫, 伊藤 佐智夫, 木浦 勝行, 清水 憲二, 谷本 光音

    日本癌学会総会記事   69回   180 - 180   2010年8月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • 高齢者非小細胞肺癌局所進展例に対するS-1併用化学放射線療法の第I相試験

    武本 充広, 吉尾 浩太郎, 山下 真子, 勝井 邦彰, 瀧川 奈義夫, 木浦 勝行, 谷本 光音, 黒田 昌宏, 榮 勝美, 金澤 右

    日本医学放射線学会学術集会抄録集   69回   S224 - S224   2010年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本医学放射線学会  

    researchmap

  • Diffuse alveolar hemorrhage with chronic thyroiditis in an advanced-age adult 査読

    Masanori Fujii, Nobuaki Miyahara, Yasushi Tanimoto, Nagio Takigawa, Masahiro Tabata, Arihiko Kanehiro, Katsuyuki Kiura, Mitsune Tanimoto

    Respiratory Medicine CME   3 ( 2 )   90 - 92   2010年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Idiopathic pulmonary hemosiderosis (IPH) is one of the rare causes of diffuse alveolar hemorrhage (DAH), and usually occurs in children. The mechanism underlying this disease development has not been defined. During the acute phase, death due to massive alveolar hemorrhage and subsequent severe respiratory failure with multiple organ failure often occurs. We report a case of IPH which occurred in an advanced-aged adult during following thyroidectomy for chronic thyroiditis. Following surgery this 83-year-old male developed acute onset dyspnea and pulmonary hemorrhage. In a search for underlying causes, no disorders were found and the only finding was the presence of anti-thyroid antibody. Systemic corticosteroid therapy was effective and he fully recovered. To our knowledge, this is the second documentation of IPH in association with chronic thyroiditis. © 2009 Elsevier Ltd.

    DOI: 10.1016/j.rmedc.2009.04.006

    Scopus

    researchmap

  • Obstructive jaundice at the initial presentation in small-cell lung cancer. 国際誌

    Nobuaki Ochi, Nagio Takigawa, Masayuki Yasugi, Etsuji Ishida, Hirofumi Kawamoto, Akihiko Taniguchi, Daijiro Harada, Eiko Hayashi, Hiroko Toda, Hiroyuki Yanai, Mitsune Tanimoto, Katsuyuki Kiura

    International medical case reports journal   3   9 - 12   2010年

     詳細を見る

    記述言語:英語  

    Obstructive jaundice sometimes may develop in association with advanced small-cell lung cancer (SCLC); however, SCLC initially presenting with obstructive jaundice is rare. This report presents the cases of two SCLC patients with obstructive jaundice at the initial diagnosis. A 64-year-old male presented with obstructive jaundice due to a tumor at the head of the pancreas. He was diagnosed with SCLC by transbronchial biopsy from a lung tumor in the left upper lobe. Another 74-year-old male was admitted with jaundice due to a tumor in the porta hepatis. He was also diagnosed with SCLC by a fine-needle aspiration biopsy of a lung tumor in the left lower lobe. Both cases were successfully treated with systemic chemotherapy after endoscopic retrograde biliary drainage.

    PubMed

    researchmap

  • EGFRチロシンキナーゼ阻害剤感受性株、耐性株に対するMicroRNA-7による腫瘍形成抑制効果の検討

    頼 冠名, 瀧川 奈義夫, 伊藤 佐智夫, 保田 立二, 清水 憲二, 谷本 光音, 木浦 勝行

    肺癌   49 ( 5 )   696 - 696   2009年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • EGFR T790Mを有する肺腺癌細胞株に対するバンデタニブの効果

    市原 英基, 大橋 圭明, 瀧川 奈義夫, 大澤 昌弘, 高田 三郎, 荻野 敦子, 堀田 勝幸, 田端 雅弘, 谷本 光音, 木浦 勝行

    肺癌   49 ( 5 )   785 - 785   2009年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 異種移植マウスモデルを利用したゲフィチニブ獲得耐性における肝細胞増殖因子(HGF)の関与

    柏原 宏美, 市原 英基, 高田 三郎, 大橋 圭明, 大澤 昌宏, 久保 寿夫, 武田 洋正, 藤井 昌学, 頼 冠名, 瀧川 奈義夫, 谷本 光音, 木浦 勝行

    肺癌   49 ( 5 )   697 - 697   2009年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 非喫煙関連肺癌マウスモデルにおけるvandetanibの化学予防効果

    久保 寿夫, 大橋 圭明, 大澤 昌宏, 武田 洋正, 市原 英基, 藤井 昌学, 柏原 宏美, 瀧川 奈義夫, 谷本 光音, 木浦 勝行

    肺癌   49 ( 5 )   659 - 659   2009年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • ゼノグラフトモデルでのゲフィチニブに対する腫瘍の感受性における肝細胞増殖因子の効果(Effect of hepatocyte growth factor on tumors sensitive to gefitinib in a xenograft model)

    柏原 宏美, 市原 英基, 高田 三郎, 大橋 圭明, 大澤 昌宏, 久保 寿夫, 武田 洋正, 藤井 昌学, 頼 冠名, 瀧川 奈義夫, 谷本 光音, 木浦 勝行

    日本癌学会総会記事   68回   479 - 479   2009年8月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • ゲフィチニブ感受性および耐性細胞株の上皮成長因子受容体に対するMicro-RNA 7による抑制効果(MicroRNA-7 downregulates epidermal growth factor receptor in gefitinib resistant lung adenocarcinoma cells)

    頼 冠名, 瀧川 奈義夫, 伊藤 佐智夫, 木浦 勝行, 保田 立二, 清水 憲二, 谷本 光音

    日本癌学会総会記事   68回   238 - 239   2009年8月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • 上皮成長因子受容体遺伝子変異は喫煙・性別とは独立に肺腺癌患者のゲフィチニブ治療における予後に関係する

    豊岡 伸一, 高野 利実, 高坂 貴行, 堀田 勝幸, 松尾 恵太郎, 市原 周治, 藤原 義朗, 宗 淳一, 大谷 弘樹, 木浦 勝行, 青江 啓介, 谷田部 恭, 大江 裕一郎, 光冨 徹哉, 伊達 洋至

    肺癌   49 ( 4 )   409 - 415   2009年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    目的.ゲフィチニブ投与患者では上皮成長因子受容体(EGFR)変異例で予後が良いことが報告されている。一方、喫煙、性差はEGFR変異に影響し、さらに、肺癌の予後因子であることが示唆されている。本研究では、EGFR変異、性差、喫煙が、ゲフィチニブ治療を受けた肺腺癌患者の生存期間に与える影響を検討した。対象と方法.ゲフィチニブにより治療された肺腺癌患者362例において、EGFR変異、性差、喫煙が全生存期間(OS)および無増悪生存期間(PFS)に及ぼす影響を評価した。結果.EGFR変異は169例(46.7%)に認めた。多変量解析では、変異例で野生型例に比べOSおよびPFSが有意に長かった(P<0.001)。EGFR変異の有無による群別で性差、喫煙量は、OSおよびPFSの延長とは関連がなかった。一方、性別、および、喫煙により分類した群別での解析では、EGFR変異は、OS、PFSの延長と有意な関連を認めた(P<0.001)。結論.本検討から、ゲフィチニブ投与を行う患者を選択する際、EGFR変異は重要な指標であると考えられる。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2009&ichushi_jid=J01244&link_issn=&doc_id=20090924340013&doc_link_id=%2Fec7jaluc%2F2009%2F004904%2F013%2F0409-0415%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fec7jaluc%2F2009%2F004904%2F013%2F0409-0415%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • すりガラス陰影を伴う肺腺癌の進展におけるSTAT3の関与(The role of STAT3 in the progression of lung adenocarcinoma)

    高田 三郎, 瀧川 奈義夫, 大橋 圭明, 畝川 芳彦, 寺本 典弘, 山下 素弘, 新海 哲, 上月 稔幸, 堀田 勝幸, 田端 雅弘, 谷本 光音, 木浦 勝行

    日本癌学会総会記事   68回   319 - 319   2009年8月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 非喫煙者肺癌マウスモデルにおけるバンデタニブによる化学予防効果(Chemopreventive effect of vandetanib on tumorigenesis in a mouse model of non-smoking related lung cancer)

    久保 寿夫, 大橋 圭明, 大澤 昌宏, 武田 洋正, 市原 英基, 藤井 昌学, 柏原 宏美, 瀧川 奈義夫, 谷本 光音, 木浦 勝行

    日本癌学会総会記事   68回   75 - 75   2009年8月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • EGFR mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma 査読

    Toyooka S, Takano T, Kosaka T, Hotta K, Matsuo K, Ichihara S, Fujiwara Y, Soh J, Otani H, Kiura K, Aoe K, Yatabe Y, Ohe Y, Mitsudomi T, Date H

    Japanese Journal of Lung Cancer   49 ( 4 )   409 - 415   2009年

  • A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization. 国際誌

    Katsuyuki Hotta, Katsuyuki Kiura, Akinori Shirahige, Saburo Takata, Nagio Takigawa, Masahiro Tabata, Hirokazu Watanabe, Mitsune Tanimoto

    Acta oncologica (Stockholm, Sweden)   48 ( 3 )   471 - 3   2009年

     詳細を見る

  • EGFR変異とUracil-Tegafurによる肺腺癌術後補助療法の関連性についての検討

    末久 弘, 豊岡 伸一, 堀田 勝幸, 内田 亜希子, 宗 淳一, 藤原 義朗, 松尾 恵太郎, 大内田 守, 高田 穣, 木浦 勝行, 伊達 洋至

    岡山医学会雑誌   120 ( 3 )   265 - 269   2008年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:岡山医学会  

    完全切除された肺腺癌患者に補助療法としてUracil-Tegafur(UFT)を投与した場合における、EGFR変異の予後判定因子としての可能性を検討した。また、in vitro系のEGFR遺伝子導入細胞株における5-FUの効果も検討した。UFT投与群68例、手術のみの経過観察群119例であった。EGFR変異は187例中79例に認め、49例がエクソン19欠失変異、30例がエクソン21点突然変異であった。女性、非喫煙者に有意に変異が多かった。単変量解析では、UFT投与群が経過観察群よりも、EGFR変異群が野生群よりも予後がよい傾向であった。多変量解析では、術後補助療法が独立して有意に予後を延長していた。EGFR変異群では術後補助療法による予後延長の効果は認めなかった。EGFR変異型細胞株は5-FU低感受性を有することが示唆された。

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2008&ichushi_jid=J00175&link_issn=&doc_id=20081205250002&doc_link_id=10.4044%2Fjoma.120.265&url=https%3A%2F%2Fdoi.org%2F10.4044%2Fjoma.120.265&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • ゲフィチニブ未使用肺癌におけるMET遺伝子増幅について

    久保 孝文, 山本 寛斉, 宗 淳一, 藤井 徹也, 大内田 守, 瀧川 奈義夫, 木浦 勝行, 清水 憲二, 伊達 洋至, 豊岡 伸一

    肺癌   48 ( 5 )   508 - 508   2008年10月

  • 限局型小細胞肺癌(LD-SCLC)に対する化学放射線療法における早期奏効の臨床的意義

    藤井 昌学, 堀田 勝幸, 藤原 義朗, 久保 寿夫, 武田 洋正, 柏原 宏美, 大澤 昌宏, 大橋 圭明, 市原 英基, 高田 三郎, 平木 章夫, 瀧川 奈義夫, 田端 雅弘, 木浦 勝行, 谷本 光音

    肺癌   48 ( 5 )   417 - 417   2008年10月

  • EGFR遺伝子異常を伴う肺癌細胞株におけるTAE226の抗腫瘍効果

    大谷 弘樹, 豊岡 伸一, 渡辺 信之, 治田 賢, 高岡 宗徳, 久保 孝文, 山本 寛斉, 山根 正修, 大藤 剛宏, 大橋 圭明, 荻野 敦子, 木浦 勝行, 猶本 良夫, 佐野 由文

    日本癌治療学会誌   43 ( 2 )   798 - 798   2008年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • すりガラス陰影を伴う肺腺癌の進展におけるEGFRシグナルの関与

    高田 三郎, 瀧川 奈義夫, 大橋 圭明, 畝川 芳彦, 山下 素弘, 寺本 典弘, 新海 哲, 上月 稔幸, 堀田 勝幸, 田端 雅弘, 木浦 勝行, 谷本 光音

    肺癌   48 ( 5 )   511 - 511   2008年10月

  • 変異EGFRトランスジェニックマウスに対するvandetanibの有用性

    大澤 昌宏, 大橋 圭明, 久保 寿夫, 市原 英基, 高田 三郎, 瀧川 奈義夫, 田端 雅弘, 谷本 光音, 木浦 勝行

    肺癌   48 ( 5 )   476 - 476   2008年10月

  • ゲフィチニブ未使用肺癌におけるMET遺伝子増幅について(METGene Amplification in Lung Cancers Untreated With Gefitinib)

    久保 孝文, 山本 寛斉, 宗 淳一, 大内田 守, 瀧川 奈義夫, 木浦 勝行, 清水 憲二, 伊達 洋至, 豊岡 伸一

    日本癌学会総会記事   67回   275 - 275   2008年9月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • 喫煙と関連性が低い肺癌マウスモデルに対するゲフィチニブの化学予防効果(Chemopreventive Effect of Gefitinib on Smoking-unrelated Lung Cancer Mouse Model)

    大橋 圭明, 大澤 昌宏, 久保 寿夫, 武田 洋正, 市原 英基, 堀田 勝幸, 平木 章夫, 瀧川 奈義夫, 吉野 正, 田端 雅弘, 高田 穣, 木浦 勝行, 谷本 光音

    日本癌学会総会記事   67回   90 - 90   2008年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • バンデタニブ曝露により誘導された肺腺癌細胞株におけるEGFR T790M遺伝子変異(Emergence of the EGFR T790M mutation in a lung adenocarcinoma cell line after vandetanib treatment)

    市原 英基, 大橋 圭明, 瀧川 奈義夫, 堀田 勝幸, 平木 章夫, 田端 雅弘, 木浦 勝行, 谷本 光音

    日本癌学会総会記事   67回   151 - 151   2008年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 限局型小細胞肺癌(LD-SCLC)に対する化学放射線療法における早期奏効の臨床的意義

    藤井 昌学, 堀田 勝幸, 藤原 義朗, 久保 寿夫, 武田 洋正, 柏原 宏美, 大澤 昌宏, 大橋 圭明, 市原 英基, 高田 三郎, 瀧川 奈義夫, 田端 雅弘, 木浦 勝行, 谷本 光音, 平木 章夫

    肺癌   48 ( 4 )   367 - 367   2008年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • ゲフィチニブ単剤療法が施行された肺非小細胞癌における予後因子としての血清KL-6

    藤原 義朗, 木浦 勝行, 瀧川 奈義夫, 豊岡 伸一, 堀田 勝幸, 宗 淳一, 宮原 信明, 谷本 安, 金廣 有彦, 田端 雅弘, 加藤 勝也, 伊達 洋至, 谷本 光音

    日本呼吸器学会雑誌   46 ( 増刊 )   131 - 131   2008年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • 早期に診断し得た肺ランゲルハンス細胞性組織球症の1例

    古賀 光, 谷本 安, 渕本 康子, 大橋 圭明, 宮原 信明, 瀧川 奈義夫, 田端 雅弘, 金廣 有彦, 木浦 勝行, 片岡 幹男, 谷本 光音

    気管支学   30 ( 3 )   160 - 160   2008年5月

  • Super scan using positron emission tomography in lung cancer patients. 国際誌

    Masanori Fujii, Katsuyuki Kiura, Nagio Takigawa, Hiromasa Takeda, Mitsune Tanimoto

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   2 ( 11 )   1042 - 3   2007年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PubMed

    researchmap

  • [Coinfection with Mycoplasma pneumoniae and Chlamydophila pneumoniae in a middle-aged adult]. 査読

    Kubo T, Takigawa N, Tanimoto Y, Ichihara E, Tabata M, Miyahara N, Kanehiro A, Kiura K, Tanimoto M

    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society   45 ( 10 )   808 - 811   2007年10月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    PubMed

    researchmap

  • 肺非小細胞癌における治療前血清KL-6値とゲフィチニブ単剤療法の治療効果の関連

    藤原 義朗, 木浦 勝行, 瀧川 奈義夫, 豊岡 伸一, 堀田 勝幸, 宗 淳一, 田端 雅弘, 加藤 勝也, 伊達 洋至, 谷本 光音

    肺癌   47 ( 5 )   629 - 629   2007年10月

  • EGFR変異とUFTによる肺腺癌術後補助療法の関連性についての検討

    末久 弘, 豊岡 伸一, 堀田 勝幸, 内田 亜希子, 宗 淳一, 藤原 義朗, 松尾 恵太郎, 大内田 守, 高田 穣, 木浦 勝行, 伊達 洋至

    肺癌   47 ( 5 )   513 - 513   2007年10月

  • 抗悪性腫瘍薬の至適投与法確立を目指して 非小細胞肺癌(NSCLC)症例における、腫瘍EGFR遺伝子変異の殺細胞性抗癌剤治療効果への影響の検討

    堀田 勝幸, 木浦 勝行, 豊岡 伸一, 瀧川 奈義夫, 宗 淳一, 藤原 義朗, 田端 雅弘, 伊達 洋至, 谷本 光音

    肺癌   47 ( 5 )   450 - 450   2007年10月

  • 第3相試験に登録された未治療進行非小細胞肺癌症例に対する予後の経年的変化に関する検討

    堀田 勝幸, 藤原 義朗, 松尾 恵太郎, 鈴木 勇史, 木浦 勝行, 田端 雅弘, 瀧川 奈義夫, 高田 三郎, 大澤 昌宏, 市原 英基, 内田 亜希子, 大橋 圭明, 荻野 敦子, 上岡 博, 谷本 光音

    肺癌   47 ( 5 )   480 - 480   2007年10月

  • The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. 査読 国際誌

    Toyooka S, Matsuo K, Shigematsu H, Kosaka T, Tokumo M, Yatabe Y, Ichihara S, Inukai M, Suehisa H, Soh J, Kiura K, Fong KM, Lee H, Wistuba II, Gazdar AF, Mitsudomi T, Date H

    Clinical cancer research : an official journal of the American Association for Cancer Research   13 ( 19 )   5763 - 5768   2007年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:19  

    DOI: 10.1158/1078-0432.CCR-07-0216

    Scopus

    PubMed

    researchmap

    その他リンク: http://orcid.org/0000-0003-1761-6314

  • マウス上皮成長因子受容体遺伝子改変マウスの作製

    頼 冠名, 大橋 圭明, 木浦 勝行, 大澤 昌宏, 瀧川 奈義夫, 吉野 正, 藤原 義朗, 内田 亜希子, 荻野 敦子, 谷本 光音

    肺癌   47 ( 5 )   486 - 486   2007年10月

  • EGFR遺伝子D761Yを有する肺腺癌患者の臨床経過と分子生物学的検討

    内田 亜希子, 久本 晃子, 上月 稔幸, 荻野 敦子, 大橋 圭明, 瀧川 奈義夫, 畝川 芳彦, 田端 雅弘, 木浦 勝行, 谷本 光音

    肺癌   47 ( 5 )   484 - 484   2007年10月

  • ゲフィチニブにて治療したNSCLC患者の血清KL-6値の予後的意義(Prognostic value of serum KL-6 level in NSCLC patients treated with gefitinib)

    藤原 義朗, 木浦 勝行, 瀧川 奈義夫, 豊岡 伸一, 堀田 勝幸, 宗 淳一, 田端 雅弘, 加藤 勝也, 伊達 洋至, 谷本 光音

    日本癌治療学会誌   42 ( 2 )   370 - 370   2007年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • 肺非小細胞癌における、腫瘍EGFR遺伝子変異の殺細胞性抗癌剤治療効果への影響の検討

    大澤 昌宏, 堀田 勝幸, 木浦 勝行, 豊岡 信一, 瀧川 奈義夫, 宗 淳一, 藤原 義郎, 田端 雅弘, 伊達 洋至, 谷本 光音

    日本癌治療学会誌   42 ( 2 )   369 - 369   2007年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • EGFR遺伝子D761Yを有する肺腺癌患者の臨床経過と分子生物学的検討

    内田 亜希子, 上月 稔幸, 久本 晃子, 荻野 敦子, 大橋 圭明, 滝川 奈義夫, 畝川 芳彦, 田端 雅弘, 木浦 勝行, 谷本 光音

    日本癌治療学会誌   42 ( 2 )   801 - 801   2007年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • マウスEGFR変異組み換えネズミにおける肺腺癌の発生(Transgenic mice with mouse Egfr mutation developed lung adenocarcinoma)

    大橋 圭明, 木浦 勝行, 頼 冠名, 大澤 昌宏, 平野 世紀, 藤原 義朗, 内田 亜希子, 荻野 敦子, 瀧川 奈義夫, 田端 雅弘, 吉野 正, 高田 穣, 谷本 光音

    日本癌学会総会記事   66回   119 - 119   2007年8月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 扁桃腫瘤で発見された再発肺腺癌

    武田 洋正, 瀧川 奈義夫, 木浦 勝行, 大橋 圭明, 大澤 昌宏, 田端 雅弘, 谷本 光音, 豊岡 伸一, 伊達 洋至

    肺癌   47 ( 4 )   387 - 387   2007年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • EGFR変異とUFTによる肺腺癌術後補助療法の関連性についての検討

    末久 弘, 豊岡 伸一, 堀田 勝幸, 内田 亜希子, 宗 淳一, 木浦 勝行, 浅野 博昭, 藤原 義朗, 松尾 恵太郎, 青江 基, 高田 穣, 清水 信義, 伊達 洋至

    日本呼吸器外科学会雑誌   21 ( 3 )   404 - 404   2007年4月

  • 上皮成長因子受容体(EGFR)遺伝子D761Yを有する肺腺癌患者の臨床経過と分子生物学的検討

    内田 亜希子, 上月 稔幸, 久本 晃子, 荻野 敦子, 大橋 圭明, 瀧川 奈義夫, 畝川 芳彦, 田端 雅弘, 木浦 勝行, 谷本 光音

    日本呼吸器学会雑誌   45 ( 増刊 )   168 - 168   2007年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • 肺非小細胞癌(NSCLC)患者におけるゲフィチニブ効果予測因子としての早期血清CEA値変化測定の有用性に関する検討

    高田 三郎, 堀田 勝幸, 藤原 義朗, 市原 英基, 大澤 昌宏, 大橋 圭明, 梅村 茂樹, 久本 晃子, 内田 亜希子, 荻野 敦子, 徳田 佳之, 瀧川 奈義夫, 田端 雅弘, 木浦 勝行, 谷本 光音

    日本呼吸器学会雑誌   45 ( 増刊 )   240 - 240   2007年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • シスプラチン耐性非小細胞肺癌細胞株(EBC-2/R)のHER3高発現とゲフィチニブ感受性増強について

    梅村 茂樹, 片山 英樹, 田端 雅弘, 上月 稔幸, 徳田 佳之, 大橋 圭明, 市原 英基, 大澤 昌宏, 高田 三郎, 瀧川 奈義夫, 木浦 勝行, 谷本 光音

    肺癌   46 ( 5 )   526 - 526   2006年11月

  • 非小細胞肺癌におけるゲフィチニブの臨床効果とHER2、EGFR遺伝子異常の関係

    宗 淳一, 豊岡 伸一, 市原 周二, 青江 啓介, 山根 正修, 青江 基, 佐野 由文, 藤原 義朗, 堀田 勝之, 木浦 勝行, 伊達 洋至

    日本癌学会総会記事   65回   234 - 234   2006年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本癌学会  

    researchmap

  • 定位脳照射後に長期不変である肺癌脳転移の検討

    大橋 圭明, 木浦 勝行, 田端 雅弘, 瀧川 奈義夫, 堀田 勝幸, 上月 稔幸, 梅村 茂樹, 内田 亜希, 荻野 敦子, 藤原 義郎, 谷本 光音

    日本呼吸器学会雑誌   44 ( 増刊 )   264 - 264   2006年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • 血清Arginine vasopressin(AVP)値と進展型小細胞肺癌の予後に関する検討

    梅村 茂樹, 上岡 博, 堀田 勝幸, 畝川 芳彦, 瀧川 奈義夫, 田端 雅弘, 木浦 勝行, 上月 稔幸, 久本 晃子, 徳田 佳之, 大橋 圭明, 別所 昭宏, 新海 哲, 谷本 光音

    肺癌   45 ( 5 )   501 - 501   2005年11月

  • EGFR遺伝子L858R変異を有するGefitinib非感受性肺癌の2例

    豊岡 伸一, 徳毛 誠樹, 木浦 勝行, 市原 周治, 細川 忍, 青江 基, 佐野 由文, 岡部 和倫, 大橋 圭明, 田端 雅弘, 伊達 洋至, 清水 信義

    日本癌治療学会誌   40 ( 2 )   347 - 347   2005年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • 転移を有する,あるいは再発した小細胞肺癌患者に対するトポテカン(T)とアムルビシン(A)の併用療法の第I相試験

    大橋 圭明, 堀田 勝幸, 瀧川 奈義夫, 田端 雅弘, 木浦 勝行, 谷本 光音, 柴山 卓夫, 畝川 芳彦, 張田 信悟, 上岡 博, 平木 俊吉

    肺癌   45 ( 4 )   396 - 397   2005年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 胃癌に対し内視鏡的治療を施行し得た胃癌合併肺癌の2例

    古賀 光, 田端 雅弘, 大橋 圭明, 淵本 康子, 近藤 稔人, 谷本 安, 金廣 有彦, 木浦 勝行, 谷本 光音

    肺癌   45 ( 4 )   399 - 400   2005年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • [A case of pneumonitis induced by CDDP and 5-FU]. 査読

    Hirano A, Tanimoto Y, Kimura G, Kiura K, Ueoka H, Kataoka M, Tanimoto M

    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society   43 ( 5 )   323 - 327   2005年5月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:5  

    PubMed

    researchmap

  • Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer 査読 国際誌

    N Nogami, S Harita, H Ueoka, T Yonei, K Kiura, H Kamei, M Tabata, Y Segawa, K Gemba, M Tanimoto

    LUNG CANCER   45 ( 1 )   85 - 91   2004年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCI IRELAND LTD  

    The role of non-platinum combination chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC) has not yet been clarified. In this phase I study, the dose-Limiting toxicity (DLT), the maximum tolerable dose (MTD) and the antitumor activity of a two-drug combination of docetaxel (DCT) and irinotecan (CPT) in patients with advanced NSCLC were evaluated. Previously untreated patients with NSCLC in stage IIIB with malignant pleural effusion or stage IV were eligible. Both drugs were administered by 1-h intravenous infusion on day 1, and repeated every 3 weeks. DCT was given before CPT administration. Five escalating dose levels of DCT/CPT (40/135, 50/135, 50/150, 60/150, and 60/165 mg/ml) were studied. Eighteen patients received 44 courses. The DLT was considered to be neutropenia, because grade 4 neutropenia lasting for 3 days or more was observed in three patients, which was accompanied with three episodes of febrile neutropenia. As a non-hematological toxicity, grade 3 diarrhea occurred in three patients. Since all the three patients treated at the fifth dose level (DCT at 60 mg/ml and CPT at 165 mg/ml) experienced DLT (grade 4 neutropenia in two patients and grade 3 hepatic toxicity in one), this dose level was determined to be the MTD. The objective response rate was 33.3%, and the median survival time was 13.6 months. To confirm the effectiveness of this combination for advanced NSCLC which was suggested in the present study, a phase 11 study with the recommended doses (1150 mg/m(2) for CPT and 50-60 mg/m(2) for DCT) is warranted. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

    DOI: 10.1016/j.lungcan.2003.12.008

    Web of Science

    PubMed

    researchmap

  • [Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib]. 査読

    Nishiwaki Y, Yano S, Tamura T, Nakagawa K, Kudoh S, Horai T, Noda K, Takata I, Watanabe K, Saka H, Takeda K, Imamura F, Matsui K, Katakami N, Yokoyama A, Sawa Y, Takada M, Kiura K, Sugiura T, Fukuoka M, Uchida H

    Gan to kagaku ryoho. Cancer & chemotherapy   31 ( 4 )   567 - 73   2004年4月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    PubMed

    researchmap

  • [Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer].

    Atsuhiko Tada, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Mitsuhiro Takemoto, Hiromichi Yamane, Junichiro Hiyama, Keisuke Aoe, Takuo Shibayama, Haruhito Kamei, Shin Kawahara, Shingo Harita, Toshio Sato, Makoto Kobayashi, Kenji Eguchi, Shunkichi Hiraki, Yoshio Hiraki, Mitsune Tanimoto

    Gan to kagaku ryoho. Cancer & chemotherapy   29 ( 5 )   751 - 6   2002年5月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    Eighteen elderly patients aged 76 years or older with small cell lung cancer were treated with carboplatin (AUC = 4 mg/ml.min, i.v. day 1) and etoposide (70 mg/m2 i.v. day 1-3) and 17 patients were evaluable. The median age of the study population was 77 years (range: 76-81). Eight patients had limited disease (LD) and nine did extensive disease (ED). The overall response rate was 88% for LD patients and 67% for ED patients. Median survival time was 219 days for LD patients and 158 days for ED patients. Grade 3 and 4 leukopenia, neutropenia, thrombocytopenia and anemia occurred in 41%, 76%, 24% and 6% of patients, respectively. There was one treatment-related death due to pneumonitis.

    PubMed

    researchmap

  • [High dose chemotherapy with autologous peripheral blood stem cell transplantation in lung cancer].

    Katsuyuki Kiura, Mine Harada

    Nihon rinsho. Japanese journal of clinical medicine   60 Suppl 5   463 - 8   2002年5月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    PubMed

    researchmap

  • A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV) cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma - Results of long term follow-up 査読

    H Ueoka, K Kiura, M Tabata, H Kamei, K Gemba, K Sakae, Y Hiraki, S Hiraki, Y Segawa, M Harada

    CANCER   83 ( 2 )   283 - 290   1998年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-LISS  

    BACKGROUND. In an attempt to determine the efficacy of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) hybrid chemotherapy (HYB), a rapidly alternating chemotherapy, in patients with small cell lung carcinoma (SCLC), the authors conducted a randomized study to compare HYB with CAV-PVP sequential chemotherapy (SEQ).
    METHODS. Patients in the HYB group received the 3-drug CAV combination on Day 1 and the 2-drug PVP combination on Day 8, repeated every 4 weeks for up to 6 cycles. Patients in the SEQ group received 3 cycles each of CAV and PVP sequentially every 4 weeks, delivered on Days 1 and 8. All responding patients with limited disease (LD) received thoracic irradiation (50 gray) after chemotherapy.
    RESULTS. Between April 1988 and October 1992, 129 patients were evaluated fully. There were no significant differences in the treatment outcome between patients in the HYB and SEQ groups in terms of the complete response rate (59% for LD patients and 21% for extensive disease [ED] patients in the HYB group vs. 45% for LD patients and 16% for ED patients in the SEQ group), or median survival time (17.9 months for LD patients and 9.7 months for ED patients in the HYB group vs. 20.6 months for LD patients and 12.2 months for ED patients in the SEQ group).
    CONCLUSIONS. Hybrid CAV-PVP therapy is effective for the treatment of SCLC, but appears to be no better than sequential therapy with the same regimen. (C) 1998 American Cancer Society.

    Web of Science

    researchmap

  • Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids 査読

    T Moritaka, K Kiura, H Ueoka, M Tabata, Y Segawa, T Shibayama, N Takigawa, T Ohnoshi, M Harada

    ANTICANCER RESEARCH   18 ( 2A )   927 - 933   1998年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:INT INST ANTICANCER RESEARCH  

    A cisplatin-resistant cell line, SBC-3/CDDP, was established from a human small-cell lung cancer cell line, SBC-3. The SBC-3/CDDP cells were 13.1-fold more resistant to cisplatin than the parent SBC-3 cells. We investigated the cellular changes of this cell line with regard to the development of resistance to cisplatin. The SBC-3/CDDP cells showed various characteristics as follows: a) increased intracellular glutathione and glutathione S-transferase content b) decreased intracellular accumulation of cisplatin, c) increased topoisomerase I activity and the same topoisomerase II activity as the parent SBC-3 cells, and 4) strong cross-resistance to the platinum analogues and mitomycin C, moderate cross-resistance to 7-ethyl-10-hydroxy-camptothecin (SN-38), 4-hydroperoxy cyclophosphamide, etoposide, Adriamycin and methotrexate, and collateral sensitivity to vinca alkaloids and 5-fluorouracil. From these observations, the SBC-3/CDDP cells could be useful as a well characterized cisplatin-resistant cell line and the resistance pattern in this cell line will give us much information for eradication of cisplatin-resistant tumor cells.

    Web of Science

    researchmap

  • COMPARATIVE-STUDY OF PROPHYLACTIC CRANIAL IRRADIATION IN PATIENTS WITH SMALL-CELL LUNG-CANCER ACHIEVING A COMPLETE RESPONSE - A LONG-TERM FOLLOW-UP RESULT 査読

    T OHONOSHI, H UEOKA, S KAWAHARA, K KIURA, H KAMEI, Y HIRAKI, Y SEGAWA, S HIRAKI, KIMURA, I

    LUNG CANCER   10 ( 1-2 )   47 - 54   1993年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCI IRELAND LTD  

    Between 1981 and 1986, a total of 46 patients with small cell lung cancer (SCLC) achieving a complete response by chemotherapy with or without chest irradiation were randomized either to receive prophylactic cranial irradiation (PCI) or not. With a median follow-up time of 8.5 years for both groups, only five of 23 patients (22%) in the PCI group developed brain relapse, while 12 out of 23 (52%) in the no PCI group did so (P &lt; 0.05). The frequency of patients developing a sole brain relapse during their whole clinical course was 4/o for the PCI group and 17% for the no PCI group, however, the difference was not statistically significant. Patient survival was better for the PCI group (median survial time of 21 months, and 5-year survival rate of 22%) as compared with the no PCI group (median survival time of 15 months, and 5-year survival rate of 13%), showing a marginal significance (P = 0.097). Late neurologic toxicity was infrequent; only one developed a mild deterioration among seven long-term disease-free survivors in the PCI group. These results appear to warrant further clinical trials to clarify the utility of PCI in patients with SCLC achieving a complete response.

    Web of Science

    researchmap

  • PILOT-STUDY OF CYCLOPHOSPHAMIDE-DOXORUBICIN-VINCRISTINE-CISPLATIN-ETOPOSIDE HYBRID CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER 査読

    T OHNOSHI, S HIRAKI, H UEOKA, K KIURA, H KAMEI, T HORIGUCHI, T KODANI, T MAEDA, M TABATA, T SHIBAYAMA, Y SEGAWA, K MIYATAKE, N TAKIGAWA, KIMURA, I

    CANCER   72 ( 5 )   1597 - 1601   1993年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-LISS  

    Background. Small cell lung cancer (SCLC) is highly sensitive to chemotherapy. Despite the introduction of intensive combination chemotherapy, long-term disease-free survivors are still rare. The emergence of drug-resistant tumor cells during chemotherapy is presumed to be the major cause of poor outcome.
    Methods. A pilot Phase II study of hybrid chemotherapy for patients with SCLC was conducted between October 1986 and March 1988. Dose and schedule for each drug in the regimen were as follows: cyclophosphamide, 700 mg/m2 intravenously (IV), day 1; doxorubicin, 30 mg/m2 IV, day 1; vincristine, 1.4 mg/m2 IV, day 1; cisplatin, 60 mg/m2 IV, day 8; and etoposide, 100 mg/m2 IV, days 8 and 9. Courses were repeated every 4 weeks for up to six cycles. Patients with limited disease (LD) received chest irradiation of 5000 cGy when a maximal response was achieved. Only patients with LD who achieved a complete response (CR) received prophylactic cranial irradiation of 3000 cGy.
    Results. Thirty-six patients were enrolled and fully evaluated for tumor response and toxicity. All 20 patients with LD responded to the regimen, and 14 (70%) of those achieved a CR. Of 16 patients with.extensive disease (ED), 7 CR and 7 partial responses were noted, indicating an overall response rate of 88%. The median survival time was 23.6 months for patients with LD and 12.6 months for those with ED. Myelosuppression was the major toxicity, but it was generally well tolerated.
    Conclusions. These results indicate that the hybrid regimen is a highly active one for the treatment of patients with SCLC and warrants additional clinical trials.

    Web of Science

    researchmap

  • MDR1 GENE-EXPRESSION AND TREATMENT OUTCOME IN SMALL-CELL LUNG-CANCER - MDR1 GENE-EXPRESSION AS AN INDEPENDENT PROGNOSTIC FACTOR 査読

    M TABATA, T OHNOSHI, H UEOKA, K KIURA, KIMURA, I

    ACTA MEDICA OKAYAMA   47 ( 4 )   243 - 248   1993年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OKAYAMA UNIV MED SCHOOL  

    We report a preliminary study to determine whether MDR1 gene expression level in small cell lung cancer (SCLC) tumors is a useful predictor of tumor response to chemotherapy and patient survival in association with myc amplification in the tumor. We analyzed 18 patients with SCLC receiving adriamycin and etoposide combination chemotherapy between August 1989 and November 1991; 16 males and 2 females, median age of 68 years, and 7 with limited disease and 11 with extensive disease. MDR1 mRNA expression level and myc family gene amplification were simultaneously determined by polymerase chain reaction using transbronchial biopsy specimens which were obtained at diagnosis. Patients with tumors expressing low MDR1 mRNA responded more favorably to chemotherapy than those with tumors expressing high MDRI mRNA, however, the difference in tumor response was statistically not significant (84.6 % versus 40 %). The overall survival was significantly shorter in the latter than in the former (7.2 months versus 11.7 months; p=0.023). The survival of the 4 patients with tumor showing myc family gene amplification was almost identical to that of patients with tumors showing no amplification of the gene (8.2 months versus 8.8 months;p=0.73). Multivariate Cox's regression analysis supports the notion that MDR1 may be a useful independent prognostic factor.

    Web of Science

    researchmap

  • IMMUNOHISTOCHEMICAL DETECTION OF P-GLYCOPROTEIN AND CARCINOEMBRYONIC ANTIGEN IN SMALL-CELL LUNG-CANCER - WITH REFERENCE TO PREDICTABILITY OF RESPONSE TO CHEMOTHERAPY 査読

    Y SEGAWA, T OHNOSHI, S HIRAKI, H UEOKA, K KIURA, H KAMEI, M TABATA, T SHIBAYAMA, K MIYATAKE, K GENBA, T MATSUMURA, KIMURA, I

    ACTA MEDICA OKAYAMA   47 ( 3 )   181 - 189   1993年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OKAYAMA UNIV MED SCHOOL  

    In an attempt to elucidate the tumor properties relating to responsiveness to chemotherapy, we examined immunohistochemically the expression of P-glycoprotein (P-gp) and carcinoembryonic antigen (CEA) in small cell lung cancer (SCLC) tumors. Tumor specimens from 33 patients were obtained at the time of diagnosis and relapse. Four patients expressed P-gp in their initial tumors, and 7 others did in recurrent tumors. The overall response rate to chemotherapy of the initial tumors was 75 % for P-gp-positive initial tumors and 86 % for P-gp-negative tumors, whereas the disease-free and overall survival times were significantly shorter in the former than the latter. Three patients showed CEA in their initial tumors, and 5 others did in recurrent tumors. The patients with CEA-positive initial tumors tended to relapse earlier than those with CEA-negative tumors. In addition, recurrent tumors expressing CEA were resistant to salvage chemotherapy. A clear correlation between CEA expression by tumors and the CEA level in the serum was observed at diagnosis as well as at relapse. These findings indicate that P-gp and/or CEA expression by a tumor and elevated CEA level in the serum may predict refractoriness of the tumor to chemotherapy.

    Web of Science

    researchmap

  • MORTALITY AND MORBIDITY IN 2-YEAR DISEASE-FREE SURVIVORS OF SMALL-CELL LUNG-CANCER AFTER TREATMENT WITH COMBINATION CHEMOTHERAPY WITH OR WITHOUT IRRADIATION 査読

    T OHNOSHI, S HIRAKI, M FUJII, H UEOKA, T YONEI, M TAMURA, T MORITAKA, Y MIMA, T HORIGUCHI, K KIURA, H KAMEI, T KODANI, Y HIRAKI, KIMURA, I

    ACTA MEDICA OKAYAMA   47 ( 3 )   209 - 214   1993年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OKAYAMA UNIV MED SCHOOL  

    We evaluated the long-term outcome of 148 Patients with small cell lung cancer (SCLC) who had been entered into clinical trials of chemotherapy with or without thoracic and prophylactic cranial irradiation (PCI) between 1981 and 1987. Eighteen patients (12%) survived for 2 or more years. With a minimum follow-up of 4.5 years, 10 of the 18 patients who remained disease-free at 2 years are currently alive and free of SCLC. Seven of these 10 patients currently function as they did before diagnosis. However, three suffer from central nervous system changes of varying degrees in severity which appeared 2-3 years after PCI. Eight of the 18 patients who were disease-free at 2 years have died. Two died of isolated relapse in the brain at 3.6 and 4.2 years after initiation of chemotherapy. Five died of other malignancies while continuing their complete response to SCLC; two of non-small cell lung cancer, two of acute myelogenous leukemia, and one of hepatocellular carcinoma. Another patient died of an unrelated disease without any evidence of SCLC. A small but substantial proportion of patients who underwent intensive treatment will achieve long-term survival; however, these patients remain at higher risk for second cancers and late toxicities. Therefore, attention must be directed to defining the safest way to employ such treatment in the management of SCLC.

    Web of Science

    researchmap

  • LONG-TERM RESULTS OF COMBINATION CHEMOTHERAPY WITH OR WITHOUT IRRADIATION IN SMALL-CELL LUNG-CANCER - A 5-YEAR TO 11-YEAR FOLLOW-UP 査読

    T OHNOSHI, S HIRAKI, N UEDA, M FUJII, K MACHIDA, H UEOKA, T YONEI, K KIURA, H KAMEI, Y SEGAWA, M TABATA, T SHIBAYAMA, K MIYATAKE, T MAEDA, KIMURA, I

    INTERNAL MEDICINE   32 ( 3 )   215 - 220   1993年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JAPAN SOC INTERNAL MEDICINE  

    Between April 1981 and December 1987, 148 patients with newly diagnosed small cell lung cancer (SCLC) were treated using combination chemotherapy with or without thoracic irradiation and prophylactic cranial irradiation (PCI) in a series of cooperative therapeutic trials. With a minimum follow-up of 4.7 years, 13 (9%) patients survived and were free of SCLC. These included 11 (15%) of 76 patients with limited disease and two (3%) of 72 patients with extensive disease. Three died without any evidence of SCLC (one each from second leukemia, non-small cell lung cancer, and unrelated disease). The remaining 10 (7%) patients are currently alive and free of SCLC beyond 4.7 years. Since late relapse beyond 5 years is a very rare event, these patients may have been cured. However, late toxicity of PCI must be kept in mind. Three among the 10 patients have suffered from neuropsychologic symptoms of varying degrees in severity. Although the long-term survival rate is a benchmark in the treatment of SCLC, modifications of therapy that may potentially avoid such toxicities should be considered hereafter.

    Web of Science

    researchmap

  • MDR1 GENE-EXPRESSION AND TREATMENT OUTCOME IN SMALL-CELL LUNG-CANCER 査読

    M TABATA, T OHNOSHI, H UEOKA, K KIURA, T SHIBAYAMA, N TAKIGAWA, KIMURA, I

    MECHANISM AND NEW APPROACH ON DRUG RESISTANCE OF CANCER CELLS   1026   63 - 69   1993年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(国際会議プロシーディングス)   出版者・発行元:ELSEVIER SCIENCE PUBL B V  

    Web of Science

    researchmap

  • AN ADRIAMYCIN-RESISTANT HUMAN SMALL-CELL LUNG-CANCER CELL-LINE (SBC-3/ADM100) SHOWS COLLATERAL SENSITIVITY TO ANTIFOLATES 査読

    K KIURA, T OHNOSHI, H UEOKA, M TABATA, Y SEGAWA, T SHIBAYAMA, T CHIKAMORI, N TAKIGAWA, KIMURA, I

    MECHANISM AND NEW APPROACH ON DRUG RESISTANCE OF CANCER CELLS   1026   111 - 114   1993年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(国際会議プロシーディングス)   出版者・発行元:ELSEVIER SCIENCE PUBL B V  

    Web of Science

    researchmap

  • NEURAL CELL-ADHESION MOLECULE EXPRESSION IN AND CLINICAL-FEATURES OF SMALL-CELL LUNG-CANCER WITH SPECIAL REFERENCE TO TREATMENT OUTCOME 査読

    Y SEGAWA, T OHNOSHI, H UEOKA, K KIURA, M TABATA, T SHIBAYAMA, KIMURA, I

    MECHANISM AND NEW APPROACH ON DRUG RESISTANCE OF CANCER CELLS   1026   233 - 236   1993年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(国際会議プロシーディングス)   出版者・発行元:ELSEVIER SCIENCE PUBL B V  

    Web of Science

    researchmap

  • AN ADRIAMYCIN-RESISTANT SUBLINE IS MORE SENSITIVE THAN THE PARENT HUMAN SMALL-CELL LUNG-CANCER CELL-LINE TO LONIDAMINE 査読

    K KIURA, T OHNOSHI, H UEOKA, N TAKIGAWA, M TABATA, Y SEGAWA, T SHIBAYAMA, KIMURA, I

    ANTI-CANCER DRUG DESIGN   7 ( 6 )   463 - 470   1992年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OXFORD UNIV PRESS UNITED KINGDOM  

    Lonidamine, a unique new type of anticancer agent, has been shown to exert marginal activity in patients with resistant small cell lung cancer. We have assessed cytotoxic activity using seven human small cell lung cancer cell lines and the drug resistant small cell lung cancer sublines, Adriamycin-resistant SBC-3/ADM100, etoposide-resistant SBC-3/ETP and cisplatin-resistant SBC-3/CDDP. Although lonidamine had only a minimal activity in seven human small cell lung cancer cell lines, SBC-3/ADM100 cells were more sensitive to lonidamine than the parent SBC-3 cells to a 1.6-fold extent in terms of IC50. SBC-3/CDDP and SBC-3/ETP had no cross-resistance to lonidamine at all. These observations may bc of potential clinical significance in treating small cell lung cancer.

    Web of Science

    researchmap

  • ESTABLISHMENT AND CHARACTERIZATION OF AN ETOPOSIDE-RESISTANT HUMAN SMALL-CELL LUNG-CANCER CELL-LINE 査読

    N TAKIGAWA, T OHNOSHI, H UEOKA, K KIURA, KIMURA, I

    ACTA MEDICA OKAYAMA   46 ( 3 )   203 - 212   1992年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OKAYAMA UNIV MED SCHOOL  

    An etoposide-resistant subline, SBC-3/ETP, from a human small cell lung cancer cell line, SBC-3, was developed by continuous exposure to increasing concentrations of etoposide in culture. The SBC-3/ETP was 52.1-fold more resistant to etoposide than the parent cell line. The SBC-3/ETP was highly cross-resistant to teniposide, adriamycin, vinca alkaloids, 4-hydroperoxycyclophosphamide, CPT-11 and mitomycin C, and marginally cross-resistant to cisplatin, while the subline showed a collateral sensitivity to bleomycin. Topoisomerase I activity in the SBC-3/ETP was reduced to an extent of one half and topoisomerase II activity to an extent of one eighth in comparison with those of the SBC-3. Intracellular accumulation of [H-3] -etoposide in the SBC-3/ETP was significantly lower in comparison to the SBC-3. An overexpression of MDR1 mRNA, and the presence of its product, P-glycoprotein, were detected in the SBC-3/ETP by Northern blotting and flowcytometry using a monoclonal antibody of the protein, MRK16. These results indicate that a decreased activity of topoisomerase II is the major factor for the development of etoposide resistance, and that an overexpression of the MDR1 gene is responsible, in part, for the development of resistance to the drug and some structurally unrelated compounds such as adriamycin and vinca alkaloids.

    Web of Science

    researchmap

  • PHASE II STUDY OF IFOSFAMIDE, CISPLATIN, AND VINDESINE COMBINATION IN ADVANCED NON-SMALL-CELL LUNG-CANCER 査読

    T OHNOSHI, S HIRAKI, N UEDA, M FUJII, K MACHIDA, H UEOKA, S KAWAHARA, A KOZUKA, K KIURA, T MORITAKA, T KODANI, H KAMEI, KIMURA, I

    ACTA MEDICA OKAYAMA   45 ( 5 )   357 - 361   1991年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OKAYAMA UNIV MED SCHOOL  

    Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3 g/m2, on days 1 to 5; cisplatin, 20 mg/m2, on days 1 to 5; and vindesine, 3 mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with III A/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials.

    Web of Science

    researchmap

  • 肺重複癌の臨床的検討

    藤井 昌史, 木浦 勝行, 木村 誠, 森脇 昭介

    医療   43 ( 8 )   816 - 819   1989年

     詳細を見る

    記述言語:日本語   出版者・発行元:Japanese Society of National Medical Services  

    原発性肺癌991例のうち, 他臓器癌を合併した58例(5.9%)について検討した. 合併臓器は胃が最も多く, ついで喉頭, 子宮, 乳腺の順であつた. 頭頸部癌では喫煙との関連が示唆された. 二重癌のうち, 他臓器癌先行例では肺癌先行例に比べ, (1)発見間隔が有意に長い, (2)肺癌病期の進行例が多い, (3)肺癌関連死が多い, (4)生存期間中央値が短い, などの傾向がみられた. 重複癌として発生頻度の高い臓器での第2癌発生に対する早期診断, 早期治療が重複癌の予後の改善につながるものとおもわれる.

    DOI: 10.11261/iryo1946.43.816

    CiNii Article

    researchmap

  • 肺癌患者における血清中および気管支肺胞洗浄液中腫ようマーカーの臨床評価

    藤井 昌史, 木浦 勝行

    医療   42 ( 11 )   1012 - 1016   1988年

     詳細を見る

    記述言語:日本語   出版者・発行元:Japanese Society of National Medical Services  

    原発性肺癌71例, 良性肺疾患36例, 健常人100例において, 血清中および気管支肺胞洗浄液中の各種腫瘍マーカーを測定検討した. 血清中CEAは平均値10.9ng/ml, 陽性率43.7%であり, 良性肺疾患の1.6ng/ml, 8.3%に比べ有意に高値であつた. 血清中NSEで肺癌で平均値14.8ng/ml, 45.1%と良性肺疾患の6.5ng/ml, 11.1%に比べ有意に高値を示し, 特に小細胞癌では54.9ng/ml, 80.0%と著しく高かつた. 血清中TPAとIAPの陽性率は肺癌で有意に高かつたが, 良性肺疾患においても比較的高率であつた. 血清中ferritinとβ2MGでは肺癌と良性肺疾患の間に有意差を認めなかつた. 気管支肺胞洗浄液中のCEA, ferritin, β2MGの平均値はいずれも肺癌では良性肺疾患, 健常人に比べ有意に高値を示した. 今後, これら有効ないくつかの腫瘍マーカーを組み合わせることにより, 肺癌の補助診断としての有効性を高めることが期待される.

    DOI: 10.11261/iryo1946.42.1012

    CiNii Article

    researchmap

▼全件表示

書籍等出版物

  • 呼吸器ジャーナル

    医学書院  2017年 

     詳細を見る

  • 1361専門家による 私の治療[2020−21年度版]【電子版付】

    猿田, 享男, 北村, 惣一郎( 担当: 分担執筆 ,  範囲: 呼吸器疾患 「非小細胞肺癌(ドライバー遺伝子変異陰性))

    日本医事新報社  2021年9月  ( ISBN:4784946519

     詳細を見る

    総ページ数:1568   記述言語:日本語

    CiNii Books

    ASIN

    researchmap

  • 新呼吸器専門医テキスト

    日本呼吸器学会( 担当: 分担執筆)

    南江堂  2020年8月  ( ISBN:9784524226894

     詳細を見る

    総ページ数:xxxi, 694p   記述言語:日本語

    CiNii Books

    researchmap

  • 2020 今日の治療指針 : 私はこう治療している

    日野原, 重明, 阿部, 正和, 稲垣, 義明, 多賀須, 幸男, 山口, 徹, 北原, 光夫, 福井, 次矢, 高木, 誠, 小室, 一成, 荒木, 淑郎, 石井, 明, 石井, 清一, 相沢, 好治, 赤司, 浩一(大学教員), 尾形, 悦郎( 担当: 分担執筆 ,  範囲: 5呼吸器疾患 悪性胸膜中皮腫)

    医学書院  2020年1月  ( ISBN:4260107704

     詳細を見る

    総ページ数:冊   記述言語:日本語

    CiNii Books

    researchmap

  • 間質性肺炎合併肺癌に関するステートメント

    日本呼吸器学会, 日本呼吸器学会腫瘍学術部会, 日本呼吸器学会びまん性肺疾患学術部会( 担当: 編集 ,  範囲: ステートメント編集委員会 委員長)

    南江堂  2017年10月  ( ISBN:9784524255368

     詳細を見る

    総ページ数:xi, 114p   記述言語:日本語

    CiNii Books

    researchmap

  • インフォームドコンセントのための図説シリーズ 肺癌 改訂5版 (共著)

    医薬ジャーナル社  2017年  ( ISBN:9784753225231

     詳細を見る

  • 内科学 第11版 (共著)

    朝倉書店  2017年 

     詳細を見る

  • 速習 肺癌免疫療法 (共著)

    南江堂  2016年  ( ISBN:9784524251476

     詳細を見る

  • 「II 各論 15Oncology Emergency 6 腫瘍溶解症候群」 入門腫瘍内科学 (共著)

    篠原出版新社  2015年 

     詳細を見る

  • 呼吸器専門医テキスト 日本呼吸器学会編集 (共著)

    日本呼吸器学会 南江堂  2015年  ( ISBN:9784524266654

     詳細を見る

  • 抗がん薬の薬理 (分担・単著)

    南山堂  2013年  ( ISBN:9784525423414

     詳細を見る

  • 手術不能Ⅲ期非小細胞肺癌

    日本臨床学会  2013年 

     詳細を見る

  • 手術不能ⅢA期N2肺非小細胞肺癌症例に対する術前治療

    呼吸器内科学会  2013年 

     詳細を見る

  • 【治療効果の判定基準と臨床試験のendpoint】 PFS or OS 肺がん.

    腫瘍内科学会  2013年 

     詳細を見る

  • 【分子標的治療】 肺癌と分子標的薬.

    岡山医学会雑誌  2013年 

     詳細を見る

  • 発熱性好中球減少のガイドライン,肝炎ウィルスキャリアの癌患者の治療ガイドライン

    金原出版  2013年 

     詳細を見る

  • 治療効果の判定基準と臨床試験のendpoint

    腫瘍内科学会  2013年 

     詳細を見る

  • エビデンスに基づいた癌化学療法ハンドブック2012

    メディカルレビュー社  2012年 

     詳細を見る

  • インフォームドコンセントのための図説シリーズ 肺癌 改訂4版 (共著)

    医薬ジャーナル社  2011年  ( ISBN:9784753225231

     詳細を見る

  • インフォームドコンセントのための図説シリーズ 抗悪性腫瘍薬 肺癌 改訂版 (共著)

    医薬ジャーナル社  2011年  ( ISBN:9784753225248

     詳細を見る

  • 肺がん 改訂4版

    医薬ジャーナル社  2011年 

     詳細を見る

  • 抗悪性腫瘍薬 肺がん 改訂版

    医薬ジャーナル社  2011年 

     詳細を見る

  • インフォームドコンセントのための図説シリーズ 抗悪性腫瘍薬 分子標的治療薬 (共著)

    医薬ジャーナル社  2010年  ( ISBN:9784753224159

     詳細を見る

  • 「III章 肺がん薬物療法の実際 1.化学療法の実際 Q11 化学放射線治療中に抗がん剤の副作用が強く現れた場合,その後の化学療法をどうしたら良いのですか」 肺がん0薬物療法 Q & A 臨床現場での考え方

    南江堂  2009年  ( ISBN:9784524260034

     詳細を見る

  • 「肺癌治療 5)治療の合併症 ④分子標的薬」 インフォームドコンセントのための図説シリーズ 肺癌 改訂3版

    医薬ジャーナル社  2009年  ( ISBN:9784753223589

     詳細を見る

  • 1.各種のがん 3)胸部 肺がん」 がん診療update 生涯教育シリーズ-76

    日本医師会  2009年 

     詳細を見る

  • 「第22章 横隔膜・胸壁疾患(邦訳)」フレーザー呼吸器病学エッセンス

    西村書店  2009年  ( ISBN:9784890133840

     詳細を見る

  • 「II各論 15 Oncology Emergency 6 腫瘍溶解症候群」 入門腫瘍内科学

    篠原出版新社  2009年 

     詳細を見る

  • 「第5章 予後因子・治療効果予測因子(バイオマーカー) 3.治療効果予測因子と個別化治療 a.遺伝子変異・増幅・欠損(EGFR,KRAS等)」 がん化学療法・分子標的治療update

    中外医学社  2009年  ( ISBN:9784498022447

     詳細を見る

  • Methods of Cancer Diagnosis, Therapy and Prognosis : General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma (Methods of Cancer Diagnosis, Therapy and Prognosis) 〈Vol. 2〉

    Springer Netherlands  2008年 

     詳細を見る

  • Methods of Cancer Diagnosis, Therapy and Prognosis : General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma (Methods of Cancer Diagnosis, Therapy and Prognosis) 〈Vol. 2〉

    Springer Netherlands  2008年 

     詳細を見る

  • 原発性肺癌者における二次発癌化学予防に関する基礎的研究

    木浦, 勝行

    木浦勝行  2007年4月 

     詳細を見る

    総ページ数:1冊   記述言語:英語

    CiNii Books

    researchmap

  • ASCO2007 臨床腫瘍学の最前線 -第43回 米国臨床腫瘍学会より -

    (株)電通  2007年 

     詳細を見る

  • ASCO2007 Highlights

    エルゼビア・ジャパン株式会社  2007年 

     詳細を見る

  • EBM 呼吸器疾患の治療

    中外医学社  2007年 

     詳細を見る

  • 抗悪性腫瘍マニュアル

    中外医学社  2007年 

     詳細を見る

  • 肺癌のすべて,呼吸器common diseaseの診療

    文光堂  2007年 

     詳細を見る

  • MOOK 肺癌の臨床 2007〜2008

    篠原出版新社  2007年 

     詳細を見る

  • 実例から学ぶ安全で有効な化学療法の実践

    先端医学社  2007年 

     詳細を見る

  • 呼吸器診療のコツと落とし穴 第3巻 びまん性肺疾患・肺腫瘍 薬物療法

    中山書店  2006年 

     詳細を見る

  • Signal Japan Vol. 6 Issue 2 pp 2-37, 2006

    Adia International Ltd  2006年 

     詳細を見る

  • 新臨床腫瘍学-がん薬物療法専門医のために 日本臨床腫瘍学会「新臨床腫瘍学」

    南江堂,東京  2006年 

     詳細を見る

  • 呼吸器診療のコツと落とし穴 第3巻 びまん性肺疾患・肺腫瘍 薬物療法

    中山書店,東京  2005年 

     詳細を見る

  • 呼吸器診療のコツと落とし穴 第3巻 びまん性肺疾患・肺腫瘍 薬物療法

    中山書店,東京  2005年 

     詳細を見る

  • 若年発症肺癌(30歳未満)における分子生物学的特性と遺伝子異常の検討

    木浦, 勝行

    木浦勝行  2004年5月 

     詳細を見る

    総ページ数:1冊  

    CiNii Books

    researchmap

  • 肺がん治療症例集〜分子標的治療薬ゲフィチニブ〜

    医薬ジャーナル社,大阪  2004年 

     詳細を見る

  • 平成12年度 日本茶に含まれている有効成分に関する茶学術研究助成事業成果発表 第3回宇治茶健康フォーラム・市民公開講演会 講演要旨集

    京都府茶業会議所  2001年 

     詳細を見る

  • 末梢血幹細胞移植の実際

    南江堂  2001年 

     詳細を見る

  • 喫煙者に対するらせんCT検診の有用性 平成12年度老人対策強化事業費報告書

    岡山県健康づくり財団  2001年 

     詳細を見る

  • 肺癌領域における自已造血幹細胞移植 KEY WORD 1999-2000 呼吸器疾患

    先端医学社  1999年  ( ISBN:4915892794

     詳細を見る

▼全件表示

MISC

  • 生物学的製剤の効果予測 当院においてデュピルマブを使用した気管支喘息症例の検討

    谷口 暁彦, 中村 尚季, 角南 良太, 板野 純子, 妹尾 賢, 大野 恵美, 後川 真輝, 木浦 勝行, 前田 嘉信, 宮原 信明

    アレルギー   70 ( 6-7 )   803 - 803   2021年8月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本アレルギー学会  

    researchmap

  • Phase I/II study of osimertinib in EGFR exon 20 insertion mutations in non-small cell lung cancer patients: AEX20.

    Eiki Ichihara, Hiroyuki Yasuda, Yuta Takashima, Yoshitaka Zenke, Shinji Takeuchi, Masahiro Morise, Katsuyuki Hotta, Mineyoshi Sato, Shingo Matsumoto, Azusa Tanimoto, Reiko Matsuzawa, Katsuyuki Kiura, Hideki Terai, Shinnosuke Ikemura, Koichi Goto, Kenzo Soejima

    CANCER RESEARCH   81 ( 13 )   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:会議報告等   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    Web of Science

    researchmap

  • 災害ボランティア後にアスペルギローマとアレルギー性気管支肺アスペルギルス症を合併した一例

    久保 寿夫, 中須賀 崇匡, 谷口 暁彦, 二宮 貴一朗, 大橋 圭明, 頼 冠名, 堀田 勝幸, 宮原 信明, 田端 雅弘, 木浦 勝行

    気管支学   43 ( Suppl. )   S284 - S284   2021年6月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本呼吸器内視鏡学会  

    researchmap

  • 気管支鏡下再生検にて診断しえたIgG4関連疾患におけるEGFR変異肺腺癌合併の一例

    大橋 圭明, 大川 祥, 頼 冠名, 木浦 勝行

    気管支学   43 ( Suppl. )   S297 - S297   2021年6月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本呼吸器内視鏡学会  

    researchmap

  • 肺癌登録事業報告

    吉野 一郎, 鈴木 秀海, 新谷 康, 中西 良一, 川口 知哉, 山本 信之, 門倉 光隆, 高橋 和久, 木浦 勝行, 遠藤 俊輔, 千田 雅之, 浅村 尚生, 宮岡 悦良, 伊達 洋至, 肺癌登録合同委員会

    気管支学   43 ( Suppl. )   S172 - S172   2021年6月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本呼吸器内視鏡学会  

    researchmap

  • Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.

    Yuka Kato, Taku Noumi, Kazuhiko Saeki, Kiichiro Ninomiya, Toshio Kubo, Masanori Fujii, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Masahiro Tabata, Katsuyuki Hotta, Toshiyuki Kozuki, Yoshinobu Maeda, Katsuyuki Kiura

    JOURNAL OF CLINICAL ONCOLOGY   39 ( 15 )   2021年5月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    DOI: 10.1200/JCO.2021.39.15_suppl.e20590

    Web of Science

    researchmap

  • 肺癌登録事業報告 新たな研究の展開

    鈴木 秀海, 吉野 一郎, 新谷 康, 中西 良一, 川口 知哉, 山本 信之, 門倉 光隆, 高橋 和久, 木浦 勝行, 遠藤 俊輔, 千田 雅之, 淺村 尚生, 宮岡 悦良, 伊達 洋至

    日本呼吸器外科学会雑誌   35 ( 3 )   肺癌登録合同委員会報告 - 肺癌登録合同委員会報告   2021年5月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本呼吸器外科学会  

    researchmap

  • 第61回日本肺癌学会学術集会 “肺癌撲滅を目指して2020” 招待

    木浦勝行

    岡山医学会雑誌   133 ( 1 )   80 - 82   2021年4月

     詳細を見る

    担当区分:筆頭著者, 最終著者, 責任著者   記述言語:日本語  

    DOI: 10.4044/joma.133.80

    researchmap

  • 肺癌登録事業の年次報告 新たな事業に向けて(肺癌登録合同委員会)

    鈴木 秀海, 吉野 一郎, 新谷 康, 中西 良一, 川口 知哉, 山本 信之, 門倉 光隆, 高橋 和久, 木浦 勝行, 遠藤 俊輔, 千田 雅之, 浅村 尚生, 富岡 悦良, 伊達 洋至, 全国肺癌登録合同委員会

    日本呼吸器学会誌   10 ( 増刊 )   84 - 84   2021年4月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • リンパ脈管筋腫症(LAM)に気管支喘息が併発した2例(アンコール演題)

    谷本 安, 板野 純子, 谷口 暁彦, 大上 康広, 石賀 充典, 藤原 義朗, 田中 寿明, 藤井 誠, 宮原 信明, 木村 五郎, 木浦 勝行

    日本呼吸器学会誌   10 ( 増刊 )   248 - 248   2021年4月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • 間質性肺炎急性増悪症例のBALF検体におけるIL-23濃度の検討

    妹尾 賢, 谷口 暁彦, 板野 純子, 小田 尚廣, 森近 大介, 藤井 詩子, 角南 良太, 金廣 有彦, 時岡 史明, 木浦 勝行, 前田 嘉信, 宮原 信明

    日本呼吸器学会誌   10 ( 増刊 )   140 - 140   2021年4月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • ALK融合遺伝子陽性非小細胞肺癌患者におけるアレクチニブ耐性後のクリゾチニブの有効性を検討する第II相試験

    高田 一郎, 小田 尚廣, 磯崎 英子, 原田 大二郎, 上月 稔幸, 別所 昭宏, 細川 忍, 横山 俊秀, 吉岡 弘鎮, 瀧川 奈義夫, 堀田 勝幸, 木浦 勝行, 岡山肺癌治療研究会

    日本呼吸器学会誌   10 ( 増刊 )   227 - 227   2021年4月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients (vol 111, pg 1685, 2020)

    Ikuo Sekine, Yasushi Shintani, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Hirotoshi Dosaka-Akita, Yuichi Takiguchi, Etsuo Miyaoka, Meinoshin Okumura, Ichiro Yoshino

    CANCER SCIENCE   112 ( 3 )   1332 - 1332   2021年3月

     詳細を見る

    記述言語:英語   掲載種別:会議報告等   出版者・発行元:WILEY  

    DOI: 10.1111/cas.14831

    Web of Science

    researchmap

  • アレクチニブ耐性のALK陽性非小細胞肺癌に対するクリゾチニブの第II相試験

    瀧川 奈義夫, 中川 望, 磯崎 英子, 原田 大二郎, 上月 稔幸, 別所 昭宏, 横山 俊秀, 高田 一郎, 堀田 勝幸, 木浦 勝行

    日本内科学会雑誌   110 ( Suppl. )   150 - 150   2021年2月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本内科学会  

    researchmap

  • Lung stereotactic body radiation therapy for elderly patients aged >= 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study 国際誌

    Kenta Watanabe, Kuniaki Katsui, Soichiro Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    RADIATION ONCOLOGY   16 ( 1 )   39 - 39   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:会議報告等   出版者・発行元:BMC  

    Background Stereotactic body radiation therapy (SBRT) is an established therapy for medically inoperable early-stage non-small cell lung cancer (NSCLC). Many elderly patients are medically inoperable owing to comorbidities. Therefore, SBRT may be a useful therapy for elderly patients. However, the application of SBRT for patients aged >= 80 years has not been completely elucidated. Therefore, this study aimed to assess the clinical utility of SBRT for elderly patients aged >= 80 years with pathologically proven early-stage NSCLC. Methods We retrospectively evaluated the data of patients aged >= 80 years with pathologically proven primary NSCLC who underwent SBRT at our institution between January 2009 and March 2020. Treatment outcomes and toxicities were analyzed. We used the Kaplan-Meier method to estimate survival curves and the log-rank test to compare the survival curves. We performed univariate and multivariate Cox regression analyses. p-values < 0.05 were regarded significant. Results Sixty-four patients (65 lesions) were included, and the median follow-up period was 38.7 (range 3.5-95.7) months. The median age was 82.9 (range 80.0-94.8) years. Sixteen patients were medically operable, and 48 patients were medically inoperable. The prescribed dose of SBRT was either 48 Gy in four fractions or 60 Gy in 10 fractions. The median survival time was 60.0 months (95% confidence interval, 43.5-71.1). The 1-, 3-, and 5-year local control, cancer-specific survival, progression-free survival, and overall survival rates were 98.4%, 98.4%, 81.0%, and 88.9%; 90.1%, 93.7%, 58.9%, and 68.3%; and 87.4%, 83.5%, 38.2%, and 47.5%, respectively. Multivariate analysis revealed that inoperability and solid nodules were the predictors of poor overall survival after SBRT in elderly patients. Two patients (3.1%) had grade 3 radiation pneumonitis, and one patient (1.6%) had grade 5 radiation pneumonitis. Conclusions SBRT was feasible in patients aged >= 80 years with NSCLC. It achieved good local control with minimal toxicity. SBRT may be beneficial in elderly patients with early-stage NSCLC.

    DOI: 10.1186/s13014-021-01769-7

    Web of Science

    PubMed

    researchmap

  • レンバチニブが有効であった右上顎腺様嚢胞癌の一例

    西 達也, 西森 久和, 亀井 裕子, 二宮 貴一朗, 加藤 有加, 久保 寿夫, 堀田 勝幸, 田端 雅弘, 木浦 勝行, 前田 嘉信

    日本内科学会雑誌   110 ( Suppl. )   169 - 169   2021年2月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本内科学会  

    researchmap

  • 免疫チェックポイント阻害薬治療中インフルエンザワクチン接種の安全性を検討するための前向き観察研究

    近森 研一, 玄馬 顕一, 小田 尚廣, 井上 政昭, 久山 彰一, 肥後 寿夫, 瀧川 奈義夫, 久保 寿夫, 市原 英基, 堀田 勝幸, 前田 嘉信, 木浦 勝行

    肺癌   60 ( 6 )   639 - 639   2020年10月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 当院においてベンラリズマブを使用した重症気管支喘息症例の検討

    谷口 暁彦, 板野 純子, 妹尾 賢, 金廣 有彦, 木浦 勝行, 前田 嘉信, 宮原 信明

    アレルギー   69 ( 臨時増刊号 )   309 - 309   2020年10月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本アレルギー学会  

    researchmap

  • 肺癌登録事業の年次報告 新たな事業について

    鈴木 秀海, 吉野 一郎, 新谷 康, 中西 良一, 川口 知哉, 山本 信之, 門倉 光隆, 高橋 和久, 木浦 勝行, 遠藤 俊輔, 千田 雅之, 淺村 尚生, 宮岡 悦良, 伊達 洋至, 全国肺癌登録合同委員会

    肺癌   60 ( 6 )   514 - 514   2020年10月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 85歳以上の超高齢非小細胞肺癌患者における免疫チェックポイント阻害剤の有効性と安全性についての検討

    岩本 佳隆, 原田 大二郎, 井上 考司, 柴山 卓夫, 細川 忍, 岸野 大蔵, 張田 信吾, 久保 寿夫, 前田 嘉信, 木浦 勝行

    日本老年医学会雑誌   57 ( 4 )   518 - 518   2020年10月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本老年医学会  

    researchmap

  • 進行肺癌の治癒を目指して

    木浦 勝行

    肺癌   60 ( 6 )   438 - 438   2020年10月

     詳細を見る

    担当区分:筆頭著者, 最終著者, 責任著者   記述言語:日本語   掲載種別:記事・総説・解説・論説等(学術雑誌)   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 当院でオマリズマブを使用した気管支喘息症例についての検討

    角南 良太, 谷口 暁彦, 高田 健二, 大川 祥, 板野 純子, 妹尾 賢, 金廣 有彦, 木浦 勝行, 前田 嘉信, 宮原 信明

    日本職業・環境アレルギー学会雑誌   28 ( 1 )   77 - 77   2020年10月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:日本職業・環境アレルギー学会  

    researchmap

  • メポリズマブからベンラリズマブへの切り替えを行った重症喘息症例の検討

    谷口 暁彦, 大川 祥, 角南 良太, 高田 健二, 板野 純子, 妹尾 賢, 金廣 有彦, 木浦 勝行, 前田 嘉信, 宮原 信明

    日本職業・環境アレルギー学会雑誌   28 ( 1 )   78 - 78   2020年10月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:日本職業・環境アレルギー学会  

    researchmap

  • 癌治療におけるリアルワールドデータ活用:現状と課題 肺癌登録合同委員会の成果と今後

    新谷 康, 山本 信之, 中西 良一, 木浦 勝行, 高橋 和久, 門倉 光隆, 川口 知哉, 遠藤 俊輔, 千田 雅之, 淺村 尚生, 宮岡 悦良, 鈴木 秀海, 吉野 一郎, 伊達 洋至

    日本癌治療学会学術集会抄録集   58回   SSY4 - 1   2020年10月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • ドライバー変異陰性非小細胞肺癌に対する免疫チェックポイント阻害剤の実態調査

    上月 稔幸, 津端 由佳里, 石川 暢久, 藤高 一慶, 石井 知也, 山崎 正弘, 瀧川 奈義夫, 藤本 伸一, 小谷 昌広, 藤原 慶一, 窪田 哲也, 久山 彰一, 上田 裕, 井上 政昭, 福田 泰, 三好 誠吾, 山下 夏美, 堀田 勝幸, 木浦 勝行, CS-Lung-003研究グループ

    肺癌   60 ( 6 )   582 - 582   2020年10月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • EGFR遺伝子変異陽性肺癌症例における再生検の状況

    工藤 健一郎, 槇本 剛, 津端 由佳里, 石川 暢久, 山口 覚博, 藤本 伸一, 山崎 正弘, 瀧川 奈義夫, 小谷 昌広, 藤原 慶一, 窪田 哲也, 井上 政昭, 上月 稔幸, 上田 裕, 久山 彰一, 堀田 勝幸, 木浦 勝行, CS-Lung-003研究グループ

    肺癌   60 ( 6 )   630 - 630   2020年10月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • ALK融合遺伝子陽性非小細胞肺癌におけるアレクチニブ耐性後のクリゾチニブの有効性を検討する第II相試験

    別所 昭宏, 磯崎 英子, 細川 忍, 原田 大二郎, 上月 稔幸, 横山 俊秀, 吉岡 弘鎮, 高田 一郎, 瀧川 奈義夫, 堀田 勝幸, 木浦 勝行

    肺癌   60 ( 6 )   562 - 562   2020年10月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • EGFR遺伝子変異陽性進行肺癌に対する治療状況に関する前向きレジストリ研究

    西井 和也, 中尾 美香, 石川 暢久, 益田 武, 藤本 伸一, 山崎 正弘, 瀧川 奈義夫, 小谷 昌広, 藤原 慶一, 窪田 哲也, 井上 政昭, 上月 稔幸, 上田 裕, 久山 彰一, 堀田 勝幸, 木浦 勝行, CS-Lung-003研究グループ

    肺癌   60 ( 6 )   581 - 581   2020年10月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 肺がん患者の予定外入院に及ぼす要因と背景の検討

    藤村 真子, 祇園 由美, 酒井 美幸, 川村 夢乃, 坂本 陽子, 市原 英基, 灘 実穂, 桐山 日菜子, 原野 成美, 田原 由貴, 森本 由佳, 川原 紗弥, 前田 嘉信, 木浦 勝行

    肺癌   60 ( 6 )   782 - 782   2020年10月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • リンパ脈管筋腫症(LAM)に気管支喘息が併発した2例

    谷本 安, 板野 純子, 谷口 暁彦, 藤井 誠, 宮原 信明, 平野 淳, 河田 典子, 木村 五郎, 木浦 勝行, 宗田 良

    アレルギー   69 ( 臨時増刊号 )   297 - 297   2020年10月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本アレルギー学会  

    researchmap

  • 肺癌レジストリ(CS-Lung-003)研究デザインと現状

    西井 和也, 中尾 美香, 石井 知也, 藤高 一慶, 石川 暢久, 山崎 正弘, 小谷 昌広, 瀧川 奈義夫, 井上 政昭, 久山 彰一, 高田 一郎, 窪田 哲也, 藤本 伸一, 張田 信吾, 上月 稔幸, 藤原 慶一, 杉本 啓介, 三好 誠吾, 上田 裕, 木浦 勝行, CS-Lung-003研究グループ

    肺癌   60 ( 6 )   641 - 641   2020年10月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 日本肺癌学会による臨床試験データの統合とデータベース化 世界に対抗できるデータベース構築を目指して

    小澤 雄一, 山中 竹春, 伊藤 健太郎, 釼持 広知, 大江 裕一郎, 木浦 勝行, 菅原 俊一, 中川 和彦, 吉野 一郎, 弦間 昭彦, 山本 信之

    肺癌   60 ( 6 )   641 - 641   2020年10月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 免疫チェックポイント阻害薬が有効なEGFR遺伝子変異陽性肺癌の特徴

    市原 英基, 原田 大二郎, 井上 考司, 柴山 卓夫, 細川 忍, 岸野 大蔵, 張田 信吾, 越智 宣昭, 小田 尚廣, 原 尚史, 堀田 勝幸, 前田 嘉信, 木浦 勝行

    肺癌   60 ( 6 )   637 - 637   2020年10月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 肺癌登録合同委員会報告

    新谷 康, 木浦 勝行, 高橋 和久, 滝口 裕一, 永安 武, 中西 良一, 山本 信之, 遠藤 俊輔, 千田 雅之, 淺村 尚生, 宮岡 悦良, 奥村 明之進, 鈴木 秀海, 吉野 一郎, 伊達 洋至, 肺癌登録合同委員会

    日本呼吸器学会誌   9 ( 増刊 )   78 - 78   2020年8月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • マウス好中球性喘息モデルにおけるIL-23の役割の検討

    妹尾 賢, 谷口 暁彦, 板野 純子, 小田 尚廣, 郭 麗莉, 吉村 昭彦, 木浦 勝行, 前田 嘉信, 宮原 信明

    日本呼吸器学会誌   9 ( 増刊 )   227 - 227   2020年8月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • 肺線維症モデルにおけるNeuropeptide Y(NPY)の役割の検討

    板野 純子, 谷口 暁彦, 妹尾 賢, 小田 尚廣, 郭 麗莉, 木浦 勝行, 前田 嘉信, 宮原 信明

    日本呼吸器学会誌   9 ( 増刊 )   248 - 248   2020年8月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • 肺癌登録事業の年次報告:新しい登録事業について

    吉野 一郎, 中西 良一, 滝口 裕一, 山本 信之, 永安 武, 高橋 和久, 木浦 勝行, 遠藤 俊輔, 千田 雅之, 淺村 尚生, 宮岡 悦郎, 新谷 康, 鈴木 秀海, 伊達 洋至, 全国肺癌登録合同委員会

    日本呼吸器外科学会雑誌   34 ( 3 )   肺癌登録合同委員会報告 - 肺癌登録合同委員会報告   2020年8月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本呼吸器外科学会  

    researchmap

  • 肺癌登録事業の年次報告 我が国の肺癌診療のreal world data

    吉野 一郎, 中西 良一, 川口 知哉, 山本 信之, 門倉 光隆, 高橋 和久, 木浦 勝行, 遠藤 俊輔, 千田 雅之, 浅村 尚生, 宮岡 悦良, 新谷 康, 鈴木 秀海, 伊達 洋至, 全国肺癌登録合同委員会

    気管支学   42 ( Suppl. )   S175 - S175   2020年6月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本呼吸器内視鏡学会  

    researchmap

  • RELAY study of erlotinib (ERL) plus ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).

    Kazuto Nishio, Kazuko Sakai, Takashi Seto, Makoto Nishio, Edward B. Garon, Martin Reck, Koichi Goto, Terufumi Kato, Yoichi Nakanishi, Toshiaki Takahashi, Nobuyuki Yamamoto, Katsuyuki Kiura, Yuichiro Ohe, Tomohide Tamura, Carla M. Visseren-Grul, Rebecca R. Hozak, Sameera R. Wijayawardana, Sotaro Enatsu, Kazuhiko Nakagawa

    JOURNAL OF CLINICAL ONCOLOGY   38 ( 15 )   2020年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Web of Science

    researchmap

  • 診断に苦慮した右肺異常陰影の1例

    高田 健二, 谷口 暁彦, 角南 良太, 大川 祥, 岩本 佳隆, 平生 敦子, 二宮 貴一朗, 久保 寿夫, 頼 冠名, 市原 英基, 大橋 圭明, 堀田 勝幸, 田端 雅弘, 宮原 信明, 木浦 勝行

    岡山医学会雑誌   132 ( 1 )   46 - 46   2020年4月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:速報,短報,研究ノート等(学術雑誌)   出版者・発行元:岡山医学会  

    researchmap

  • EGFR変異陽性局所進行非小細胞肺癌に対するGefitinib導入療法と逐次化学放射線療法の第II相試験(LOGIK0902/OLCSG0905)

    原田 大二郎, 佐伯 祥, 山口 正史, 田村 朋季, 岸本 淳司, 佐々木 治一郎, 堀田 勝幸, 杉尾 賢二, 木浦 勝行

    日本内科学会雑誌   109 ( Suppl. )   225 - 225   2020年2月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本内科学会  

    researchmap

  • 非小細胞肺癌化学放射線療法における食道炎に対するアルギン酸Naの有用性を検討する無作為化比較試験(OLCSG1401)

    久山彰一, 久山彰一, 工藤健一郎, 工藤健一郎, 尾形毅, 二宮貴一朗, 尾瀬功, 吉岡弘鎮, 別所昭宏, 細川忍, 上月稔幸, 原田大二郎, 八杉昌幸, 村上斗司, 中西将元, 瀧川奈義夫, 勝井邦彰, 前田嘉信, 堀田勝幸, 木浦勝行

    日本呼吸器学会誌(Web)   9   2020年

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等  

    J-GLOBAL

    researchmap

  • NSCLCに対するICIの治療効果とBMIの関連性

    市原 英基, 原田 大二郎, 井上 考司, 佐藤 賢, 細川 忍, 岸野 大蔵, 渡邊 一彦, 越智 宜昭, 小田 尚廣, 原 尚史, 渡邉 洋美, 堀田 勝幸, 前田 嘉信, 木浦 勝行, 岡山肺癌治療研究会(OLCSG)

    肺癌   59 ( 6 )   770 - 770   2019年11月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 自己免疫疾患・高齢者・全身状態不良例に対する免疫治療 PS不良NSCLCに対するICIの治療効果と安全性の評価

    狩野 裕久, 市原 英基, 原田 大二郎, 井上 孝司, 萱谷 紘枝, 細川 忍, 岸野 大蔵, 渡邊 一彦, 越智 宜昭, 小田 尚廣, 原 尚史, 堀田 勝幸, 前田 嘉信, 木浦 勝行

    肺癌   59 ( 6 )   580 - 580   2019年11月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 人生100年時代の肺がん治療をどう考えるか 85歳以上の高齢非小細胞肺癌患者における免疫チェックポイント阻害剤の有効性と安全性

    久保 寿夫, 市原 英基, 原田 大二郎, 井上 考司, 萱谷 紘枝, 細川 忍, 岸野 大蔵, 川井 治之, 越智 宣昭, 小田 尚廣, 原 尚史, 堀田 勝幸, 田端 雅弘, 前田 嘉信, 木浦 勝行

    肺癌   59 ( 6 )   567 - 567   2019年11月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 非小細胞肺癌に対する免疫チェックポイント阻害薬の治療効果と抗菌薬使用に関する後方視的検討

    越智 宣昭, 市原 英基, 山根 弘路, 瀧川 奈義夫, 原田 大二郎, 井上 考司, 柴山 卓夫, 細川 忍, 岸野 大蔵, 張田 信吾, 小田 尚廣, 原 尚史, 堀田 勝幸, 前田 嘉信, 木浦 勝行, 岡山肺癌治療研究会

    肺癌   59 ( 6 )   704 - 704   2019年11月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 非小細胞肺癌患者における胸部照射歴と免疫チェックポイント阻害剤の治療効果の関連性に関する後方視的検討

    細川 忍, 市原 英基, 別所 昭宏, 原田 大二郎, 井上 考司, 柴山 卓夫, 岸野 大蔵, 張田 信吾, 越智 宜昭, 小田 尚廣, 原 尚史, 堀田 勝幸, 前田 嘉信, 木浦 勝行

    肺癌   59 ( 6 )   705 - 705   2019年11月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 進行非扁平上皮非小細胞肺癌に対するカルボプラチン+ナブパクリタキセル+ベバシズマブの第II相試験

    丹澤 盛, 久保 寿夫, 野上 尚之, 別所 昭宏, 深松 伸明, 池尾 聡, 横山 俊秀, 市川 靖子, 藤本 伸一, 村上 修司, 解良 恭一, 原田 敏之, 中村 香葉, 岩澤 俊一郎, 下川 恒生, 木浦 勝行, 山下 夏美, 岡本 浩明

    肺癌   59 ( 6 )   671 - 671   2019年11月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • PD-L1陽性既治療非小細胞肺癌における免疫チェックポイント阻害薬の有効性に関する後方視的検討

    森 俊太, 市原 英基, 原田 大二郎, 細川 忍, 井上 考司, 南 大輔, 岸野 大蔵, 張田 信吾, 越智 宜昭, 小田 尚廣, 原 尚史, 堀田 勝幸, 前田 嘉信, 木浦 勝行, 岡山肺癌治療研究会(OLCSG)

    肺癌   59 ( 6 )   702 - 702   2019年11月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 放射線治療:Up-to-date EGFR変異陽性局所進行肺癌に対するGefitinib導入療法と逐次化学放射線療法の第II相試験LOGIK0902/OLCSG0905

    佐伯 祥, 堀田 勝幸, 山口 正史, 原田 大二郎, 別所 昭宏, 田中 謙太郎, 井上 孝治, 玄馬 顕一, 井上 考司, 渡邉 洋美, 岸本 淳司, 塩山 善之, 勝井 邦彰, 佐々木 治一郎, 木浦 勝行, 杉尾 賢二

    肺癌   59 ( 6 )   589 - 589   2019年11月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 肺癌登録事業の年次報告 成果、現状そして将来

    吉野 一郎, 山本 信之, 中西 良一, 滝口 裕一, 永安 武, 伊達 洋至, 高橋 和久, 木浦 勝行, 遠藤 俊輔, 千田 雅之, 浅村 尚生, 新谷 康, 奥村 明之進

    肺癌   59 ( 6 )   615 - 615   2019年11月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • NSCLCに対する免疫チェックポイント阻害薬の効果予測のためのTBNAまたはセルブロック検体を用いたPD-L1測定

    原 尚史, 市原 英基, 原田 大二郎, 井上 考司, 藤原 慶一, 細川 忍, 岸野 大蔵, 川井 治之, 越智 宣昭, 小田 尚廣, 堀田 勝幸, 前田 嘉信, 木浦 勝行

    肺癌   59 ( 6 )   775 - 775   2019年11月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 間質性肺炎合併肺癌に対する免疫チェックポイント阻害薬の効果、安全性の検討

    小田 尚廣, 市原 英基, 原田 大二郎, 井上 孝司, 柴山 卓夫, 細川 忍, 岸野 大蔵, 張田 信吾, 越智 宜昭, 高田 一郎, 原 尚史, 堀田 勝幸, 前田 嘉信, 木浦 勝行

    肺癌   59 ( 6 )   778 - 778   2019年11月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 日本の肺癌治療症例のレジストリ研究

    関根 郁夫, 新谷 康, 宿谷 威仁, 高山 浩一, 井上 彰, 岡本 勇, 木浦 勝行, 高橋 和久, 秋田 弘俊, 滝口 裕一, 宮岡 悦良, 奥村 明之進, 吉野 一郎

    59 ( 6 )   734 - 734   2019年11月

     詳細を見る

    記述言語:英語   掲載種別:会議報告等  

    researchmap

  • 進行NSCLCにおけるTBNAまたはセルブロック検体でのPD-L1測定によるICIの効果予測

    原 尚史, 市原 英基, 原田 大二郎, 井上 考司, 萱谷 紘枝, 細川 忍, 岸野 大蔵, 張田 信吾, 越智 宣昭, 小田 尚廣, 堀田 勝幸, 前田 嘉信, 木浦 勝行

    日本癌治療学会学術集会抄録集   57回   P88 - 1   2019年10月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等  

    researchmap

  • 超高齢非小細胞肺癌患者における免疫チェックポイント阻害薬の効果と安全性の検討

    久保 寿夫, 市原 英基, 原田 大二郎, 井上 考司, 柴山 卓夫, 細川 忍, 岸野 大蔵, 張田 信吾, 越智 宣昭, 小田 尚廣, 原 尚史, 堀田 勝幸, 田端 雅弘, 前田 嘉信, 木浦 勝行

    日本癌治療学会学術集会抄録集   57回   P88 - 2   2019年10月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等  

    researchmap

  • 岡山県がん患者の夜間休日外来化学療法の希望について

    片山 英樹, 田端 雅弘, 久保 寿夫, 木浦 勝行, 前田 嘉信

    日本癌治療学会学術集会抄録集   57回   O4 - 2   2019年10月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等  

    researchmap

  • Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma 国際誌

    Takamasa Nakasuka, Eiki Ichihara, Go Makimoto, Yoshinobu Maeda, Katsuyuki Kiura

    JOURNAL OF THORACIC ONCOLOGY   14 ( 8 )   E168 - E169   2019年8月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:ELSEVIER SCIENCE INC  

    DOI: 10.1016/j.jtho.2019.03.009

    Web of Science

    PubMed

    researchmap

  • Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. 国際誌

    Makimoto G, Ohashi K, Tomida S, Nishii K, Matsubara T, Kayatani H, Higo H, Ninomiya K, Sato A, Watanabe H, Kano H, Ninomiya T, Kubo T, Rai K, Ichihara E, Hotta K, Tabata M, Toyooka S, Takata M, Maeda Y, Kiura K

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   14 ( 11 )   2009 - 2018   2019年7月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    DOI: 10.1016/j.jtho.2019.07.017

    Web of Science

    PubMed

    researchmap

  • Tumor immunoediting in a lung cancer mouse model harboring EGFR mutations

    Kazuya Nishii, Kadoaki Ohashi, Kiichiro Ninomiya, Go Makimoto, Hiromi Watanabe, Hirohisa Kano, Naofumi Hara, Heiichiro Udono, Katsuyuki Kiura

    CANCER RESEARCH   79 ( 13 )   2019年7月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2019-582

    Web of Science

    researchmap

  • Significant combination benefit of anti-VEGFR antibody and oncogene-targeted agents in EGFR or ALK mutant NSCLC cells

    Hiromi Watanabe, Eiki Ichihara, Hiroe Kayatani, Hisao Higo, Go Makimoto, Hirohisa Kano, Kazuya Nishii, Naofumi Hara, Kiichiro Ninomiya, Toshio Kubo, Kadoaki Ohashi, Kammei Rai, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    CANCER RESEARCH   79 ( 13 )   2019年7月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2019-2131

    Web of Science

    researchmap

  • Rapid acquired resistance to alectinib in ALK-positive lung cancers with high tumor mutation burden

    Kadoaki Ohashi, Go Makimoto, Shuta Tomida, Kazuya Nishii, Shinichi Toyooka, Katsuyuki Kiura

    CANCER RESEARCH   79 ( 13 )   2019年7月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2019-752

    Web of Science

    researchmap

  • 術後肺瘻に対してEWSを用いた気管支充填術を施行した6例の検討

    安東 千裕, 西井 和也, 頼 冠名, 山本 寛斎, 狩野 裕久, 渡邉 洋美, 妹尾 賢, 原 尚史, 久保 寿夫, 豊岡 伸一, 木浦 勝行

    気管支学   41 ( Suppl. )   S254 - S254   2019年6月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本呼吸器内視鏡学会  

    researchmap

  • 動物モデル3:その他のアレルギー疾患 肺線維症急性増悪におけるIL-23の重要性

    妹尾 賢, 谷口 暁彦, 板野 純子, 小田 尚廣, 森近 大介, 吉村 昭彦, 木浦 勝行, 金廣 有彦, 前田 嘉信, 宮原 信明

    アレルギー   68 ( 4-5 )   541 - 541   2019年5月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本アレルギー学会  

    researchmap

  • Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations:A HER2-CS STUDY subset analysis.

    Hiroe Kayatani, Keisuke Aoe, Kadoaki Ohashi, Hiroshige Yoshioka, Akihiro Bessho, Nobuhisa Ishikawa, Masahiro Yamasaki, Toshiyuki Kozuki, Nobukazu Fujimoto, Yutaka Ueda, Syuuji Bandoh, Isao Murakami, Hirohisa Ichikawa, Tetsuya Kubota, Keisuke Sugimoto, Nagio Takigawa, Takashi Sumikawa, Katsuyuki Kiura

    JOURNAL OF CLINICAL ONCOLOGY   37 ( 15 )   2019年5月

     詳細を見る

    担当区分:最終著者   記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:AMER SOC CLINICAL ONCOLOGY  

    Web of Science

    researchmap

  • リンパ脈管筋腫症(LAM)の長期フォロー中に呼吸機能低下が進行し,気管支喘息の併発が判明した1例

    谷本 安, 谷口 暁彦, 板野 純子, 宮原 信明, 平野 淳, 河田 典子, 木村 五郎, 木浦 勝行, 宗田 良

    アレルギー   68 ( 4-5 )   575 - 575   2019年5月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本アレルギー学会  

    researchmap

  • 当院においてメポリズマブを使用した重症気管支喘息症例の検討

    岩本 佳隆, 谷口 暁彦, 小田 尚廣, 板野 純子, 妹尾 賢, 金廣 有彦, 木浦 勝行, 前田 嘉信, 宮原 信明

    アレルギー   68 ( 3 )   162 - 162   2019年5月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本アレルギー学会  

    researchmap

  • 免疫チェックポイント阻害薬の効果を左右する腫瘍微小環境

    西井 和也, 大橋 圭明, 木浦 勝行

    岡山医学会雑誌   131 ( 1 )   51 - 53   2019年4月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:記事・総説・解説・論説等(商業誌、新聞、ウェブメディア)   出版者・発行元:岡山医学会  

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J00175&link_issn=&doc_id=20190412190010&doc_link_id=10.4044%2Fjoma.131.51&url=https%3A%2F%2Fdoi.org%2F10.4044%2Fjoma.131.51&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • EGFR-TKI2 活性型EGFR遺伝子変異陽性かつT790M陰性の進行・再発非小細胞肺癌に対するアファチニブを用いたEGFR-TKI再投与の有用性を検討する第II相試験

    横山 俊秀, 吉岡 弘鎮, 石田 直, 小田 尚廣, 堀田 勝幸, 南 大輔, 村上 斗司, 市川 裕久, 近森 研一, 瀧川 奈義夫, 張田 信吾, 前田 嘉信, 木浦 勝行, 岡山肺癌治療研究会(OLCSG)

    日本呼吸器学会誌   8 ( 増刊 )   166 - 166   2019年3月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • 肺線維症急性増悪におけるIL-23の役割の検討

    妹尾 賢, 谷口 暁彦, 小田 尚廣, 板野 純子, 森近 大介, 吉村 昭彦, 木浦 勝行, 前田 嘉信, 宮原 信明

    日本呼吸器学会誌   8 ( 増刊 )   193 - 193   2019年3月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • 同種骨髄移植後に難治性気胸を呈し,脳死両肺移植を施行した二次性pleuroparenchymal fibroelastosis(PPFE)の1例

    谷本 安, 細川 忍, 肥後 寿夫, 杉本 誠一郎, 別所 昭宏, 大藤 剛宏, 木浦 勝行, 山鳥 一郎

    日本呼吸器学会誌   8 ( 増刊 )   320 - 320   2019年3月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本呼吸器学会  

    researchmap

  • 当院における限局型小細胞肺癌に対する放射線治療の治療成績

    片山 敬久, 大川 広, 田邊 新, 渡邉 謙太, 金澤 右, 井原 弘貴, 勝井 邦彰, 田端 雅弘, 木浦 勝行, 前田 嘉信, 武本 充広

    Japanese Journal of Radiology   37 ( Suppl. )   52 - 52   2019年2月

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(公社)日本医学放射線学会  

    researchmap

  • EGFR遺伝子変異陽性非小細胞肺癌に対するafatinib・bevacizumab併用療法の第1相試験 OLCSG1404

    萱谷 紘枝, 南 大輔, 柴山 卓夫, 野上 尚之, 久山 彰一, 別所 昭宏, 藤本 伸一, 青江 啓介, 瀧川 奈義夫, 木浦 勝行

    肺癌   59 ( 1 )   98 - 98   2019年2月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 活性型EGFR遺伝子変異陽性かつT790M陰性の進行・再発非小細胞肺癌に対するアファチニブを用いたEGFR-TKI再投与の有用性を検討する第II相試験

    小田 尚廣, 堀田 勝幸, 南 大輔, 村上 斗司, 横山 俊秀, 市川 裕久, 近森 研一, 瀧川 奈義夫, 前田 嘉信, 木浦 勝行, 岡山肺癌治療研究会(OLCSG)

    日本内科学会雑誌   108 ( Suppl. )   283 - 283   2019年2月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等   出版者・発行元:(一社)日本内科学会  

    researchmap

  • 高齢非小細胞肺癌に対する免疫チェックポイント阻害剤の効果と安全性に関する後方視的検討

    久保寿夫, 渡邉洋美, 二宮貴一朗, 工藤健一郎, 南大輔, 村上悦子, 越智宣昭, 原田大二郎, 八杉昌幸, 市原英基, 大橋圭明, 藤原慶一, 堀田勝幸, 田端雅弘, 前田嘉信, 木浦勝行

    日本呼吸器学会誌(Web)   8   2019年

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等  

    J-GLOBAL

    researchmap

  • ニボルマブによる尋常性乾癬・ぶどう膜炎の顕在化

    河野和馬, 妹尾賢, 大橋圭明, 中須賀崇匡, 安東千裕, 原尚史, 岩本佳隆, 梅野貴裕, 二宮貴一朗, 谷口暁彦, 二宮崇, 久保寿夫, 市原英基, 頼冠名, 片山英樹, 堀田勝幸, 宮原信明, 田端雅弘, 木浦勝行, 前田嘉信

    肺癌(Web)   59 ( 1 )   2019年

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等  

    J-GLOBAL

    researchmap

  • 肺動脈血栓塞栓症を合併した全身状態不良の肺腺癌に対しpembrolizumabが奏効した1例

    濱崎友洋, 中須賀崇匡, 大橋圭明, 安東千裕, 原尚史, 梅野貴裕, 岩本佳隆, 板野純子, 二宮貴一朗, 二宮崇, 谷口暁彦, 久保寿夫, 市原英基, 堀田勝幸, 宮原信明, 田端雅弘, 木浦勝行, 前田嘉信

    肺癌(Web)   59 ( 1 )   2019年

     詳細を見る

    記述言語:日本語   掲載種別:会議報告等  

    J-GLOBAL

    researchmap

  • 豪雨災害ボランティア後に肺アスペルギローマおよびABPAを発症した一例

    安東愛理, 中須賀崇匡, 久保寿夫, 安東千裕, 岩本佳隆, 梅野貴裕, 平生敦子, 二宮貴一朗, 谷口暁彦, 頼冠名, 市原英基, 大橋圭明, 宮原信明, 堀田勝幸, 田端雅弘, 前田嘉信, 木浦勝行

    日本呼吸器学会誌(Web)   8   2019年

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等  

    J-GLOBAL

    researchmap

  • 非小細胞肺癌に対する免疫チェックポイント阻害剤の再投与についての後方視的検討

    渡邉洋美, 久保寿夫, 二宮貴一朗, 工藤健一郎, 南大輔, 村上悦子, 越智宣昭, 原田大二郎, 八杉昌幸, 市原英基, 大橋圭明, 藤原慶一, 堀田勝幸, 田端雅弘, 前田嘉信, 木浦勝行

    日本呼吸器学会誌(Web)   8   2019年

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等  

    J-GLOBAL

    researchmap

  • EGFR遺伝子変異陽性肺癌に対するオシメルチニブ再投与の有効性に関する検討

    市原英基, 堀田勝幸, 二宮貴一朗, 久保寿夫, 頼冠名, 田端雅弘, 前田嘉信, 木浦勝行

    日本呼吸器学会誌(Web)   8   2019年

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:会議報告等  

    J-GLOBAL

    researchmap

  • 縦隔腫瘍の分子標的治療の現状と展望 招待

    久保 寿夫, 木浦 勝行

    呼吸器内科   34 ( 6 )   555 - 560   2018年12月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   掲載種別:記事・総説・解説・論説等(商業誌、新聞、ウェブメディア)   出版者・発行元:(有)科学評論社  

    researchmap

  • 導入化学放射線療法後手術を施行した局所進行非小細胞肺癌患者に発症した肺アスペルギルス症

    杉本 誠一郎, 宗 淳一, 枝園 和彦, 黒崎 毅史, 大谷 真二, 山本 寛斉, 岡崎 幹生, 山根 正修, 大藤 剛宏, 木浦 勝行, 金澤 右, 豊岡 伸一

    肺癌   58 ( 6 )   569 - 569   2018年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 局所進行非小細胞肺癌に対する導入療法後肺切除術の晩期肺障害を考える

    宗 淳一, 杉本 誠一郎, 枝園 和彦, 山本 寛斉, 黒崎 毅史, 大谷 真二, 岡崎 幹生, 山根 正修, 勝井 邦彰, 大藤 剛宏, 木浦 勝行, 金澤 右, 豊岡 伸一

    肺癌   58 ( 6 )   567 - 567   2018年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 肺癌登録合同委員会定期報告

    新谷 康, 秋田 弘俊, 中西 良一, 滝口 裕一, 永安 武, 伊達 洋至, 高橋 和久, 木浦 勝行, 淺村 尚生, 遠藤 俊輔, 千田 雅之, 宮岡 悦良, 奥村 明之進, 吉野 一郎, 肺癌登録合同委員会

    肺癌   58 ( 6 )   493 - 493   2018年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 薬物耐性メカニズムの解明 ALK阻害薬に対する耐性機序

    市原 英基, 木浦 勝行

    肺癌   58 ( 6 )   430 - 430   2018年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 扁平上皮肺癌治療の現状と展望 局所進展肺非小細胞癌(LA-NSCLC)に対する放射線化学療法の無作為化比較試験(OLCSG0007)における組織型別長期予後解析

    瀧川 奈義夫, 越智 宣昭, 山根 弘路, 畝川 芳彦, 堀田 勝幸, 田端 雅弘, 前田 嘉信, 木浦 勝行

    肺癌   58 ( 6 )   458 - 458   2018年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 肺癌登録合同委員会第6次肺癌登録事業の報告

    関根 郁夫, 新谷 康, 宿谷 威仁, 高山 浩一, 井上 彰, 岡本 勇, 木浦 勝行, 高橋 和久, 秋田 弘俊, 滝口 裕一, 宮岡 悦良, 奥村 明之進, 吉野 一郎

    肺癌   58 ( 6 )   493 - 493   2018年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 肺扁平上皮癌の治療の現状と展望 査読

    妹尾 賢, 二宮 貴一朗, 堀田 勝幸, 木浦 勝行

    肺癌   58 ( 5 )   325 - 330   2018年10月

     詳細を見る

    担当区分:最終著者   記述言語:日本語   出版者・発行元:(NPO)日本肺癌学会  

    肺扁平上皮癌は、発生機序に喫煙との関連が強い癌腫であり、肺癌全体の約20〜30%を占めている。肺扁平上皮癌に対する細胞障害性抗癌剤を用いた治療開発の多くは限定的であった。しかし2010年代に入り、ネダプラチン+ドセタキセル併用療法の有効性や免疫チェックポイント阻害薬に関連した臨床試験の報告がなされるようになり、治療選択肢が大きく増えることとなった。さらに近年、化学療法と免疫チェックポイント阻害薬の併用療法などの新たなエビデンスも創られつつある。本稿では、非高齢者かつperformance statusが良好な症例を主たる対象とした各種臨床研究について紹介する。また、既存のエビデンスに加えて、2018年に入り新たに報告された試験結果を紹介したい。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J01244&link_issn=&doc_id=20181106300001&doc_link_id=%2Fec7jaluc%2F2018%2F005805%2F001%2F0325-0330%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fec7jaluc%2F2018%2F005805%2F001%2F0325-0330%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M 国際誌

    Satoru Senoo, Kadoaki Ohashi, Kazuya Nishii, Naofumi Hara, Hirohisa Kano, Kiichiro Ninomiya, Yoshinobu Maeda, Katsuyuki Kiura

    JOURNAL OF THORACIC ONCOLOGY   13 ( 8 )   E140 - E142   2018年8月

     詳細を見る

    記述言語:英語   出版者・発行元:ELSEVIER SCIENCE INC  

    DOI: 10.1016/j.jtho.2018.03.016

    Web of Science

    PubMed

    researchmap

  • In vivo efficacy of triplet therapy with osimertinib, cetuximab and bevacizumab for lung cancer cells harboring EGFR T790M

    Kazuya Nishii, Kadoaki Ohashi, Go Makimoto, Hisao Higo, Kiichiro Ninomiya, Hiroe Kayatani, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura

    CANCER RESEARCH   78 ( 13 )   2018年7月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-4818

    Web of Science

    researchmap

  • The novel osimertinib resistant lung cancer mice model harboring EGFR mutations driven by the SP-C promoter

    Kadoaki Ohashi, Hisao Higo, Go Makimoto, Kenichiro Kudo, Kazuya Nishii, Kiichiro Ninomiya, Hiroe Kayatani, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura

    CANCER RESEARCH   78 ( 13 )   2018年7月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-1160

    Web of Science

    researchmap

  • 難治性/再発性固形腫瘍に対するメトホルミンと併用したニボルマブ療法の第Ib相試験(Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors)

    久保 寿夫, 堀田 勝幸, 二宮 崇, 加藤 博也, 堀口 繁, 高本 篤, 上月 稔幸, 野上 尚之, 石井 浩, 仁科 智裕, 原田 大二郎, 豊岡 伸一, 岡田 裕之, 藤原 俊義, 鵜殿 平一郎, 木浦 勝行

    日本がん免疫学会総会プログラム・抄録集   22回 ( 15 )   141 - 141   2018年7月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:日本がん免疫学会  

    DOI: 10.1200/JCO.2018.36.15_suppl.TPS3119

    Web of Science

    researchmap

  • 免疫チェックポイント阻害剤が次治療に与える影響についての後方視的検討

    渡邉 洋美, 久保 寿夫, 二宮 貴一朗, 工藤 健一郎, 南 大輔, 越智 宣昭, 原田 大二郎, 村上 悦子, 八杉 昌幸, 二宮 崇, 市原 英基, 大橋 圭明, 堀田 勝幸, 田端 雅弘, 木浦 勝行

    日本がん免疫学会総会プログラム・抄録集   22回 ( 増刊 )   144 - 144   2018年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本がん免疫学会  

    researchmap

  • Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients.

    Hiromi Watanabe, Toshio Kubo, Kiichiro Ninomiya, Daisuke Minami, Kenichiro Kudo, Etsuko Murakami, Nobuaki Ochi, Takashi Ninomiya, Daijiro Harada, Masayuki Yasugi, Eiki Ichihara, Kadoaki Ohashi, Keiichi Fujiwara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    JOURNAL OF CLINICAL ONCOLOGY   36 ( 15 )   2018年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:AMER SOC CLINICAL ONCOLOGY  

    DOI: 10.1200/JCO.2018.36.15_suppl.e21034

    Web of Science

    researchmap

  • The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.

    Hiromi Watanabe, Toshio Kubo, Kiichiro Ninomiya, Kenichiro Kudo, Daisuke Minami, Etsuko Murakami, Nobuaki Ochi, Takashi Ninomiya, Daijiro Harada, Masayuki Yasugi, Eiki Ichihara, Kadoaki Ohashi, Keiichi Fujiwara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    JOURNAL OF CLINICAL ONCOLOGY   36 ( 15 )   2018年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:AMER SOC CLINICAL ONCOLOGY  

    DOI: 10.1200/JCO.2018.36.15_suppl.e21147

    Web of Science

    researchmap

  • 術後難治性有瘻性膿胸に対して気管支充填術により瘻孔閉鎖を行った一例

    山本 寛斉, 原 尚史, 西井 和也, 頼 冠名, 木浦 勝行, 豊岡 伸一

    気管支学   40 ( Suppl. )   S281 - S281   2018年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本呼吸器内視鏡学会  

    researchmap

  • アレルギー性気道炎症におけるY1受容体阻害薬による治療効果の検討

    小田 尚廣, 宮原 信明, 妹尾 賢, 谷口 暁彦, 森近 大介, 藤井 詩子, 前田 嘉信, 木浦 勝行, 金廣 有彦

    アレルギー   67 ( 4-5 )   563 - 563   2018年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本アレルギー学会  

    researchmap

  • 肺癌登録合同委員会報告

    新谷 康, 滝口 裕一, 永安 武, 伊達 洋至, 横井 香平, 高橋 和久, 木浦 勝行, 秋田 弘俊, 宮岡 悦良, 淺村 尚生, 奥村 明之進, 吉野 一郎, 肺癌登録合同委員会

    気管支学   40 ( Suppl. )   S184 - S184   2018年5月